<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="proliferate">
            <roleset id="proliferate.01" name="" wordnet="1">
                <roles>
                    <role n="0" descr="thing becoming abundant&#x09;&#x09;&#x09;&#x09;// gene products //&#x0A;" />
                    <role n="1" descr="situation of becoming abundant&#x0A;" />
                    <role n="2" descr="location referring to organ, vitro&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>A0 T cells are able to recover the ability to proliferate indefinitely after the introduction of Stat5a wild body stulation (Figure 6B).</text>
                    <arg n="1">after the introduction of Stat5a wild body stulation</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>A0 has been characterized by a greater proliferating ability or a reduced ability to undergo programmed cell death.</text>
                </example>
                <example src="EGRAM" no="2">
                    <text>A0 has been proliferate by a higher proliferation capacity or a reduced capacity to suffer scheduled cell death.</text>
                </example>
                <example src="EGRAM" no="3">
                    <text>A0 is characterized by a greater ability to proliferate strongly or a decrease in the ability to suffer programmed cell death.</text>
                </example>
                <example src="EGRAM" no="4">
                    <text>A0 is characterized by a greater proliferating ability or a reduced ability to suffer programmed cell death.</text>
                </example>
                <example src="EGRAM" no="5">
                    <text>A0 is proliferate by a higher capacity for strong proliferation or decreased capacity to suffer scheduled cell death.</text>
                </example>
                <example src="EGRAM" no="6">
                    <text>A0 is proliferate by greater proliferation capacity or reduced capacity to suffer scheduled cell death.</text>
                </example>
                <example src="EGRAM" no="7">
                    <text>A0, as our results have shown, has the ability to proliferate and differentiate into mature cells that show a GST expression pattern with enzymatic activities similar to those of the adult liver.</text>
                </example>
                <example src="EGRAM" no="8">
                    <text>A0, as our results have shown, may have proliferated and differentiated into mature cells that show a GST expression pattern with enzymatic activities similar to those of the adult liver.</text>
                </example>
                <example src="EGRAM" no="9">
                    <text>A0, as our results have shown, will proliferate and differentiate into mature cells that show a GST expression pattern with enzymatic activities similar to those of the adult liver.</text>
                </example>
                <example src="EGRAM" no="10">
                    <text>A0, which is unique to adults, has the ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>Adult T cells at rest, under normal conditions, have proliferated when transferred to lymphocytic hosts.</text>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>Adult T cells at rest, under normal conditions, may have A1 proliferation (proliferated to lymph node hosts).</text>
                </example>
                <example src="EGRAM" no="13">
                    <text>Adult T cells at rest, under normal conditions, may proliferate strongly when transferred to lymphocytic hosts.</text>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>Adult T cells at rest, under normal conditions, may proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>Adult T cells at rest, under normal conditions, may proliferated a sharp proliferation of transferred to lymph nodes.</text>
                    <arg n="1">transferred to lymph nodes</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>Adult T cells, at rest under normal conditions, have the ability to proliferate strongly when transferred to lymph nodes.</text>
                    <arg n="1">when transferred to lymph nodes</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>Adult T cells, at rest, under normal conditions, proliferate strongly a1 (when transferred to lymphocytic hosts).</text>
                </example>
                <example src="EGRAM" no="18">
                    <text>Adult T cells, at rest, under normal conditions, proliferate strongly when transferred to lymphocytic hosts.</text>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>Adult T cells, which are at rest in normal conditions, are proliferate as proliferative cells transferred to lymphonic hosts.</text>
                    <arg n="1">transferred to lymphonic hosts</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>Adult T cells, which are at rest in normal conditions, have the ability to proliferate strongly when transferred to lymphonic hosts.</text>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>Adult T cells, which are at rest under normal conditions, are proliferate for the proliferation of when transferred to lymphonic hosts.</text>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>Adult T cells, which are at rest under normal conditions, can proliferate when transferred to lymphonic hosts.</text>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>Adult T cells, which are at rest under normal conditions, can strongly proliferate when transferred to lymphonic hosts.</text>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>Adult T cells, which are at rest under normal conditions, have acute A1 proliferation (when proliferated to lymphonic hosts).</text>
                </example>
                <example src="EGRAM" no="25">
                    <text>Adult T cells, which are at rest under normal conditions, have proliferated when transferred to lymphonic hosts.</text>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="EGRAM" no="26">
                    <text>Adult T cells, which are at rest under normal conditions, have strongly proliferated when transferred to lymphonic hosts.</text>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="EGRAM" no="27">
                    <text>Adult T cells, which are at rest under normal conditions, may have acute A1 proliferation (when proliferated to lymphonic hosts).</text>
                </example>
                <example src="EGRAM" no="28">
                    <text>Adult T cells, which are at rest under normal conditions, may have proliferated when transferred to lymphonic hosts.</text>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="EGRAM" no="29">
                    <text>Adult T cells, which are at rest under normal conditions, may have strongly proliferated when transferred to lymphonic hosts.</text>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="EGRAM" no="30">
                    <text>Adult T cells, which are at rest under normal conditions, proliferate strongly a1 (when transferred to lymphonic hosts).</text>
                </example>
                <example src="EGRAM" no="31">
                    <text>Adult T cells, which are at rest under normal conditions, proliferate strongly when transferred to lymphonic hosts.</text>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="EGRAM" no="32">
                    <text>After androgen withdrawal and angiogen treatment, allergen prostate cancer cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="33">
                    <text>After androgen withdrawal and angiogen treatment, androgen cancer cells responded to prostate disease, ceased proliferation and were submitted to proliferate, resulting in tumor regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="EGRAM" no="34">
                    <text>After androgen withdrawal and angiogen treatment, androgen prostate cancer cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="35">
                    <text>After androgen withdrawal and angiogen treatment, androgen prostate cancer cells is able to stop proliferating and suffering from apoptosis, proliferate tumour regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="36">
                    <text>After androgen withdrawal and angiogen treatment, androgen tumour cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="EGRAM" no="37">
                    <text>After androgen withdrawal and angiogen treatment, angiogen prostate cancer cells has the ability to stop proliferating and suffering apoptosis, proliferate tumor regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="38">
                    <text>After androgen withdrawal and angiogen treatment, cancer cells from the androgen prostate which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="EGRAM" no="39">
                    <text>After androgen withdrawal and angiogen treatment, prostate cancer cells respond to androgen will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="EGRAM" no="40">
                    <text>After androgen withdrawal and angiogen treatment, prostate cancer cells responding to androgen was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="EGRAM" no="41">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen-responsive prostate cancer cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="42">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen-responsive prostate cancer cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="43">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen-responsive prostate cancer cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="44">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen-responsive prostate cancer cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="45">
                    <text>After androgen withdrawal and anti-androgen treatment, androgenic responsive prostate cancer cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="46">
                    <text>After androgen withdrawal and anti-androgen treatment, prostate cancer cells responding to androgen ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="EGRAM" no="47">
                    <text>After androgen withdrawal and anti-androgen treatment, prostate cancer cells responding to androgen ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="EGRAM" no="48">
                    <text>After androgen withdrawal and anti-androgen treatment, prostate cancer cells responding to androgen is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="EGRAM" no="49">
                    <text>After androgen withdrawal and anti-androgen treatment, prostate cancer cells responding to androgen will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="EGRAM" no="50">
                    <text>After androgen withdrawal and antiandrogen treatment, androgen-responsive prostate cancer cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="51">
                    <text>After androgen withdrawal and antiandrogen treatment, androgen-responsive prostate cancer cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="52">
                    <text>After androgen withdrawal and antiandrogen treatment, prostate cancer cells responding to androgen ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="EGRAM" no="53">
                    <text>After androgens have been removed and anti-androgen treatment, androgen-responsive prostate cancer cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="54">
                    <text>After androgens have been removed and anti-androgen treatment, androgenic responsive prostate cancer cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="55">
                    <text>After the androgen has been withdrawn and angiogen treatment, cancer cells of the androgen prostate that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="EGRAM" no="56">
                    <text>After the androgen has been withdrawn and angiogen treatment, cancer cells of the androgen prostate which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="EGRAM" no="57">
                    <text>After the androgen has been withdrawn and angiogen treatment, cancer cells of the androgen prostate which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="EGRAM" no="58">
                    <text>After the androgen has been withdrawn and angiogen treatment, cancer cells of the androgen prostate which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="EGRAM" no="59">
                    <text>After the androgen has been withdrawn and angiogen treatment, prostate cancer cells responding to androgen will proliferate tumor regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="EGRAM" no="60">
                    <text>After the androgens have been removed and the treatment of anthandrogen, prostate cancer cells (androgen response) that are able to halt proliferation and suffer apoptosis will proliferate tumor regression.</text>
                </example>
                <example src="EGRAM" no="61">
                    <text>After the androgens have been removed and the treatment of anthandrogen, the prostate cancer cells (androgen response) that are observed stop proliferate and suffer from apoptosis will proliferate tumor regression.</text>
                </example>
                <example src="EGRAM" no="62">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, androgen-resistant cancer cells can stop proliferating and undergo apoptosis, proliferate tumor regression.</text>
                </example>
                <example src="EGRAM" no="63">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, carcinogenic cells of the prostate that respond to the androgen stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="EGRAM" no="64">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, it is observed that androgens responsive prostate cancer cells stop proliferating and undergo apoptosis will proliferate tumor regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="65">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, the androgen-resistant cancer cells ceased to proliferate and suffered apoptosis, causing tumor regression.</text>
                </example>
                <example src="EGRAM" no="66">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, the androgen-resistant cancer cells with the ability to halt proliferation and suffer apoptosis will proliferate tumor regression.</text>
                </example>
                <example src="EGRAM" no="67">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, the cancerous prostate cells resistant to androgen ceased proliferation and subjected to proliferate caused tumor regression.</text>
                </example>
                <example src="EGRAM" no="68">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, the cancerous prostate cells that are resistant to androgen can stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                </example>
                <example src="EGRAM" no="69">
                    <text>Cancer cells are proliferate by a higher capacity for strong proliferation or a decrease in the capacity to suffer scheduled cell death.</text>
                </example>
                <example src="EGRAM" no="70">
                    <text>Cancer cells are proliferate by a higher proliferation capacity or a lower capacity to suffer scheduled cell death.</text>
                </example>
                <example src="EGRAM" no="71">
                    <text>Cancer cells are proliferating by a greater capacity for strong proliferation or a decrease in the ability to suffer programmed cell death.</text>
                </example>
                <example src="EGRAM" no="72">
                    <text>Cancer cells are proliferating by a higher capacity for strong proliferation or by a decrease in the capacity to suffer scheduled cell death.</text>
                </example>
                <example src="EGRAM" no="73">
                    <text>Cancer cells are proliferating by increased proliferation capacity or decreased ability to suffer programmed cell death.</text>
                </example>
                <example src="EGRAM" no="74">
                    <text>Cancer cells are proliferating by increased proliferation capacity or decreased capacity to suffer scheduled cell death.</text>
                </example>
                <example src="EGRAM" no="75">
                    <text>Cancer cells are thought to be characterized by a greater ability to proliferate or a lesser ability to suffer programmed cell death.</text>
                </example>
                <example src="EGRAM" no="76">
                    <text>Cancer cells are thought to be characterized by a greater ability to proliferate strongly or a decrease in the ability to suffer programmed cell death.</text>
                </example>
                <example src="EGRAM" no="77">
                    <text>Cancer cells can be characterized by a greater ability to proliferate strongly or a lower ability to undergo programmed cell death.</text>
                </example>
                <example src="EGRAM" no="78">
                    <text>Cancer cells can be characterized by greater ability to proliferate strongly or less ability to suffer programmed cell death.</text>
                </example>
                <example src="EGRAM" no="79">
                    <text>Cancer cells can be proliferate by greater proliferation or less programmed cell death.</text>
                </example>
                <example src="EGRAM" no="80">
                    <text>Cancer cells may be proliferate by a higher capacity for strong proliferation or a lower capacity for programmed cell death.</text>
                </example>
                <example src="EGRAM" no="81">
                    <text>Cancer cells may be proliferate by higher capacity for strong proliferation or lower capacity to suffer scheduled cell death.</text>
                </example>
                <example src="EGRAM" no="82">
                    <text>Cancer cells may be proliferate by increased proliferation or scheduled cell death.</text>
                </example>
                <example src="EGRAM" no="83">
                    <text>Fetal cells transplanted intrasplenicly, as our results, are able to proliferate and differentiate into mature cells that have GST expression patterns with enzymatic activities similar to those of the adult liver.</text>
                </example>
                <example src="EGRAM" no="84">
                    <text>HSC continued to proliferate in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="85">
                    <text>HSC continued to proliferate in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="86">
                    <text>HSC continued to proliferate strongly in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="87">
                    <text>HSC continued to proliferate strongly in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="88">
                    <text>HSC has the ability to continue to proliferate in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="89">
                    <text>HSC has the ability to continue to proliferate in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="90">
                    <text>HSC has the ability to continue to proliferate strongly in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="91">
                    <text>HSC has the ability to continue to proliferate strongly in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="92">
                    <text>HSC is a disease that proliferate with great proliferation in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tends to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="93">
                    <text>HSC is able to continue to proliferate in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="94">
                    <text>HSC is able to continue to proliferate in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="95">
                    <text>HSC is able to continue to proliferate strongly in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="96">
                    <text>HSC is able to continue to proliferate strongly in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="EGRAM" no="97">
                    <text>HSC is likely to continue to proliferate in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="98">
                    <text>HSC is likely to continue to proliferate in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="99">
                    <text>HSC is likely to continue to proliferate strongly in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="100">
                    <text>HSC is likely to continue to proliferate strongly in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="101">
                    <text>HSC is observed to continue to proliferate in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="102">
                    <text>HSC may continue to proliferate in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in phase G0/ G1.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="103">
                    <text>HSC may continue to proliferate in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="104">
                    <text>HSC may continue to proliferate strongly in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="105">
                    <text>HSC may continue to proliferate strongly in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="106">
                    <text>HSC may have continued to proliferate in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="107">
                    <text>HSC may have continued to proliferate in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="EGRAM" no="108">
                    <text>HSC may have continued to proliferate strongly in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="109">
                    <text>HSC may have continued to proliferate strongly in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="EGRAM" no="110">
                    <text>HSC will continue to proliferate in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in phase G0/ G1.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="111">
                    <text>HSC will continue to proliferate in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="112">
                    <text>HSC will continue to proliferate strongly in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="113">
                    <text>HSC will continue to proliferate strongly in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="114">
                    <text>In addition, A0 is able to proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="115">
                    <text>In addition, CCD4+ HIV-specific T cells of viremic patients has been found to proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="116">
                    <text>In addition, CCD4+ HIV-specific T cells of viremic patients has been found to proliferate strongly in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="117">
                    <text>In addition, HD CD4+ T cells specific for HIV in viremic patients is able to proliferate in response to HIV antigens when costimulation was provided by anti-CD28 antibodies in vitro.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="118">
                    <text>In addition, HD CD4+ T cells specific for HIV in viremic patients may be observed to proliferate in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="119">
                    <text>In addition, HD CD4+ T cells specific to HIV in viremics patients is able to proliferate in response to HIV A1 antigens (when costimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="120">
                    <text>In addition, HD-specific T CD4+ cells for HIV in viremic patients was observed to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="121">
                    <text>In addition, HDCD4+ T cells specific to HIV in viremics patients proliferated in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="122">
                    <text>In addition, HIV-specific A0, CD4+T cells from viremic patients were found to proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="123">
                    <text>In addition, HIV-specific CD4+ T cells in viremic patients has been shown to be highly proliferating in response to HIV antigens when costimulation was provided by anti-CD28 antibodies in vitro.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="124">
                    <text>In addition, HIV-specific CD4+ T cells in viremic patients is able to proliferate in response to HIV antigens when costimulation was provided by anti-CD28 antibodies in vitro.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="125">
                    <text>In addition, HIV-specific CD4+ T cells in viremic patients were proliferate to be proliferative in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="126">
                    <text>In addition, HIV-specific T cells CCD4+ in viremic patients was found to proliferate in response to HIV antigens when co-stimulation was provided by anti-CD28 antibodies in vitro.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="127">
                    <text>In addition, HIV-specific T-cells CCD4+ in viraemic patients has been found to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="128">
                    <text>In addition, it can be proliferate that HD CD4+ T cells specific to HIV in viremics patients proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="129">
                    <text>In addition, it could be proliferate that CD4+ HIV T cells proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="130">
                    <text>In addition, it could be shown that CCD4+ HIV-specific cells of viremic patients proliferates in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="131">
                    <text>In addition, it has been proliferate that CD4+ HIV T cells proliferate in response to HIV A1 antigens (when costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="132">
                    <text>In addition, it has been shown that HIV-specific CD4+ T cells in viremic patients proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="133">
                    <text>In addition, it has been shown that HIV-specific CD4+T blood cells in viremic patients are highly proliferating in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="134">
                    <text>In addition, it has been shown that HIV-specific CD4+T blood cells in viremic patients proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="135">
                    <text>In addition, it was observed that A0 cells (CD4+-specific HDD for HIV in viremics patients) proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="136">
                    <text>Intrasplintly transplanted fetal cells, as our results have shown, are able to proliferate and differentiate into mature cells that show a GST expression pattern with enzymatic activities similar to those of the adult liver.</text>
                </example>
                <example src="EGRAM" no="137">
                    <text>It is observed that HSC continues to proliferate in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="EGRAM" no="138">
                    <text>It is observed that HSC continues to proliferate strongly in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in phase G0/G1.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="139">
                    <text>It is observed that Stat5ab-/-peripheral T cells regains the ability to proliferate after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="EGRAM" no="140">
                    <text>It is observed that Stat5ab-/-peripheral T cells regains the ability to proliferate indefinitely after the introduction of wild body stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="EGRAM" no="141">
                    <text>It is proliferate that stat5ab/-peripheral T cells regains the undefined proliferation capability after the introduction of the full wild-length state5a (image 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="EGRAM" no="142">
                    <text>Our observations illustrate that the human placenta can be endowed with biochemical machinery to proliferate along gestation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="EGRAM" no="143">
                    <text>Our observations illustrate that the human placenta can be endowed with biochemical machinery to proliferate indefinitely along gestation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="EGRAM" no="144">
                    <text>Our observations illustrate that the human placenta could have been endowed with biochemical machinery to proliferate indefinitely along gestation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="EGRAM" no="145">
                    <text>Our observations illustrate that the human placenta has been endowed with biochemical machinery to proliferate indefinitely along gestation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="EGRAM" no="146">
                    <text>Our observations illustrate that the human placenta is endowed with biochemical machinery to proliferate indefinitely along gestation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="EGRAM" no="147">
                    <text>Our observations illustrate that the human placenta was endowed with biochemical machinery to proliferate along gestation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="EGRAM" no="148">
                    <text>Our observations illustrate that the human placenta was endowed with biochemical machinery to proliferate indefinitely along gestation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="EGRAM" no="149">
                    <text>Our observations illustrate that the human placenta will be endowed with biochemical machinery to proliferate indefinitely along gestation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="EGRAM" no="150">
                    <text>Our results illustrate that human placenta can be equipped with a biochemical machine to proliferate definitely during pregnancy, but there are intrinsic mechanisms that effectively circumvent the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="EGRAM" no="151">
                    <text>Our results illustrate that human placenta has the ability to be equipped with a biochemical machine to proliferate during pregnancy, but there are intrinsic mechanisms that actually circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="EGRAM" no="152">
                    <text>Our results illustrate that human placenta has the ability to be equipped with a biochemical machine to proliferate during pregnancy, but there are intrinsic mechanisms that really circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="EGRAM" no="153">
                    <text>Our results illustrate that human placenta is able to be equipped with a biochemical machine to proliferate during pregnancy, but there are intrinsic mechanisms that really circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="EGRAM" no="154">
                    <text>Our results illustrate that human placenta is able to be equipped with biochemical machines to proliferate pregnancy, however, there are intrinsic mechanisms that effectively circumvent the extent and duration of troblast proliferation.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="EGRAM" no="155">
                    <text>Our results illustrate that human placenta is equipped with a biochemical machine to proliferate during pregnancy, however, there are intrinsic mechanisms that actually circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="EGRAM" no="156">
                    <text>Our results illustrate that human placenta is equipped with a biochemical machine to proliferate indeterminately during pregnancy, however, there are intrinsic mechanisms that effectively circumvent the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="EGRAM" no="157">
                    <text>Our results illustrate that human placenta is shown to be equipped with a biochemical machine to proliferate during pregnancy, however, there are intrinsic mechanisms that really circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="EGRAM" no="158">
                    <text>Our results illustrate that human placenta may be equipped with a biochemical machine to proliferate during pregnancy, but there are intrinsic mechanisms that actually circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="EGRAM" no="159">
                    <text>Our results illustrate that human placenta may have been equipped with a biochemical machine to proliferate definitely during pregnancy, but there are intrinsic mechanisms that effectively circumvent the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="EGRAM" no="160">
                    <text>Our results illustrate that human placenta might have been equipped with a biochemical machine to proliferate during pregnancy, but there are intrinsic mechanisms that actually circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="EGRAM" no="161">
                    <text>Our results illustrate that human placenta was equipped with a biochemical machine to proliferate during pregnancy, however, there are intrinsic mechanisms that actually circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="EGRAM" no="162">
                    <text>Our results illustrate that human placenta was equipped with a biochemical machine to proliferate indeterminately during pregnancy, however, there are intrinsic mechanisms that actually circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="EGRAM" no="163">
                    <text>Our results illustrate that human placenta will be equipped with a biochemical machine to proliferate definitely during pregnancy, however, there are intrinsic mechanisms that effectively circumvent the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="EGRAM" no="164">
                    <text>Our results illustrate that human placenta will be equipped with a biochemical machine to proliferate during pregnancy, but there are intrinsic mechanisms that actually circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="EGRAM" no="165">
                    <text>Our results illustrate that human placenta will be equipped with a biochemical machine to proliferate during pregnancy, but there are intrinsic mechanisms that really circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="EGRAM" no="166">
                    <text>Our results illustrate that the human placenta could have been equipped with biochemical machines to proliferate through pregnancy, but there are intrinsic mechanisms that really circumscribe the extent and duration of troblast proliferation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="EGRAM" no="167">
                    <text>Our results illustrate that the human placenta has been equipped with a biochemical machine to proliferate during pregnancy, but there are intrinsic mechanisms that actually circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="EGRAM" no="168">
                    <text>Our results illustrate that the human placenta has been equipped with a biochemical machine to proliferate during pregnancy, but there are intrinsic mechanisms that really circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="EGRAM" no="169">
                    <text>Our results illustrate that the human placenta has the ability to be equipped with a biochemical machine to proliferate definitely during pregnancy, but there are intrinsic mechanisms that actually circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="EGRAM" no="170">
                    <text>Our results illustrate that the human placenta has the ability to be equipped with a biochemical machine to proliferate definitively during pregnancy, but there are intrinsic mechanisms that actually circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="EGRAM" no="171">
                    <text>Our results illustrate that the human placenta is able to be equipped with a biochemical machine to proliferate definitely during pregnancy, however, there are intrinsic mechanisms that effectively circumvent the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="EGRAM" no="172">
                    <text>Our results illustrate that the human placenta is able to be equipped with biochemical machines to proliferate definitely during pregnancy, however, there are intrinsic mechanisms that effectively circumvent the extent and duration of troblast proliferation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="EGRAM" no="173">
                    <text>Our results illustrate that the human placenta was equipped with a biochemical machine to proliferate definitively during pregnancy, however, there are intrinsic mechanisms that actually circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="EGRAM" no="174">
                    <text>Stat5ab-/-peripheral T cells can regain the ability to proliferate after the introduction of Stat5a of full-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="EGRAM" no="175">
                    <text>Stat5ab-/-peripheral T cells can regain the ability to proliferate indefinitely after the introduction of Stat5a of full-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="EGRAM" no="176">
                    <text>Stat5ab-/-peripheral T cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="EGRAM" no="177">
                    <text>Stat5ab-/-peripheral T cells has regained the ability to proliferate after the introduction of Stat5a of full-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="EGRAM" no="178">
                    <text>Stat5ab-/-peripheral T cells has the probability of recovering the ability to proliferate after the introduction of Stat5a of full-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="EGRAM" no="179">
                    <text>Stat5ab-/-peripheral T cells has the probability of recovering the ability to proliferate indefinitely after the introduction of Stat5a of full-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="EGRAM" no="180">
                    <text>Stat5ab-/-peripheral T cells may have regained the ability to proliferate after the introduction of Stat5a of full-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="EGRAM" no="181">
                    <text>Stat5ab-/-peripheral T cells may have regained the ability to proliferate indefinitely after the introduction of the full-length wild type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="EGRAM" no="182">
                    <text>Stat5ab-/-peripheral T cells regained the ability to proliferate indefinitely after the introduction of the full-length wild type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="EGRAM" no="183">
                    <text>Stat5ab-/-peripheral T cells will regain the ability to proliferate after the introduction of Stat5a of full-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="EGRAM" no="184">
                    <text>Stat5ab-/-peripheral T cells will regain the ability to proliferate indefinitely after the introduction of the Stat5a type of complete wild size (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="EGRAM" no="185">
                    <text>T A0 cells are able to proliferate the undefined proliferation capacity after the introduction of Stat5a wild body estuation (picture 6B).</text>
                    <arg n="1">after the introduction of Stat5a wild body estuation</arg>
                </example>
                <example src="EGRAM" no="186">
                    <text>T cells Stat5ab/-peripheral are able to recover the ability to proliferate after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="EGRAM" no="187">
                    <text>The A0 capacity (BT cells) that may have proliferated in vivo was examined by injection of 3? 106 LVTE cells into the muscle of the calf of 3 immunocompromised mice.</text>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="188">
                    <text>The A0 capacity (BT cells) that showed a great A2 proliferation (in vivo) was proliferated by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                </example>
                <example src="EGRAM" no="189">
                    <text>The BT cells capacity that can proliferate in vivo was examined by injection of 3? 106 LVTE cells into the muscle of the calf of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="190">
                    <text>The BT cells capacity that proliferated in vivo was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="191">
                    <text>The BT cells capacity that will proliferate strongly in vivo has been examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="192">
                    <text>The Stat5ab/-peripheral T cells regained the ability to proliferate the after the introduction of the Stat5a complete-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="EGRAM" no="193">
                    <text>The TBI cells proliferating A2 capacity (in vivo) was proliferating by injection of 3? 106 CVC cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="EGRAM" no="194">
                    <text>The ability of A0 cells (BT) observed to proliferate strongly in vivo was examined by injection of 3? 106 LVTE cells into the muscle of the calf of 3 immunocompromised mice.</text>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="195">
                    <text>The ability of A0 cells (BT) to have the ability to proliferate strongly in vivo was examined by injection of 3? 106 CVC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="196">
                    <text>The ability of A0 cells (BT) to proliferate in vivo was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="197">
                    <text>The ability of A0 cells (BT) to proliferate strongly in vivo was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="198">
                    <text>The ability of A0 cells (BT) to proliferated strongly in vivo was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="199">
                    <text>The ability of A0 cells (EBD) proliferating to in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="200">
                    <text>The ability of A0 cells (EBD) that have the ability to proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="201">
                    <text>The ability of A0 cells (EBD) that have the ability to proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="202">
                    <text>The ability of A0 cells (EBD) to proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="203">
                    <text>The ability of BI cells to proliferated in vivo was examined by injection of 3? 106 LVTE into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="204">
                    <text>The ability of BT cells that can proliferate strongly in vivo was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="205">
                    <text>The ability of BT cells that is able to proliferate strongly in vivo was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="206">
                    <text>The ability of BT cells that was observed to proliferate strongly in vivo was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="207">
                    <text>The ability of EBD cells that can proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="208">
                    <text>The ability of EBD cells that can strongly proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="209">
                    <text>The ability of EBD cells that have proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="210">
                    <text>The ability of EBD cells that have strongly proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="211">
                    <text>The ability of EBD cells that have the ability to proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="212">
                    <text>The ability of EBD cells that is capable of proliferating in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="213">
                    <text>The ability of EBD cells that is capable of strongly proliferating in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="214">
                    <text>The ability of EBD cells that may have proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="215">
                    <text>The ability of EBD cells that may have strongly proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="216">
                    <text>The ability of EBD cells that proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="217">
                    <text>The ability of EBD cells to proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="218">
                    <text>The ability of EBD cells to proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="219">
                    <text>The ability of EBD cells to strongly proliferate in vivo was proliferate by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="220">
                    <text>The ability to proliferate in vivo has been examined by injection of 3? 106 LVTE cells into the veil muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="221">
                    <text>The ability to proliferate in vivo was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="222">
                    <text>The ability to proliferate strongly in vivo was examined by injection of 3? 106 CVC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="223">
                    <text>The capacity of BT cells that may have proliferated strongly in vivo was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="224">
                    <text>The capacity of EBD cells proliferating in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="225">
                    <text>The treatment of endothelial cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="226">
                    <text>The treatment of endothelial cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="EGRAM" no="227">
                    <text>The treatment of endothelial cells of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="228">
                    <text>The treatment of endothelial cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="229">
                    <text>The treatment of endothelial cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="230">
                    <text>These results show that A0 has proliferated and differentiated in mature cells showing a TGS expression pattern with respective enzymatic activities similar to the adult liver.</text>
                </example>
                <example src="EGRAM" no="231">
                    <text>These results show that A0 has proliferated and differentiated into mature cells showing a GST expression pattern with respective enzymatic activities similar to the adult liver.</text>
                </example>
                <example src="EGRAM" no="232">
                    <text>These results show that feet cells transplanted intrasplentically proliferate and proliferate into mature cells that show a GST expression pattern with enzymatic activities similar to those of the adult liver.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="EGRAM" no="233">
                    <text>These results show that fetal liver cells transplanted intrasplenically has the ability to proliferate and differentiate into mature cells with GST expression patterns with enzymatic activities similar to the adult liver.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="EGRAM" no="234">
                    <text>These results show that fetal liver cells transplanted intrasplenically is able to proliferate and differentiate into mature cells with GST expression patterns with enzymatic activities similar to the adult liver.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="EGRAM" no="235">
                    <text>These results show that fetal liver cells transplanted intrasplenically will proliferate and differentiate into mature cells with GST expression patterns with enzymatic activities similar to the adult liver.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="EGRAM" no="236">
                    <text>These results show that intra-splenic transplant fetal cells progresses and proliferated into mature cells that have GST expression patterns with respective enzymatic activities similar to the adult liver.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="EGRAM" no="237">
                    <text>These results show that intrasplens transplanted liver cells may have proliferated and differentiated into mature cells with GST expression patterns with enzymatic activities similar to the adult liver.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="EGRAM" no="238">
                    <text>These results show that intrasplensally transplanted fetal cells may have proliferated and differentiated into mature cells that show a GST expression pattern with respective enzymatic activities similar to the adult liver.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="EGRAM" no="239">
                    <text>These results show that intrasplintly transplanted fetal cells proliferates and proliferated into mature cells that show a GST expression pattern with respective enzymatic activities similar to the adult liver.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="EGRAM" no="240">
                    <text>These results show that intrasponntically transplanted fetal cells will proliferate and differentiate into mature cells that show a GST expression pattern with respective enzymatic activities similar to the adult liver.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="EGRAM" no="241">
                    <text>These results show that intraspontically transplanted fetal cells are able to proliferate and differentiate into mature cells that show a GST expression pattern with respective enzymatic activities similar to the adult liver.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="EGRAM" no="242">
                    <text>These results show that intraspontically transplanted fetal cells have the ability to proliferate and differentiate into mature cells that show a GST expression pattern with respective enzymatic activities similar to the adult liver.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="EGRAM" no="243">
                    <text>These results show that transplant feet cells intrasplenomegaly proliferates and proliferate into mature cells that have GST expression patterns with enzymatic activities similar to those of the adult liver.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="EGRAM" no="244">
                    <text>Treatment of endothelial cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="EGRAM" no="245">
                    <text>Treatment of endothelial cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="EGRAM" no="246">
                    <text>Treatment of endothelial cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="EGRAM" no="247">
                    <text>Treatment of endothelial cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="248">
                    <text>Treatment of endothelial cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="249">
                    <text>Treatment of endothelial cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="250">
                    <text>Treatment of endothelial cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="EGRAM" no="251">
                    <text>Treatment of endothelial cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="252">
                    <text>Treatment of endothelial cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="253">
                    <text>Treatment of endothelial cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="254">
                    <text>Treatment of endothelial cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="255">
                    <text>Treatment of endothelial cells of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="256">
                    <text>Treatment of endothelial cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="EGRAM" no="257">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="EGRAM" no="258">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="EGRAM" no="259">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="EGRAM" no="260">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl, significant impairment of its proliferation capacity A1 (proliferate to FGF2</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="EGRAM" no="261">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="EGRAM" no="262">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="EGRAM" no="263">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="EGRAM" no="264">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="EGRAM" no="265">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="EGRAM" no="266">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="EGRAM" no="267">
                    <text>adult T cells, which are at rest in normal conditions, are observed to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="EGRAM" no="268">
                    <text>adult T cells, which are at rest in normal conditions, have the ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="EGRAM" no="269">
                    <text>adult T cells, which are at rest under normal conditions, are able to proliferate strongly when transferred to lymphonic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="EGRAM" no="270">
                    <text>adult T cells, which are at rest under normal conditions, are observed to strongly proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="EGRAM" no="271">
                    <text>adult T cells, which are at rest under normal conditions, can proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="EGRAM" no="272">
                    <text>adult T cells, which proliferated at rest under normal conditions, proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="EGRAM" no="273">
                    <text>adult naive T cells, which are at rest under normal conditions, are able to proliferate strongly when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="274">
                    <text>adult naive T cells, which are at rest under normal conditions, are able to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="275">
                    <text>adult naive T cells, which are at rest under normal conditions, will proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="276">
                    <text>cancer cells has been characterized by a greater ability to proliferate strongly or a decrease in the ability to undergo programmed cell death.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="EGRAM" no="277">
                    <text>cancer cells has been proliferate by a higher proliferation capacity or a decrease in the scheduled cell death capacity.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="EGRAM" no="278">
                    <text>cancer cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="EGRAM" no="279">
                    <text>cancer cells is proliferating by a greater capacity for strong proliferation or a decrease in the ability to suffer programmed cell death.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="EGRAM" no="280">
                    <text>cancer cells is proliferating by increased proliferation or decreased ability to suffer programmed cell death.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="EGRAM" no="281">
                    <text>cancer cells is proliferating by increased proliferation or decreased capacity to suffer scheduled cell death.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="EGRAM" no="282">
                    <text>feet cells transplanted intra-splintly, as our results have shown, proliferate and proliferated into mature cells that show a GST expression pattern with respective enzymatic activities similar to the adult liver.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="EGRAM" no="283">
                    <text>feet cells transplanted intrasplenically, as our results have shown, are observed to proliferate and differentiate into mature cells that show a GST expression pattern with respective enzymatic activities similar to the adult liver.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="EGRAM" no="284">
                    <text>fetal liver cells transplanted intrasplenically, as our results, has the ability to proliferate and differentiate into mature cells, presenting a GST expression pattern with their respective enzymatic activities similar to the adult liver.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="EGRAM" no="285">
                    <text>fetal liver cells transplanted intrasplenically, as our results, proliferate and proliferated into mature cells with GST expression patterns with enzymatic activities similar to the adult liver.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="EGRAM" no="286">
                    <text>fetal liver cells transplanted intrasplenically, as our results, will proliferate and differentiate into mature cells with GST expression patterns with enzymatic activities similar to the adult liver.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="EGRAM" no="287">
                    <text>ingenue T cells for adults, which proliferated at rest under normal conditions, strongly proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="EGRAM" no="288">
                    <text>ingenue T cells of adults, which are at rest in normal conditions, will proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="EGRAM" no="289">
                    <text>ingenue T cells of adults, which are at rest under normal conditions, are able to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="EGRAM" no="290">
                    <text>ingenue T cells of adults, which are at rest under normal conditions, can proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="EGRAM" no="291">
                    <text>ingenue T cells of adults, which proliferated at rest in normal conditions, strongly proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="EGRAM" no="292">
                    <text>ingenue T cells of adults, which proliferated at rest under normal conditions, proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="EGRAM" no="293">
                    <text>intra-splate transplant feet cells, as our results show, proliferate and proliferated into mature cells that have a GST expression pattern with respective enzymatic activities similar to the adult liver.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="EGRAM" no="294">
                    <text>intra-splintly transplanted fetal shapes, as our results have shown, has proliferated and differentiated into mature cells that show a GST expression pattern with respective enzymatic activities similar to the adult liver.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="EGRAM" no="295">
                    <text>intrasplens transplanted liver cells, as our results, are proliferate for proliferation and differentiation into mature cells, presenting a GST expression pattern with their respective enzymatic activities similar to the adult liver.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="EGRAM" no="296">
                    <text>intrasplensally transplanted liver cells, as a result, may have proliferated and differentiated into mature cells with GST expression patterns with enzymatic activities similar to the adult liver.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="EGRAM" no="297">
                    <text>stat5ab-/-peripheral T cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="EGRAM" no="298">
                    <text>stat5ab-/-peripheral T cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="EGRAM" no="299">
                    <text>stat5ab-/-peripheral T cells may proliferate recovered the undefined proliferation capacity after the introduction of the full wild-length Stat5a type (picture 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="EGRAM" no="300">
                    <text>stat5ab-/-peripheral T cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="EGRAM" no="301">
                    <text>stat5ab-/-peripheral T cells may proliferate the undefined proliferation capacity after the introduction of the full wild-length Stat5a (picture 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="EGRAM" no="302">
                    <text>stat5ab-/-peripheral T cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="EGRAM" no="303">
                    <text>stat5ab-/-peripheral T cells proliferate the undefined proliferation capacity after the introduction of the full wild-length Stat5a type (picture 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="EGRAM" no="304">
                    <text>stat5ab/-peripheral T cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="EGRAM" no="305">
                    <text>stat5ab/-peripheral T cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="EGRAM" no="306">
                    <text>stat5ab/peripheral T cells is likely to proliferate the undefined proliferation capacity after the introduction of the full wild-length Stat5a (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="EGRAM" no="307">
                    <text>stat5ab/peripheral T cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="EGRAM" no="308">
                    <text>stat5ab/peripheral T cells recovered the ability to proliferate after the introduction of the completely length wild-type Stat5a (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="EGRAM" no="309">
                    <text>stat5ab/peripheral T cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="EGRAM" no="310">
                    <text>stat5ab/peripheral T cells will proliferate the undefined proliferation capability after the introduction of the full wild-length state5a (image 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>A0 T cells are able to recover the ability to proliferate indefinitely after the introduction of Stat5a wild body estuation (Figure 6B).</text>
                    <arg n="1">after the introduction of Stat5a wild body estuation</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>A0 T cells are able to recover the ability to proliferate indefinitely transferred to lymph nodes (Figure 6B).</text>
                    <arg n="1">transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>A0 T cells are able to recover the ability to proliferate indefinitely transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="1">transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>A0 T cells are able to recover the ability to proliferate indefinitely when transferred to lymph nodes (Figure 6B).</text>
                    <arg n="1">when transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>A0 T cells are able to recover the ability to proliferate indefinitely when transferred to lymphocytic hosts (Figure 6B).</text>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>A0 T cells are able to recover the ability to proliferate indefinitely when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>A0, which is unique to adults, has the ability to proliferate after the introduction of Stat5a wild body estuation.</text>
                    <arg n="1">after the introduction of Stat5a wild body estuation</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>A0, which is unique to adults, has the ability to proliferate after the introduction of Stat5a wild body stulation.</text>
                    <arg n="1">after the introduction of Stat5a wild body stulation</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>A0, which is unique to adults, has the ability to proliferate transferred to lymph nodes.</text>
                    <arg n="1">transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>A0, which is unique to adults, has the ability to proliferate transferred to lymphonic hosts.</text>
                    <arg n="1">transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>A0, which is unique to adults, has the ability to proliferate when transferred to lymph nodes.</text>
                    <arg n="1">when transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>A0, which is unique to adults, has the ability to proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>Adult T cells at rest, under normal conditions, have proliferated after the introduction of Stat5a wild body estuation.</text>
                    <arg n="1">after the introduction of Stat5a wild body estuation</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>Adult T cells at rest, under normal conditions, have proliferated after the introduction of Stat5a wild body stulation.</text>
                    <arg n="1">after the introduction of Stat5a wild body stulation</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>Adult T cells at rest, under normal conditions, have proliferated transferred to lymph nodes.</text>
                    <arg n="1">transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>Adult T cells at rest, under normal conditions, have proliferated transferred to lymphonic hosts.</text>
                    <arg n="1">transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>Adult T cells at rest, under normal conditions, have proliferated when transferred to lymph nodes.</text>
                    <arg n="1">when transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>Adult T cells at rest, under normal conditions, have proliferated when transferred to lymphonic hosts.</text>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>Adult T cells at rest, under normal conditions, may proliferate after the introduction of Stat5a wild body estuation.</text>
                    <arg n="1">after the introduction of Stat5a wild body estuation</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>Adult T cells at rest, under normal conditions, may proliferate after the introduction of Stat5a wild body stulation.</text>
                    <arg n="1">after the introduction of Stat5a wild body stulation</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>Adult T cells at rest, under normal conditions, may proliferate strongly after the introduction of Stat5a wild body estuation.</text>
                    <arg n="1">after the introduction of Stat5a wild body estuation</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>Adult T cells at rest, under normal conditions, may proliferate strongly after the introduction of Stat5a wild body stulation.</text>
                    <arg n="1">after the introduction of Stat5a wild body stulation</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>Adult T cells at rest, under normal conditions, may proliferate strongly transferred to lymph nodes.</text>
                    <arg n="1">transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>Adult T cells at rest, under normal conditions, may proliferate strongly transferred to lymphonic hosts.</text>
                    <arg n="1">transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>Adult T cells at rest, under normal conditions, may proliferate strongly when transferred to lymph nodes.</text>
                    <arg n="1">when transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>Adult T cells at rest, under normal conditions, may proliferate strongly when transferred to lymphonic hosts.</text>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>Adult T cells at rest, under normal conditions, may proliferate transferred to lymph nodes.</text>
                    <arg n="1">transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>Adult T cells at rest, under normal conditions, may proliferate transferred to lymphonic hosts.</text>
                    <arg n="1">transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>Adult T cells at rest, under normal conditions, may proliferate when transferred to lymph nodes.</text>
                    <arg n="1">when transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>Adult T cells at rest, under normal conditions, may proliferate when transferred to lymphonic hosts.</text>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>Adult T cells at rest, under normal conditions, may proliferated a sharp proliferation of after the introduction of Stat5a wild body estuation.</text>
                    <arg n="1">after the introduction of Stat5a wild body estuation</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>Adult T cells at rest, under normal conditions, may proliferated a sharp proliferation of after the introduction of Stat5a wild body stulation.</text>
                    <arg n="1">after the introduction of Stat5a wild body stulation</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>Adult T cells at rest, under normal conditions, may proliferated a sharp proliferation of transferred to lymphonic hosts.</text>
                    <arg n="1">transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>Adult T cells at rest, under normal conditions, may proliferated a sharp proliferation of when transferred to lymph nodes.</text>
                    <arg n="1">when transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>Adult T cells at rest, under normal conditions, may proliferated a sharp proliferation of when transferred to lymphocytic hosts.</text>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>Adult T cells at rest, under normal conditions, may proliferated a sharp proliferation of when transferred to lymphonic hosts.</text>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>Adult T cells, at rest under normal conditions, have the ability to proliferate strongly after the introduction of Stat5a wild body estuation.</text>
                    <arg n="1">after the introduction of Stat5a wild body estuation</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>Adult T cells, at rest under normal conditions, have the ability to proliferate strongly after the introduction of Stat5a wild body stulation.</text>
                    <arg n="1">after the introduction of Stat5a wild body stulation</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>Adult T cells, at rest under normal conditions, have the ability to proliferate strongly transferred to lymph nodes.</text>
                    <arg n="1">transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>Adult T cells, at rest under normal conditions, have the ability to proliferate strongly transferred to lymphonic hosts.</text>
                    <arg n="1">transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>Adult T cells, at rest under normal conditions, have the ability to proliferate strongly when transferred to lymphocytic hosts.</text>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>Adult T cells, at rest under normal conditions, have the ability to proliferate strongly when transferred to lymphonic hosts.</text>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>Adult T cells, at rest, under normal conditions, proliferate strongly after the introduction of Stat5a wild body estuation.</text>
                    <arg n="1">after the introduction of Stat5a wild body estuation</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>Adult T cells, at rest, under normal conditions, proliferate strongly after the introduction of Stat5a wild body stulation.</text>
                    <arg n="1">after the introduction of Stat5a wild body stulation</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>Adult T cells, at rest, under normal conditions, proliferate strongly transferred to lymph nodes.</text>
                    <arg n="1">transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>Adult T cells, at rest, under normal conditions, proliferate strongly transferred to lymphonic hosts.</text>
                    <arg n="1">transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>Adult T cells, at rest, under normal conditions, proliferate strongly when transferred to lymph nodes.</text>
                    <arg n="1">when transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>Adult T cells, at rest, under normal conditions, proliferate strongly when transferred to lymphonic hosts.</text>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>Adult T cells, which are at rest in normal conditions, are proliferate as proliferative cells after the introduction of Stat5a wild body estuation.</text>
                    <arg n="1">after the introduction of Stat5a wild body estuation</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>Adult T cells, which are at rest in normal conditions, are proliferate as proliferative cells after the introduction of Stat5a wild body stulation.</text>
                    <arg n="1">after the introduction of Stat5a wild body stulation</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>Adult T cells, which are at rest in normal conditions, are proliferate as proliferative cells transferred to lymph nodes.</text>
                    <arg n="1">transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>Adult T cells, which are at rest in normal conditions, are proliferate as proliferative cells when transferred to lymph nodes.</text>
                    <arg n="1">when transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>Adult T cells, which are at rest in normal conditions, are proliferate as proliferative cells when transferred to lymphocytic hosts.</text>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>Adult T cells, which are at rest in normal conditions, are proliferate as proliferative cells when transferred to lymphonic hosts.</text>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>Adult T cells, which are at rest in normal conditions, have the ability to proliferate strongly after the introduction of Stat5a wild body estuation.</text>
                    <arg n="1">after the introduction of Stat5a wild body estuation</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>Adult T cells, which are at rest in normal conditions, have the ability to proliferate strongly after the introduction of Stat5a wild body stulation.</text>
                    <arg n="1">after the introduction of Stat5a wild body stulation</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>Adult T cells, which are at rest in normal conditions, have the ability to proliferate strongly transferred to lymph nodes.</text>
                    <arg n="1">transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>Adult T cells, which are at rest in normal conditions, have the ability to proliferate strongly transferred to lymphonic hosts.</text>
                    <arg n="1">transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>Adult T cells, which are at rest in normal conditions, have the ability to proliferate strongly when transferred to lymph nodes.</text>
                    <arg n="1">when transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>Adult T cells, which are at rest in normal conditions, have the ability to proliferate strongly when transferred to lymphocytic hosts.</text>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>Adult T cells, which are at rest under normal conditions, are proliferate for the proliferation of after the introduction of Stat5a wild body estuation.</text>
                    <arg n="1">after the introduction of Stat5a wild body estuation</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>Adult T cells, which are at rest under normal conditions, are proliferate for the proliferation of after the introduction of Stat5a wild body stulation.</text>
                    <arg n="1">after the introduction of Stat5a wild body stulation</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>Adult T cells, which are at rest under normal conditions, are proliferate for the proliferation of transferred to lymph nodes.</text>
                    <arg n="1">transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>Adult T cells, which are at rest under normal conditions, are proliferate for the proliferation of transferred to lymphonic hosts.</text>
                    <arg n="1">transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>Adult T cells, which are at rest under normal conditions, are proliferate for the proliferation of when transferred to lymph nodes.</text>
                    <arg n="1">when transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>Adult T cells, which are at rest under normal conditions, are proliferate for the proliferation of when transferred to lymphocytic hosts.</text>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>Adult T cells, which are at rest under normal conditions, can proliferate after the introduction of Stat5a wild body estuation.</text>
                    <arg n="1">after the introduction of Stat5a wild body estuation</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>Adult T cells, which are at rest under normal conditions, can proliferate after the introduction of Stat5a wild body stulation.</text>
                    <arg n="1">after the introduction of Stat5a wild body stulation</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>Adult T cells, which are at rest under normal conditions, can proliferate transferred to lymph nodes.</text>
                    <arg n="1">transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>Adult T cells, which are at rest under normal conditions, can proliferate transferred to lymphonic hosts.</text>
                    <arg n="1">transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>Adult T cells, which are at rest under normal conditions, can proliferate when transferred to lymph nodes.</text>
                    <arg n="1">when transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>Adult T cells, which are at rest under normal conditions, can proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>Adult T cells, which are at rest under normal conditions, can strongly proliferate after the introduction of Stat5a wild body estuation.</text>
                    <arg n="1">after the introduction of Stat5a wild body estuation</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>Adult T cells, which are at rest under normal conditions, can strongly proliferate after the introduction of Stat5a wild body stulation.</text>
                    <arg n="1">after the introduction of Stat5a wild body stulation</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>Adult T cells, which are at rest under normal conditions, can strongly proliferate transferred to lymph nodes.</text>
                    <arg n="1">transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>Adult T cells, which are at rest under normal conditions, can strongly proliferate transferred to lymphonic hosts.</text>
                    <arg n="1">transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>Adult T cells, which are at rest under normal conditions, can strongly proliferate when transferred to lymph nodes.</text>
                    <arg n="1">when transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>Adult T cells, which are at rest under normal conditions, can strongly proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>Adult T cells, which are at rest under normal conditions, have proliferated after the introduction of Stat5a wild body estuation.</text>
                    <arg n="1">after the introduction of Stat5a wild body estuation</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>Adult T cells, which are at rest under normal conditions, have proliferated after the introduction of Stat5a wild body stulation.</text>
                    <arg n="1">after the introduction of Stat5a wild body stulation</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>Adult T cells, which are at rest under normal conditions, have proliferated transferred to lymph nodes.</text>
                    <arg n="1">transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>Adult T cells, which are at rest under normal conditions, have proliferated transferred to lymphonic hosts.</text>
                    <arg n="1">transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>Adult T cells, which are at rest under normal conditions, have proliferated when transferred to lymph nodes.</text>
                    <arg n="1">when transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>Adult T cells, which are at rest under normal conditions, have proliferated when transferred to lymphocytic hosts.</text>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>Adult T cells, which are at rest under normal conditions, have strongly proliferated after the introduction of Stat5a wild body estuation.</text>
                    <arg n="1">after the introduction of Stat5a wild body estuation</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>Adult T cells, which are at rest under normal conditions, have strongly proliferated after the introduction of Stat5a wild body stulation.</text>
                    <arg n="1">after the introduction of Stat5a wild body stulation</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>Adult T cells, which are at rest under normal conditions, have strongly proliferated transferred to lymph nodes.</text>
                    <arg n="1">transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>Adult T cells, which are at rest under normal conditions, have strongly proliferated transferred to lymphonic hosts.</text>
                    <arg n="1">transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>Adult T cells, which are at rest under normal conditions, have strongly proliferated when transferred to lymph nodes.</text>
                    <arg n="1">when transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>Adult T cells, which are at rest under normal conditions, have strongly proliferated when transferred to lymphocytic hosts.</text>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>Adult T cells, which are at rest under normal conditions, may have proliferated after the introduction of Stat5a wild body estuation.</text>
                    <arg n="1">after the introduction of Stat5a wild body estuation</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>Adult T cells, which are at rest under normal conditions, may have proliferated after the introduction of Stat5a wild body stulation.</text>
                    <arg n="1">after the introduction of Stat5a wild body stulation</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>Adult T cells, which are at rest under normal conditions, may have proliferated transferred to lymph nodes.</text>
                    <arg n="1">transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>Adult T cells, which are at rest under normal conditions, may have proliferated transferred to lymphonic hosts.</text>
                    <arg n="1">transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>Adult T cells, which are at rest under normal conditions, may have proliferated when transferred to lymph nodes.</text>
                    <arg n="1">when transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>Adult T cells, which are at rest under normal conditions, may have proliferated when transferred to lymphocytic hosts.</text>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>Adult T cells, which are at rest under normal conditions, may have strongly proliferated after the introduction of Stat5a wild body estuation.</text>
                    <arg n="1">after the introduction of Stat5a wild body estuation</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>Adult T cells, which are at rest under normal conditions, may have strongly proliferated after the introduction of Stat5a wild body stulation.</text>
                    <arg n="1">after the introduction of Stat5a wild body stulation</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>Adult T cells, which are at rest under normal conditions, may have strongly proliferated transferred to lymph nodes.</text>
                    <arg n="1">transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>Adult T cells, which are at rest under normal conditions, may have strongly proliferated transferred to lymphonic hosts.</text>
                    <arg n="1">transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>Adult T cells, which are at rest under normal conditions, may have strongly proliferated when transferred to lymph nodes.</text>
                    <arg n="1">when transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>Adult T cells, which are at rest under normal conditions, may have strongly proliferated when transferred to lymphocytic hosts.</text>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>Adult T cells, which are at rest under normal conditions, proliferate strongly after the introduction of Stat5a wild body estuation.</text>
                    <arg n="1">after the introduction of Stat5a wild body estuation</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>Adult T cells, which are at rest under normal conditions, proliferate strongly after the introduction of Stat5a wild body stulation.</text>
                    <arg n="1">after the introduction of Stat5a wild body stulation</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>Adult T cells, which are at rest under normal conditions, proliferate strongly transferred to lymph nodes.</text>
                    <arg n="1">transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>Adult T cells, which are at rest under normal conditions, proliferate strongly transferred to lymphonic hosts.</text>
                    <arg n="1">transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>Adult T cells, which are at rest under normal conditions, proliferate strongly when transferred to lymph nodes.</text>
                    <arg n="1">when transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>Adult T cells, which are at rest under normal conditions, proliferate strongly when transferred to lymphocytic hosts.</text>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>After androgen withdrawal and angiogen treatment, Stat5ab-/-peripheral T cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>After androgen withdrawal and angiogen treatment, Stat5ab-/-peripheral T cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>After androgen withdrawal and angiogen treatment, Stat5ab-/-peripheral T cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>After androgen withdrawal and angiogen treatment, Stat5ab-/-peripheral T cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>After androgen withdrawal and angiogen treatment, Stat5ab-/-peripheral T cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>After androgen withdrawal and angiogen treatment, Stat5ab-/-peripheral T cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>After androgen withdrawal and angiogen treatment, allergen prostate cancer cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>After androgen withdrawal and angiogen treatment, allergen prostate cancer cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>After androgen withdrawal and angiogen treatment, allergen prostate cancer cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>After androgen withdrawal and angiogen treatment, allergen prostate cancer cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>After androgen withdrawal and angiogen treatment, allergen prostate cancer cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>After androgen withdrawal and angiogen treatment, androgen prostate cancer cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>After androgen withdrawal and angiogen treatment, androgen prostate cancer cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>After androgen withdrawal and angiogen treatment, androgen prostate cancer cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>After androgen withdrawal and angiogen treatment, androgen prostate cancer cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>After androgen withdrawal and angiogen treatment, androgen prostate cancer cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>After androgen withdrawal and angiogen treatment, androgen tumour cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>After androgen withdrawal and angiogen treatment, androgen tumour cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>After androgen withdrawal and angiogen treatment, androgen tumour cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>After androgen withdrawal and angiogen treatment, androgen tumour cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>After androgen withdrawal and angiogen treatment, androgen tumour cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>After androgen withdrawal and angiogen treatment, androgen-responsive prostate cancer cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>After androgen withdrawal and angiogen treatment, androgen-responsive prostate cancer cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>After androgen withdrawal and angiogen treatment, androgen-responsive prostate cancer cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>After androgen withdrawal and angiogen treatment, androgen-responsive prostate cancer cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>After androgen withdrawal and angiogen treatment, androgen-responsive prostate cancer cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>After androgen withdrawal and angiogen treatment, androgen-responsive prostate cancer cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>After androgen withdrawal and angiogen treatment, androgenic responsive prostate cancer cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>After androgen withdrawal and angiogen treatment, androgenic responsive prostate cancer cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>After androgen withdrawal and angiogen treatment, androgenic responsive prostate cancer cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>After androgen withdrawal and angiogen treatment, androgenic responsive prostate cancer cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>After androgen withdrawal and angiogen treatment, androgenic responsive prostate cancer cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>After androgen withdrawal and angiogen treatment, androgenic responsive prostate cancer cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>After androgen withdrawal and angiogen treatment, cancer cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>After androgen withdrawal and angiogen treatment, cancer cells from the androgen prostate able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>After androgen withdrawal and angiogen treatment, cancer cells from the androgen prostate may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>After androgen withdrawal and angiogen treatment, cancer cells from the androgen prostate was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>After androgen withdrawal and angiogen treatment, cancer cells from the androgen prostate which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>After androgen withdrawal and angiogen treatment, cancer cells from the androgen prostate will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>After androgen withdrawal and angiogen treatment, cancer cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>After androgen withdrawal and angiogen treatment, cancer cells of the androgen prostate able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>After androgen withdrawal and angiogen treatment, cancer cells of the androgen prostate may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>After androgen withdrawal and angiogen treatment, cancer cells of the androgen prostate was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>After androgen withdrawal and angiogen treatment, cancer cells of the androgen prostate which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="153">
                    <text>After androgen withdrawal and angiogen treatment, cancer cells of the androgen prostate which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="154">
                    <text>After androgen withdrawal and angiogen treatment, cancer cells of the androgen prostate will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="155">
                    <text>After androgen withdrawal and angiogen treatment, cancer cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="156">
                    <text>After androgen withdrawal and angiogen treatment, cancer cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="157">
                    <text>After androgen withdrawal and angiogen treatment, cancer cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="158">
                    <text>After androgen withdrawal and angiogen treatment, cancer cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="159">
                    <text>After androgen withdrawal and angiogen treatment, carcinogenic cells of the prostate that respond to the androgen able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="160">
                    <text>After androgen withdrawal and angiogen treatment, carcinogenic cells of the prostate that respond to the androgen may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="161">
                    <text>After androgen withdrawal and angiogen treatment, carcinogenic cells of the prostate that respond to the androgen was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="162">
                    <text>After androgen withdrawal and angiogen treatment, carcinogenic cells of the prostate that respond to the androgen which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="163">
                    <text>After androgen withdrawal and angiogen treatment, carcinogenic cells of the prostate that respond to the androgen which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="164">
                    <text>After androgen withdrawal and angiogen treatment, carcinogenic cells of the prostate that respond to the androgen will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="165">
                    <text>After androgen withdrawal and angiogen treatment, endothelial cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="166">
                    <text>After androgen withdrawal and angiogen treatment, endothelial cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="167">
                    <text>After androgen withdrawal and angiogen treatment, endothelial cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="168">
                    <text>After androgen withdrawal and angiogen treatment, endothelial cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="169">
                    <text>After androgen withdrawal and angiogen treatment, endothelial cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="170">
                    <text>After androgen withdrawal and angiogen treatment, endothelial cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="171">
                    <text>After androgen withdrawal and angiogen treatment, prostate cancer cells respond to androgen able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="172">
                    <text>After androgen withdrawal and angiogen treatment, prostate cancer cells respond to androgen may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="173">
                    <text>After androgen withdrawal and angiogen treatment, prostate cancer cells respond to androgen was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="174">
                    <text>After androgen withdrawal and angiogen treatment, prostate cancer cells respond to androgen which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="175">
                    <text>After androgen withdrawal and angiogen treatment, prostate cancer cells respond to androgen which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="176">
                    <text>After androgen withdrawal and angiogen treatment, prostate cancer cells responding to androgen able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="177">
                    <text>After androgen withdrawal and angiogen treatment, prostate cancer cells responding to androgen may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="178">
                    <text>After androgen withdrawal and angiogen treatment, prostate cancer cells responding to androgen which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="179">
                    <text>After androgen withdrawal and angiogen treatment, prostate cancer cells responding to androgen which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="180">
                    <text>After androgen withdrawal and angiogen treatment, prostate cancer cells responding to androgen will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="181">
                    <text>After androgen withdrawal and angiogen treatment, stat5ab-/-peripheral T cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="182">
                    <text>After androgen withdrawal and angiogen treatment, stat5ab-/-peripheral T cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="183">
                    <text>After androgen withdrawal and angiogen treatment, stat5ab-/-peripheral T cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="184">
                    <text>After androgen withdrawal and angiogen treatment, stat5ab-/-peripheral T cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="185">
                    <text>After androgen withdrawal and angiogen treatment, stat5ab-/-peripheral T cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="186">
                    <text>After androgen withdrawal and angiogen treatment, stat5ab-/-peripheral T cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="187">
                    <text>After androgen withdrawal and angiogen treatment, stat5ab/-peripheral T cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="188">
                    <text>After androgen withdrawal and angiogen treatment, stat5ab/-peripheral T cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="189">
                    <text>After androgen withdrawal and angiogen treatment, stat5ab/-peripheral T cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="190">
                    <text>After androgen withdrawal and angiogen treatment, stat5ab/-peripheral T cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="191">
                    <text>After androgen withdrawal and angiogen treatment, stat5ab/-peripheral T cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="192">
                    <text>After androgen withdrawal and angiogen treatment, stat5ab/-peripheral T cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="193">
                    <text>After androgen withdrawal and angiogen treatment, stat5ab/peripheral T cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="194">
                    <text>After androgen withdrawal and angiogen treatment, stat5ab/peripheral T cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="195">
                    <text>After androgen withdrawal and angiogen treatment, stat5ab/peripheral T cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="196">
                    <text>After androgen withdrawal and angiogen treatment, stat5ab/peripheral T cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="197">
                    <text>After androgen withdrawal and angiogen treatment, stat5ab/peripheral T cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="198">
                    <text>After androgen withdrawal and angiogen treatment, stat5ab/peripheral T cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="199">
                    <text>After androgen withdrawal and anti-androgen treatment, Stat5ab-/-peripheral T cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="200">
                    <text>After androgen withdrawal and anti-androgen treatment, Stat5ab-/-peripheral T cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="201">
                    <text>After androgen withdrawal and anti-androgen treatment, Stat5ab-/-peripheral T cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="202">
                    <text>After androgen withdrawal and anti-androgen treatment, Stat5ab-/-peripheral T cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="203">
                    <text>After androgen withdrawal and anti-androgen treatment, Stat5ab-/-peripheral T cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="204">
                    <text>After androgen withdrawal and anti-androgen treatment, Stat5ab-/-peripheral T cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="205">
                    <text>After androgen withdrawal and anti-androgen treatment, Stat5ab-/-peripheral T cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="206">
                    <text>After androgen withdrawal and anti-androgen treatment, Stat5ab-/-peripheral T cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="207">
                    <text>After androgen withdrawal and anti-androgen treatment, Stat5ab-/-peripheral T cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="208">
                    <text>After androgen withdrawal and anti-androgen treatment, allergen prostate cancer cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="209">
                    <text>After androgen withdrawal and anti-androgen treatment, allergen prostate cancer cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="210">
                    <text>After androgen withdrawal and anti-androgen treatment, allergen prostate cancer cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="211">
                    <text>After androgen withdrawal and anti-androgen treatment, allergen prostate cancer cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="212">
                    <text>After androgen withdrawal and anti-androgen treatment, allergen prostate cancer cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="213">
                    <text>After androgen withdrawal and anti-androgen treatment, allergen prostate cancer cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="214">
                    <text>After androgen withdrawal and anti-androgen treatment, allergen prostate cancer cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="215">
                    <text>After androgen withdrawal and anti-androgen treatment, allergen prostate cancer cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="216">
                    <text>After androgen withdrawal and anti-androgen treatment, allergen prostate cancer cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="217">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen prostate cancer cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="218">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen prostate cancer cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="219">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen prostate cancer cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="220">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen prostate cancer cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="221">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen prostate cancer cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="222">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen prostate cancer cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="223">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen prostate cancer cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="224">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen prostate cancer cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="225">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen prostate cancer cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="226">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen tumour cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="227">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen tumour cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="228">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen tumour cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="229">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen tumour cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="230">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen tumour cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="231">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen tumour cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="232">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen tumour cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="233">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen tumour cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="234">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen tumour cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="235">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen-responsive prostate cancer cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="236">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen-responsive prostate cancer cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="237">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen-responsive prostate cancer cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="238">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen-responsive prostate cancer cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="239">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen-responsive prostate cancer cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="240">
                    <text>After androgen withdrawal and anti-androgen treatment, androgenic responsive prostate cancer cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="241">
                    <text>After androgen withdrawal and anti-androgen treatment, androgenic responsive prostate cancer cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="242">
                    <text>After androgen withdrawal and anti-androgen treatment, androgenic responsive prostate cancer cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="243">
                    <text>After androgen withdrawal and anti-androgen treatment, androgenic responsive prostate cancer cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="244">
                    <text>After androgen withdrawal and anti-androgen treatment, androgenic responsive prostate cancer cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="245">
                    <text>After androgen withdrawal and anti-androgen treatment, androgenic responsive prostate cancer cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="246">
                    <text>After androgen withdrawal and anti-androgen treatment, androgenic responsive prostate cancer cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="247">
                    <text>After androgen withdrawal and anti-androgen treatment, androgenic responsive prostate cancer cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="248">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="249">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="250">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="251">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells from the androgen prostate ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="252">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells from the androgen prostate ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="253">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells from the androgen prostate failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="254">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells from the androgen prostate has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="255">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells from the androgen prostate is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="256">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells from the androgen prostate may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="257">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells from the androgen prostate which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="258">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells from the androgen prostate which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="259">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells from the androgen prostate will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="260">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="261">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="262">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="263">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells of the androgen prostate ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="264">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells of the androgen prostate ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="265">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells of the androgen prostate failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="266">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells of the androgen prostate has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="267">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells of the androgen prostate is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="268">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells of the androgen prostate may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="269">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells of the androgen prostate which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="270">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells of the androgen prostate which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="271">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells of the androgen prostate will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="272">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="273">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="274">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="275">
                    <text>After androgen withdrawal and anti-androgen treatment, carcinogenic cells of the prostate that respond to the androgen ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="276">
                    <text>After androgen withdrawal and anti-androgen treatment, carcinogenic cells of the prostate that respond to the androgen ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="277">
                    <text>After androgen withdrawal and anti-androgen treatment, carcinogenic cells of the prostate that respond to the androgen failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="278">
                    <text>After androgen withdrawal and anti-androgen treatment, carcinogenic cells of the prostate that respond to the androgen has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="279">
                    <text>After androgen withdrawal and anti-androgen treatment, carcinogenic cells of the prostate that respond to the androgen is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="280">
                    <text>After androgen withdrawal and anti-androgen treatment, carcinogenic cells of the prostate that respond to the androgen may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="281">
                    <text>After androgen withdrawal and anti-androgen treatment, carcinogenic cells of the prostate that respond to the androgen which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="282">
                    <text>After androgen withdrawal and anti-androgen treatment, carcinogenic cells of the prostate that respond to the androgen which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="283">
                    <text>After androgen withdrawal and anti-androgen treatment, carcinogenic cells of the prostate that respond to the androgen will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="284">
                    <text>After androgen withdrawal and anti-androgen treatment, endothelial cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="285">
                    <text>After androgen withdrawal and anti-androgen treatment, endothelial cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="286">
                    <text>After androgen withdrawal and anti-androgen treatment, endothelial cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="287">
                    <text>After androgen withdrawal and anti-androgen treatment, endothelial cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="288">
                    <text>After androgen withdrawal and anti-androgen treatment, endothelial cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="289">
                    <text>After androgen withdrawal and anti-androgen treatment, endothelial cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="290">
                    <text>After androgen withdrawal and anti-androgen treatment, endothelial cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="291">
                    <text>After androgen withdrawal and anti-androgen treatment, endothelial cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="292">
                    <text>After androgen withdrawal and anti-androgen treatment, endothelial cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="293">
                    <text>After androgen withdrawal and anti-androgen treatment, prostate cancer cells respond to androgen ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="294">
                    <text>After androgen withdrawal and anti-androgen treatment, prostate cancer cells respond to androgen ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="295">
                    <text>After androgen withdrawal and anti-androgen treatment, prostate cancer cells respond to androgen failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="296">
                    <text>After androgen withdrawal and anti-androgen treatment, prostate cancer cells respond to androgen has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="297">
                    <text>After androgen withdrawal and anti-androgen treatment, prostate cancer cells respond to androgen is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="298">
                    <text>After androgen withdrawal and anti-androgen treatment, prostate cancer cells respond to androgen may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="299">
                    <text>After androgen withdrawal and anti-androgen treatment, prostate cancer cells respond to androgen which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="300">
                    <text>After androgen withdrawal and anti-androgen treatment, prostate cancer cells respond to androgen which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="301">
                    <text>After androgen withdrawal and anti-androgen treatment, prostate cancer cells respond to androgen will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="302">
                    <text>After androgen withdrawal and anti-androgen treatment, prostate cancer cells responding to androgen failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="303">
                    <text>After androgen withdrawal and anti-androgen treatment, prostate cancer cells responding to androgen has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="304">
                    <text>After androgen withdrawal and anti-androgen treatment, prostate cancer cells responding to androgen may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="305">
                    <text>After androgen withdrawal and anti-androgen treatment, prostate cancer cells responding to androgen which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="306">
                    <text>After androgen withdrawal and anti-androgen treatment, prostate cancer cells responding to androgen which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="307">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab-/-peripheral T cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="308">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab-/-peripheral T cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="309">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab-/-peripheral T cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="310">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab-/-peripheral T cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="311">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab-/-peripheral T cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="312">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab-/-peripheral T cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="313">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab-/-peripheral T cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="314">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab-/-peripheral T cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="315">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab-/-peripheral T cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="316">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/-peripheral T cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="317">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/-peripheral T cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="318">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/-peripheral T cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="319">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/-peripheral T cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="320">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/-peripheral T cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="321">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/-peripheral T cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="322">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/-peripheral T cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="323">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/-peripheral T cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="324">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/-peripheral T cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="325">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/peripheral T cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="326">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/peripheral T cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="327">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/peripheral T cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="328">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/peripheral T cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="329">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/peripheral T cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="330">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/peripheral T cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="331">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/peripheral T cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="332">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/peripheral T cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="333">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/peripheral T cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="334">
                    <text>After androgen withdrawal and antiandrogen treatment, Stat5ab-/-peripheral T cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="335">
                    <text>After androgen withdrawal and antiandrogen treatment, Stat5ab-/-peripheral T cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="336">
                    <text>After androgen withdrawal and antiandrogen treatment, allergen prostate cancer cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="337">
                    <text>After androgen withdrawal and antiandrogen treatment, allergen prostate cancer cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="338">
                    <text>After androgen withdrawal and antiandrogen treatment, androgen prostate cancer cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="339">
                    <text>After androgen withdrawal and antiandrogen treatment, androgen prostate cancer cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="340">
                    <text>After androgen withdrawal and antiandrogen treatment, androgen tumour cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="341">
                    <text>After androgen withdrawal and antiandrogen treatment, androgen tumour cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="342">
                    <text>After androgen withdrawal and antiandrogen treatment, androgenic responsive prostate cancer cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="343">
                    <text>After androgen withdrawal and antiandrogen treatment, androgenic responsive prostate cancer cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="344">
                    <text>After androgen withdrawal and antiandrogen treatment, cancer cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="345">
                    <text>After androgen withdrawal and antiandrogen treatment, cancer cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="346">
                    <text>After androgen withdrawal and antiandrogen treatment, cancer cells from the androgen prostate ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="347">
                    <text>After androgen withdrawal and antiandrogen treatment, cancer cells from the androgen prostate ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="348">
                    <text>After androgen withdrawal and antiandrogen treatment, cancer cells of the androgen prostate ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="349">
                    <text>After androgen withdrawal and antiandrogen treatment, cancer cells of the androgen prostate ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="350">
                    <text>After androgen withdrawal and antiandrogen treatment, carcinogenic cells of the prostate that respond to the androgen ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="351">
                    <text>After androgen withdrawal and antiandrogen treatment, carcinogenic cells of the prostate that respond to the androgen ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="352">
                    <text>After androgen withdrawal and antiandrogen treatment, endothelial cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="353">
                    <text>After androgen withdrawal and antiandrogen treatment, endothelial cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="354">
                    <text>After androgen withdrawal and antiandrogen treatment, prostate cancer cells respond to androgen ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="355">
                    <text>After androgen withdrawal and antiandrogen treatment, prostate cancer cells respond to androgen ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="356">
                    <text>After androgen withdrawal and antiandrogen treatment, prostate cancer cells responding to androgen ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="357">
                    <text>After androgen withdrawal and antiandrogen treatment, stat5ab-/-peripheral T cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="358">
                    <text>After androgen withdrawal and antiandrogen treatment, stat5ab-/-peripheral T cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="359">
                    <text>After androgen withdrawal and antiandrogen treatment, stat5ab/-peripheral T cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="360">
                    <text>After androgen withdrawal and antiandrogen treatment, stat5ab/-peripheral T cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="361">
                    <text>After androgen withdrawal and antiandrogen treatment, stat5ab/peripheral T cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="362">
                    <text>After androgen withdrawal and antiandrogen treatment, stat5ab/peripheral T cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="363">
                    <text>After androgens have been removed and anti-androgen treatment, Stat5ab-/-peripheral T cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="364">
                    <text>After androgens have been removed and anti-androgen treatment, Stat5ab-/-peripheral T cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="365">
                    <text>After androgens have been removed and anti-androgen treatment, allergen prostate cancer cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="366">
                    <text>After androgens have been removed and anti-androgen treatment, allergen prostate cancer cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="367">
                    <text>After androgens have been removed and anti-androgen treatment, androgen prostate cancer cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="368">
                    <text>After androgens have been removed and anti-androgen treatment, androgen prostate cancer cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="369">
                    <text>After androgens have been removed and anti-androgen treatment, androgen tumour cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="370">
                    <text>After androgens have been removed and anti-androgen treatment, androgen tumour cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="371">
                    <text>After androgens have been removed and anti-androgen treatment, androgen-responsive prostate cancer cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="372">
                    <text>After androgens have been removed and anti-androgen treatment, androgenic responsive prostate cancer cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="373">
                    <text>After androgens have been removed and anti-androgen treatment, cancer cells from the androgen prostate that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="374">
                    <text>After androgens have been removed and anti-androgen treatment, cancer cells from the androgen prostate which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="375">
                    <text>After androgens have been removed and anti-androgen treatment, cancer cells of the androgen prostate that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="376">
                    <text>After androgens have been removed and anti-androgen treatment, cancer cells of the androgen prostate which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="377">
                    <text>After androgens have been removed and anti-androgen treatment, cancer cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="378">
                    <text>After androgens have been removed and anti-androgen treatment, cancer cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="379">
                    <text>After androgens have been removed and anti-androgen treatment, carcinogenic cells of the prostate that respond to the androgen that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="380">
                    <text>After androgens have been removed and anti-androgen treatment, carcinogenic cells of the prostate that respond to the androgen which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="381">
                    <text>After androgens have been removed and anti-androgen treatment, endothelial cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="382">
                    <text>After androgens have been removed and anti-androgen treatment, endothelial cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="383">
                    <text>After androgens have been removed and anti-androgen treatment, prostate cancer cells respond to androgen that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="384">
                    <text>After androgens have been removed and anti-androgen treatment, prostate cancer cells respond to androgen which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="385">
                    <text>After androgens have been removed and anti-androgen treatment, prostate cancer cells responding to androgen that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="386">
                    <text>After androgens have been removed and anti-androgen treatment, prostate cancer cells responding to androgen which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="387">
                    <text>After androgens have been removed and anti-androgen treatment, stat5ab-/-peripheral T cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="388">
                    <text>After androgens have been removed and anti-androgen treatment, stat5ab-/-peripheral T cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="389">
                    <text>After androgens have been removed and anti-androgen treatment, stat5ab/-peripheral T cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="390">
                    <text>After androgens have been removed and anti-androgen treatment, stat5ab/-peripheral T cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="391">
                    <text>After androgens have been removed and anti-androgen treatment, stat5ab/peripheral T cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="392">
                    <text>After androgens have been removed and anti-androgen treatment, stat5ab/peripheral T cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="393">
                    <text>After the androgen has been withdrawn and angiogen treatment, Stat5ab-/-peripheral T cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="394">
                    <text>After the androgen has been withdrawn and angiogen treatment, Stat5ab-/-peripheral T cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="395">
                    <text>After the androgen has been withdrawn and angiogen treatment, Stat5ab-/-peripheral T cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="396">
                    <text>After the androgen has been withdrawn and angiogen treatment, Stat5ab-/-peripheral T cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="397">
                    <text>After the androgen has been withdrawn and angiogen treatment, Stat5ab-/-peripheral T cells will proliferate tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="398">
                    <text>After the androgen has been withdrawn and angiogen treatment, allergen prostate cancer cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="399">
                    <text>After the androgen has been withdrawn and angiogen treatment, allergen prostate cancer cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="400">
                    <text>After the androgen has been withdrawn and angiogen treatment, allergen prostate cancer cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="401">
                    <text>After the androgen has been withdrawn and angiogen treatment, allergen prostate cancer cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="402">
                    <text>After the androgen has been withdrawn and angiogen treatment, allergen prostate cancer cells will proliferate tumor regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="403">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen prostate cancer cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="404">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen prostate cancer cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="405">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen prostate cancer cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="406">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen prostate cancer cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="407">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen prostate cancer cells will proliferate tumor regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="408">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen tumour cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="409">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen tumour cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="410">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen tumour cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="411">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen tumour cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="412">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen tumour cells will proliferate tumor regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="413">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen-responsive prostate cancer cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="414">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen-responsive prostate cancer cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="415">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen-responsive prostate cancer cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="416">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen-responsive prostate cancer cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="417">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen-responsive prostate cancer cells will proliferate tumor regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="418">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgenic responsive prostate cancer cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="419">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgenic responsive prostate cancer cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="420">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgenic responsive prostate cancer cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="421">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgenic responsive prostate cancer cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="422">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgenic responsive prostate cancer cells will proliferate tumor regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="423">
                    <text>After the androgen has been withdrawn and angiogen treatment, cancer cells from the androgen prostate that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="424">
                    <text>After the androgen has been withdrawn and angiogen treatment, cancer cells from the androgen prostate which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="425">
                    <text>After the androgen has been withdrawn and angiogen treatment, cancer cells from the androgen prostate which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="426">
                    <text>After the androgen has been withdrawn and angiogen treatment, cancer cells from the androgen prostate which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="427">
                    <text>After the androgen has been withdrawn and angiogen treatment, cancer cells from the androgen prostate will proliferate tumor regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="428">
                    <text>After the androgen has been withdrawn and angiogen treatment, cancer cells of the androgen prostate will proliferate tumor regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="429">
                    <text>After the androgen has been withdrawn and angiogen treatment, cancer cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="430">
                    <text>After the androgen has been withdrawn and angiogen treatment, cancer cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="431">
                    <text>After the androgen has been withdrawn and angiogen treatment, cancer cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="432">
                    <text>After the androgen has been withdrawn and angiogen treatment, cancer cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="433">
                    <text>After the androgen has been withdrawn and angiogen treatment, cancer cells will proliferate tumor regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="434">
                    <text>After the androgen has been withdrawn and angiogen treatment, carcinogenic cells of the prostate that respond to the androgen that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="435">
                    <text>After the androgen has been withdrawn and angiogen treatment, carcinogenic cells of the prostate that respond to the androgen which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="436">
                    <text>After the androgen has been withdrawn and angiogen treatment, carcinogenic cells of the prostate that respond to the androgen which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="437">
                    <text>After the androgen has been withdrawn and angiogen treatment, carcinogenic cells of the prostate that respond to the androgen which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="438">
                    <text>After the androgen has been withdrawn and angiogen treatment, carcinogenic cells of the prostate that respond to the androgen will proliferate tumor regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="439">
                    <text>After the androgen has been withdrawn and angiogen treatment, endothelial cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="440">
                    <text>After the androgen has been withdrawn and angiogen treatment, endothelial cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="441">
                    <text>After the androgen has been withdrawn and angiogen treatment, endothelial cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="442">
                    <text>After the androgen has been withdrawn and angiogen treatment, endothelial cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="443">
                    <text>After the androgen has been withdrawn and angiogen treatment, endothelial cells will proliferate tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="444">
                    <text>After the androgen has been withdrawn and angiogen treatment, prostate cancer cells respond to androgen that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="445">
                    <text>After the androgen has been withdrawn and angiogen treatment, prostate cancer cells respond to androgen which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="446">
                    <text>After the androgen has been withdrawn and angiogen treatment, prostate cancer cells respond to androgen which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="447">
                    <text>After the androgen has been withdrawn and angiogen treatment, prostate cancer cells respond to androgen which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="448">
                    <text>After the androgen has been withdrawn and angiogen treatment, prostate cancer cells respond to androgen will proliferate tumor regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="449">
                    <text>After the androgen has been withdrawn and angiogen treatment, prostate cancer cells responding to androgen that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="450">
                    <text>After the androgen has been withdrawn and angiogen treatment, prostate cancer cells responding to androgen which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="451">
                    <text>After the androgen has been withdrawn and angiogen treatment, prostate cancer cells responding to androgen which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="452">
                    <text>After the androgen has been withdrawn and angiogen treatment, prostate cancer cells responding to androgen which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="453">
                    <text>After the androgen has been withdrawn and angiogen treatment, stat5ab-/-peripheral T cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="454">
                    <text>After the androgen has been withdrawn and angiogen treatment, stat5ab-/-peripheral T cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="455">
                    <text>After the androgen has been withdrawn and angiogen treatment, stat5ab-/-peripheral T cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="456">
                    <text>After the androgen has been withdrawn and angiogen treatment, stat5ab-/-peripheral T cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="457">
                    <text>After the androgen has been withdrawn and angiogen treatment, stat5ab-/-peripheral T cells will proliferate tumor regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="458">
                    <text>After the androgen has been withdrawn and angiogen treatment, stat5ab/-peripheral T cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="459">
                    <text>After the androgen has been withdrawn and angiogen treatment, stat5ab/-peripheral T cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="460">
                    <text>After the androgen has been withdrawn and angiogen treatment, stat5ab/-peripheral T cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="461">
                    <text>After the androgen has been withdrawn and angiogen treatment, stat5ab/-peripheral T cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="462">
                    <text>After the androgen has been withdrawn and angiogen treatment, stat5ab/-peripheral T cells will proliferate tumor regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="463">
                    <text>After the androgen has been withdrawn and angiogen treatment, stat5ab/peripheral T cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="464">
                    <text>After the androgen has been withdrawn and angiogen treatment, stat5ab/peripheral T cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="465">
                    <text>After the androgen has been withdrawn and angiogen treatment, stat5ab/peripheral T cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="466">
                    <text>After the androgen has been withdrawn and angiogen treatment, stat5ab/peripheral T cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="467">
                    <text>After the androgen has been withdrawn and angiogen treatment, stat5ab/peripheral T cells will proliferate tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="468">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, Stat5ab-/-peripheral T cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="469">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, allergen prostate cancer cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="470">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, androgen prostate cancer cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="471">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, androgen tumour cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="472">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, androgen-responsive prostate cancer cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="473">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, androgenic responsive prostate cancer cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="474">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, cancer cells from the androgen prostate stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="475">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, cancer cells of the androgen prostate stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="476">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, cancer cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="477">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, endothelial cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="478">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, prostate cancer cells respond to androgen stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="479">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, prostate cancer cells responding to androgen stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="480">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, stat5ab-/-peripheral T cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="481">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, stat5ab/-peripheral T cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="482">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, stat5ab/peripheral T cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="483">
                    <text>HD CD4+ T cells specific for HIV in viremic patients continued to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="484">
                    <text>HD CD4+ T cells specific for HIV in viremic patients continued to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="485">
                    <text>HD CD4+ T cells specific for HIV in viremic patients has the ability to continue to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="486">
                    <text>HD CD4+ T cells specific for HIV in viremic patients has the ability to continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="487">
                    <text>HD CD4+ T cells specific for HIV in viremic patients is a disease that proliferate with great proliferation in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tends to be in the G0/G1 phase.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="488">
                    <text>HD CD4+ T cells specific for HIV in viremic patients is able to continue to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="489">
                    <text>HD CD4+ T cells specific for HIV in viremic patients is able to continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="490">
                    <text>HD CD4+ T cells specific for HIV in viremic patients is likely to continue to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="491">
                    <text>HD CD4+ T cells specific for HIV in viremic patients is likely to continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="492">
                    <text>HD CD4+ T cells specific for HIV in viremic patients is observed to continue to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="493">
                    <text>HD CD4+ T cells specific for HIV in viremic patients may continue to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in phase G0/ G1.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="494">
                    <text>HD CD4+ T cells specific for HIV in viremic patients may continue to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="495">
                    <text>HD CD4+ T cells specific for HIV in viremic patients may continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="496">
                    <text>HD CD4+ T cells specific for HIV in viremic patients may continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="497">
                    <text>HD CD4+ T cells specific for HIV in viremic patients may have continued to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="498">
                    <text>HD CD4+ T cells specific for HIV in viremic patients may have continued to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="499">
                    <text>HD CD4+ T cells specific for HIV in viremic patients will continue to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in phase G0/ G1.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="500">
                    <text>HD CD4+ T cells specific for HIV in viremic patients will continue to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="501">
                    <text>HD CD4+ T cells specific for HIV in viremic patients will continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="502">
                    <text>HD CD4+ T cells specific for HIV in viremic patients will continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="503">
                    <text>HIV-specific CD4+ T cells in viremic patients continued to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="504">
                    <text>HIV-specific CD4+ T cells in viremic patients continued to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="505">
                    <text>HIV-specific CD4+ T cells in viremic patients has the ability to continue to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="506">
                    <text>HIV-specific CD4+ T cells in viremic patients has the ability to continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="507">
                    <text>HIV-specific CD4+ T cells in viremic patients is a disease that proliferate with great proliferation in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tends to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="508">
                    <text>HIV-specific CD4+ T cells in viremic patients is able to continue to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="509">
                    <text>HIV-specific CD4+ T cells in viremic patients is able to continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="510">
                    <text>HIV-specific CD4+ T cells in viremic patients is likely to continue to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="511">
                    <text>HIV-specific CD4+ T cells in viremic patients is likely to continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="512">
                    <text>HIV-specific CD4+ T cells in viremic patients is observed to continue to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="513">
                    <text>HIV-specific CD4+ T cells in viremic patients may continue to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in phase G0/ G1.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="514">
                    <text>HIV-specific CD4+ T cells in viremic patients may continue to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="515">
                    <text>HIV-specific CD4+ T cells in viremic patients may continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="516">
                    <text>HIV-specific CD4+ T cells in viremic patients may continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="517">
                    <text>HIV-specific CD4+ T cells in viremic patients may have continued to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="518">
                    <text>HIV-specific CD4+ T cells in viremic patients may have continued to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="519">
                    <text>HIV-specific CD4+ T cells in viremic patients will continue to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in phase G0/ G1.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="520">
                    <text>HIV-specific CD4+ T cells in viremic patients will continue to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="521">
                    <text>HIV-specific CD4+ T cells in viremic patients will continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="522">
                    <text>HIV-specific CD4+ T cells in viremic patients will continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="523">
                    <text>HIV-specific T cells CCD4+ in viremic patients continued to proliferate in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="524">
                    <text>HIV-specific T cells CCD4+ in viremic patients continued to proliferate strongly in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="525">
                    <text>HIV-specific T cells CCD4+ in viremic patients has the ability to continue to proliferate in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="526">
                    <text>HIV-specific T cells CCD4+ in viremic patients has the ability to continue to proliferate strongly in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="527">
                    <text>HIV-specific T cells CCD4+ in viremic patients is a disease that proliferate with great proliferation in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tends to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="528">
                    <text>HIV-specific T cells CCD4+ in viremic patients is able to continue to proliferate in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="529">
                    <text>HIV-specific T cells CCD4+ in viremic patients is able to continue to proliferate strongly in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="530">
                    <text>HIV-specific T cells CCD4+ in viremic patients is likely to continue to proliferate in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="531">
                    <text>HIV-specific T cells CCD4+ in viremic patients is likely to continue to proliferate strongly in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="532">
                    <text>HIV-specific T cells CCD4+ in viremic patients is observed to continue to proliferate in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="533">
                    <text>HIV-specific T cells CCD4+ in viremic patients may continue to proliferate in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in phase G0/ G1.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="534">
                    <text>HIV-specific T cells CCD4+ in viremic patients may continue to proliferate in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="535">
                    <text>HIV-specific T cells CCD4+ in viremic patients may continue to proliferate strongly in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="536">
                    <text>HIV-specific T cells CCD4+ in viremic patients may continue to proliferate strongly in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="537">
                    <text>HIV-specific T cells CCD4+ in viremic patients may have continued to proliferate in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="538">
                    <text>HIV-specific T cells CCD4+ in viremic patients may have continued to proliferate strongly in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="539">
                    <text>HIV-specific T cells CCD4+ in viremic patients will continue to proliferate in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in phase G0/ G1.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="540">
                    <text>HIV-specific T cells CCD4+ in viremic patients will continue to proliferate in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="541">
                    <text>HIV-specific T cells CCD4+ in viremic patients will continue to proliferate strongly in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="542">
                    <text>HIV-specific T cells CCD4+ in viremic patients will continue to proliferate strongly in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="543">
                    <text>HSC continued to proliferate in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="544">
                    <text>HSC continued to proliferate in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="545">
                    <text>HSC continued to proliferate in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="546">
                    <text>HSC continued to proliferate in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="547">
                    <text>HSC continued to proliferate in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="548">
                    <text>HSC continued to proliferate in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="549">
                    <text>HSC continued to proliferate strongly in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="550">
                    <text>HSC continued to proliferate strongly in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="551">
                    <text>HSC continued to proliferate strongly in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="552">
                    <text>HSC continued to proliferate strongly in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="553">
                    <text>HSC continued to proliferate strongly in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="554">
                    <text>HSC continued to proliferate strongly in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="555">
                    <text>HSC has the ability to continue to proliferate in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="556">
                    <text>HSC has the ability to continue to proliferate in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="557">
                    <text>HSC has the ability to continue to proliferate in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="558">
                    <text>HSC has the ability to continue to proliferate in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="559">
                    <text>HSC has the ability to continue to proliferate in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="560">
                    <text>HSC has the ability to continue to proliferate in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="561">
                    <text>HSC has the ability to continue to proliferate strongly in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="562">
                    <text>HSC has the ability to continue to proliferate strongly in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="563">
                    <text>HSC has the ability to continue to proliferate strongly in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="564">
                    <text>HSC has the ability to continue to proliferate strongly in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="565">
                    <text>HSC has the ability to continue to proliferate strongly in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="566">
                    <text>HSC has the ability to continue to proliferate strongly in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="567">
                    <text>HSC is a disease that proliferate with great proliferation in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tends to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="568">
                    <text>HSC is a disease that proliferate with great proliferation in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tends to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="569">
                    <text>HSC is a disease that proliferate with great proliferation in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tends to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="570">
                    <text>HSC is a disease that proliferate with great proliferation in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tends to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="571">
                    <text>HSC is a disease that proliferate with great proliferation in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tends to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="572">
                    <text>HSC is a disease that proliferate with great proliferation in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tends to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="573">
                    <text>HSC is a disease that proliferate with great proliferation in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tends to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="574">
                    <text>HSC is able to continue to proliferate in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="575">
                    <text>HSC is able to continue to proliferate in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="576">
                    <text>HSC is able to continue to proliferate in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="577">
                    <text>HSC is able to continue to proliferate in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="578">
                    <text>HSC is able to continue to proliferate in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="579">
                    <text>HSC is able to continue to proliferate in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="580">
                    <text>HSC is able to continue to proliferate strongly in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="581">
                    <text>HSC is able to continue to proliferate strongly in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="582">
                    <text>HSC is able to continue to proliferate strongly in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="583">
                    <text>HSC is able to continue to proliferate strongly in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="584">
                    <text>HSC is able to continue to proliferate strongly in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="585">
                    <text>HSC is able to continue to proliferate strongly in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="586">
                    <text>HSC is likely to continue to proliferate in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="587">
                    <text>HSC is likely to continue to proliferate in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="588">
                    <text>HSC is likely to continue to proliferate in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="589">
                    <text>HSC is likely to continue to proliferate in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="590">
                    <text>HSC is likely to continue to proliferate in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="591">
                    <text>HSC is likely to continue to proliferate in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="592">
                    <text>HSC is likely to continue to proliferate strongly in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="593">
                    <text>HSC is likely to continue to proliferate strongly in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="594">
                    <text>HSC is likely to continue to proliferate strongly in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="595">
                    <text>HSC is likely to continue to proliferate strongly in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="596">
                    <text>HSC is likely to continue to proliferate strongly in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="597">
                    <text>HSC is likely to continue to proliferate strongly in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="598">
                    <text>HSC is observed to continue to proliferate in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="599">
                    <text>HSC is observed to continue to proliferate in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="600">
                    <text>HSC is observed to continue to proliferate in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="601">
                    <text>HSC is observed to continue to proliferate in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="602">
                    <text>HSC is observed to continue to proliferate in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="603">
                    <text>HSC is observed to continue to proliferate in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="604">
                    <text>HSC is observed to continue to proliferate in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="605">
                    <text>HSC may continue to proliferate in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in phase G0/ G1.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="606">
                    <text>HSC may continue to proliferate in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="607">
                    <text>HSC may continue to proliferate in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="608">
                    <text>HSC may continue to proliferate in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in phase G0/ G1.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="609">
                    <text>HSC may continue to proliferate in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="610">
                    <text>HSC may continue to proliferate in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in phase G0/ G1.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="611">
                    <text>HSC may continue to proliferate in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in phase G0/ G1.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="612">
                    <text>HSC may continue to proliferate in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="613">
                    <text>HSC may continue to proliferate in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in phase G0/ G1.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="614">
                    <text>HSC may continue to proliferate in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="615">
                    <text>HSC may continue to proliferate in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tended to be in phase G0/ G1.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="616">
                    <text>HSC may continue to proliferate in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="617">
                    <text>HSC may continue to proliferate in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in phase G0/ G1.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="618">
                    <text>HSC may continue to proliferate in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="619">
                    <text>HSC may continue to proliferate strongly in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="620">
                    <text>HSC may continue to proliferate strongly in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="621">
                    <text>HSC may continue to proliferate strongly in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="622">
                    <text>HSC may continue to proliferate strongly in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="623">
                    <text>HSC may continue to proliferate strongly in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="624">
                    <text>HSC may continue to proliferate strongly in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="625">
                    <text>HSC may continue to proliferate strongly in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="626">
                    <text>HSC may continue to proliferate strongly in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="627">
                    <text>HSC may continue to proliferate strongly in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="628">
                    <text>HSC may continue to proliferate strongly in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="629">
                    <text>HSC may continue to proliferate strongly in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="630">
                    <text>HSC may continue to proliferate strongly in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="631">
                    <text>HSC may continue to proliferate strongly in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="632">
                    <text>HSC may continue to proliferate strongly in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="633">
                    <text>HSC may have continued to proliferate in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="634">
                    <text>HSC may have continued to proliferate in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="635">
                    <text>HSC may have continued to proliferate in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="636">
                    <text>HSC may have continued to proliferate in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="637">
                    <text>HSC may have continued to proliferate in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="638">
                    <text>HSC may have continued to proliferate in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="639">
                    <text>HSC may have continued to proliferate strongly in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="640">
                    <text>HSC may have continued to proliferate strongly in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="641">
                    <text>HSC may have continued to proliferate strongly in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="642">
                    <text>HSC may have continued to proliferate strongly in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="643">
                    <text>HSC may have continued to proliferate strongly in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="644">
                    <text>HSC may have continued to proliferate strongly in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="645">
                    <text>HSC will continue to proliferate in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="646">
                    <text>HSC will continue to proliferate in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in phase G0/ G1.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="647">
                    <text>HSC will continue to proliferate in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="648">
                    <text>HSC will continue to proliferate in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in phase G0/ G1.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="649">
                    <text>HSC will continue to proliferate in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="650">
                    <text>HSC will continue to proliferate in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in phase G0/ G1.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="651">
                    <text>HSC will continue to proliferate in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="652">
                    <text>HSC will continue to proliferate in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in phase G0/ G1.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="653">
                    <text>HSC will continue to proliferate in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in phase G0/ G1.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="654">
                    <text>HSC will continue to proliferate in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="655">
                    <text>HSC will continue to proliferate in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tended to be in phase G0/ G1.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="656">
                    <text>HSC will continue to proliferate in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="657">
                    <text>HSC will continue to proliferate in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in phase G0/ G1.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="658">
                    <text>HSC will continue to proliferate in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="659">
                    <text>HSC will continue to proliferate strongly in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="660">
                    <text>HSC will continue to proliferate strongly in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="661">
                    <text>HSC will continue to proliferate strongly in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="662">
                    <text>HSC will continue to proliferate strongly in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="663">
                    <text>HSC will continue to proliferate strongly in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="664">
                    <text>HSC will continue to proliferate strongly in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="665">
                    <text>HSC will continue to proliferate strongly in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="666">
                    <text>HSC will continue to proliferate strongly in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="667">
                    <text>HSC will continue to proliferate strongly in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="668">
                    <text>HSC will continue to proliferate strongly in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="669">
                    <text>HSC will continue to proliferate strongly in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="670">
                    <text>HSC will continue to proliferate strongly in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="671">
                    <text>HSC will continue to proliferate strongly in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="672">
                    <text>HSC will continue to proliferate strongly in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="673">
                    <text>In addition, A0 is able to proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="674">
                    <text>In addition, BI cells has been found to proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vivo.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="675">
                    <text>In addition, BI cells has been found to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="676">
                    <text>In addition, BI cells has been found to proliferate strongly in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vivo.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="677">
                    <text>In addition, BI cells is able to proliferate in response to HIV A1 antigens (when costimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="678">
                    <text>In addition, BI cells may be observed to proliferate in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="679">
                    <text>In addition, BI cells proliferated in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="680">
                    <text>In addition, BI cells was observed to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="681">
                    <text>In addition, BT cells has been found to proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vivo.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="682">
                    <text>In addition, BT cells has been found to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="683">
                    <text>In addition, BT cells has been found to proliferate strongly in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vivo.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="684">
                    <text>In addition, BT cells is able to proliferate in response to HIV A1 antigens (when costimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="685">
                    <text>In addition, BT cells may be observed to proliferate in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="686">
                    <text>In addition, BT cells proliferated in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="687">
                    <text>In addition, BT cells was observed to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="688">
                    <text>In addition, CCD4+ HIV-specific T cells of viremic patients has been found to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="689">
                    <text>In addition, CCD4+ HIV-specific T cells of viremic patients is able to proliferate in response to HIV A1 antigens (when costimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="690">
                    <text>In addition, CCD4+ HIV-specific T cells of viremic patients may be observed to proliferate in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="691">
                    <text>In addition, CCD4+ HIV-specific T cells of viremic patients proliferated in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="692">
                    <text>In addition, CCD4+ HIV-specific T cells of viremic patients was observed to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="693">
                    <text>In addition, CCD4+ HIV-specific cells of viremic patients has been found to proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="694">
                    <text>In addition, CCD4+ HIV-specific cells of viremic patients has been found to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="695">
                    <text>In addition, CCD4+ HIV-specific cells of viremic patients has been found to proliferate strongly in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="696">
                    <text>In addition, CCD4+ HIV-specific cells of viremic patients is able to proliferate in response to HIV A1 antigens (when costimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="697">
                    <text>In addition, CCD4+ HIV-specific cells of viremic patients may be observed to proliferate in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="698">
                    <text>In addition, CCD4+ HIV-specific cells of viremic patients proliferated in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="699">
                    <text>In addition, CCD4+ HIV-specific cells of viremic patients was observed to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="700">
                    <text>In addition, EBD cells has been found to proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vivo.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="701">
                    <text>In addition, EBD cells has been found to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="702">
                    <text>In addition, EBD cells has been found to proliferate strongly in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vivo.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="703">
                    <text>In addition, EBD cells is able to proliferate in response to HIV A1 antigens (when costimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="704">
                    <text>In addition, EBD cells may be observed to proliferate in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="705">
                    <text>In addition, EBD cells proliferated in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="706">
                    <text>In addition, EBD cells was observed to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="707">
                    <text>In addition, HD CD4+ T cells specific for HIV in viremic patients has been found to proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="708">
                    <text>In addition, HD CD4+ T cells specific for HIV in viremic patients has been found to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="709">
                    <text>In addition, HD CD4+ T cells specific for HIV in viremic patients has been found to proliferate strongly in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="710">
                    <text>In addition, HD CD4+ T cells specific for HIV in viremic patients has been shown to be highly proliferating in response to HIV antigens when costimulation was provided by anti-CD28 antibodies in vitro.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="711">
                    <text>In addition, HD CD4+ T cells specific for HIV in viremic patients is able to proliferate in response to HIV A1 antigens (when costimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="712">
                    <text>In addition, HD CD4+ T cells specific for HIV in viremic patients proliferated in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="713">
                    <text>In addition, HD CD4+ T cells specific for HIV in viremic patients was found to proliferate in response to HIV antigens when costimulation was provided by anti-CD28 antibodies in vitro.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="714">
                    <text>In addition, HD CD4+ T cells specific for HIV in viremic patients was observed to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="715">
                    <text>In addition, HD CD4+ T cells specific to HIV in viremics patients has been found to proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="716">
                    <text>In addition, HD CD4+ T cells specific to HIV in viremics patients has been found to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="717">
                    <text>In addition, HD CD4+ T cells specific to HIV in viremics patients has been found to proliferate strongly in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="718">
                    <text>In addition, HD CD4+ T cells specific to HIV in viremics patients may be observed to proliferate in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="719">
                    <text>In addition, HD CD4+ T cells specific to HIV in viremics patients proliferated in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="720">
                    <text>In addition, HD CD4+ T cells specific to HIV in viremics patients was observed to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="721">
                    <text>In addition, HD-specific T CD4+ cells for HIV in viremic patients has been found to proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="722">
                    <text>In addition, HD-specific T CD4+ cells for HIV in viremic patients has been found to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="723">
                    <text>In addition, HD-specific T CD4+ cells for HIV in viremic patients has been found to proliferate strongly in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="724">
                    <text>In addition, HD-specific T CD4+ cells for HIV in viremic patients is able to proliferate in response to HIV A1 antigens (when costimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="725">
                    <text>In addition, HD-specific T CD4+ cells for HIV in viremic patients may be observed to proliferate in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="726">
                    <text>In addition, HD-specific T CD4+ cells for HIV in viremic patients proliferated in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="727">
                    <text>In addition, HDCD4+ T cells specific to HIV in viremics patients has been found to proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="728">
                    <text>In addition, HDCD4+ T cells specific to HIV in viremics patients has been found to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="729">
                    <text>In addition, HDCD4+ T cells specific to HIV in viremics patients has been found to proliferate strongly in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="730">
                    <text>In addition, HDCD4+ T cells specific to HIV in viremics patients is able to proliferate in response to HIV A1 antigens (when costimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="731">
                    <text>In addition, HDCD4+ T cells specific to HIV in viremics patients may be observed to proliferate in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="732">
                    <text>In addition, HDCD4+ T cells specific to HIV in viremics patients was observed to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="733">
                    <text>In addition, HIV-specific A0, CD4+T cells from viremic patients were found to proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vivo.</text>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="734">
                    <text>In addition, HIV-specific CD4+ T cells in viremic patients was found to proliferate in response to HIV antigens when costimulation was provided by anti-CD28 antibodies in vitro.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="735">
                    <text>In addition, HIV-specific CD4+ T cells in viremic patients were proliferate to be proliferative in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="736">
                    <text>In addition, HIV-specific T cells CCD4+ in viremic patients has been shown to be highly proliferating in response to HIV antigens when co-stimulation was provided by anti-CD28 antibodies in vitro.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="737">
                    <text>In addition, HIV-specific T cells CCD4+ in viremic patients is able to proliferate in response to HIV antigens when co-stimulation was provided by anti-CD28 antibodies in vitro.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="738">
                    <text>In addition, HIV-specific T-cells CCD4+ in viraemic patients has been found to proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="739">
                    <text>In addition, HIV-specific T-cells CCD4+ in viraemic patients has been found to proliferate strongly in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="740">
                    <text>In addition, HIV-specific T-cells CCD4+ in viraemic patients is able to proliferate in response to HIV A1 antigens (when costimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="741">
                    <text>In addition, HIV-specific T-cells CCD4+ in viraemic patients may be observed to proliferate in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="742">
                    <text>In addition, HIV-specific T-cells CCD4+ in viraemic patients proliferated in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="743">
                    <text>In addition, HIV-specific T-cells CCD4+ in viraemic patients was observed to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="744">
                    <text>In addition, HSC has been shown to be highly proliferating in response to HIV antigens approximately 8 days of treatment with G-CSF in bone marrow and splendor.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="745">
                    <text>In addition, HSC has been shown to be highly proliferating in response to HIV antigens roughly 8 days of treatment with G-CSF in bone marrow and splendor.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="746">
                    <text>In addition, HSC has been shown to be highly proliferating in response to HIV antigens through 8 days of G-CSF treatment in bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="747">
                    <text>In addition, HSC has been shown to be highly proliferating in response to HIV antigens through 8 days of treatment with G-CSF in bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="748">
                    <text>In addition, HSC has been shown to be highly proliferating in response to HIV antigens via 8 days of G-CSF treatment in bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="749">
                    <text>In addition, HSC has been shown to be highly proliferating in response to HIV antigens via 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="750">
                    <text>In addition, HSC has been shown to be highly proliferating in response to HIV antigens via 8 days of treatment with G-CSF in bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="751">
                    <text>In addition, HSC has been shown to be highly proliferating in response to HIV antigens with 8 days of treatment with G-CSF in bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="752">
                    <text>In addition, HSC is able to proliferate in response to HIV antigens approximately 8 days of treatment with G-CSF in bone marrow and splendor.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="753">
                    <text>In addition, HSC is able to proliferate in response to HIV antigens roughly 8 days of treatment with G-CSF in bone marrow and splendor.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="754">
                    <text>In addition, HSC is able to proliferate in response to HIV antigens through 8 days of G-CSF treatment in bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="755">
                    <text>In addition, HSC is able to proliferate in response to HIV antigens through 8 days of treatment with G-CSF in bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="756">
                    <text>In addition, HSC is able to proliferate in response to HIV antigens via 8 days of G-CSF treatment in bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="757">
                    <text>In addition, HSC is able to proliferate in response to HIV antigens via 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="758">
                    <text>In addition, HSC is able to proliferate in response to HIV antigens via 8 days of treatment with G-CSF in bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="759">
                    <text>In addition, HSC is able to proliferate in response to HIV antigens with 8 days of treatment with G-CSF in bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="760">
                    <text>In addition, HSC was found to proliferate in response to HIV antigens approximately 8 days of treatment with G-CSF in bone marrow and splendor.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="761">
                    <text>In addition, HSC was found to proliferate in response to HIV antigens roughly 8 days of treatment with G-CSF in bone marrow and splendor.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="762">
                    <text>In addition, HSC was found to proliferate in response to HIV antigens through 8 days of G-CSF treatment in bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="763">
                    <text>In addition, HSC was found to proliferate in response to HIV antigens through 8 days of treatment with G-CSF in bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="764">
                    <text>In addition, HSC was found to proliferate in response to HIV antigens via 8 days of G-CSF treatment in bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="765">
                    <text>In addition, HSC was found to proliferate in response to HIV antigens via 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="766">
                    <text>In addition, HSC was found to proliferate in response to HIV antigens via 8 days of treatment with G-CSF in bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="767">
                    <text>In addition, HSC was found to proliferate in response to HIV antigens with 8 days of treatment with G-CSF in bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="768">
                    <text>In addition, it could be shown that BI cells proliferates in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vivo.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="769">
                    <text>In addition, it could be shown that BT cells proliferates in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vivo.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="770">
                    <text>In addition, it could be shown that CCD4+ HIV-specific T cells of viremic patients proliferates in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="771">
                    <text>In addition, it could be shown that EBD cells proliferates in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vivo.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="772">
                    <text>In addition, it could be shown that HD CD4+ T cells specific for HIV in viremic patients proliferates in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="773">
                    <text>In addition, it could be shown that HD CD4+ T cells specific to HIV in viremics patients proliferates in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="774">
                    <text>In addition, it could be shown that HD-specific T CD4+ cells for HIV in viremic patients proliferates in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="775">
                    <text>In addition, it could be shown that HDCD4+ T cells specific to HIV in viremics patients proliferates in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="776">
                    <text>In addition, it could be shown that HIV-specific T-cells CCD4+ in viraemic patients proliferates in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="777">
                    <text>In addition, it has been shown that HIV-specific CD4+ T cells in viremic patients proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vivo.</text>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="778">
                    <text>In addition, it has been shown that HIV-specific CD4+T blood cells in viremic patients are highly proliferating in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="779">
                    <text>In addition, it has been shown that HIV-specific CD4+T blood cells in viremic patients proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="780">
                    <text>In addition, it was observed that A0 cells (CD4+-specific HDD for HIV in viremics patients) proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="781">
                    <text>It is observed that HD CD4+ T cells specific for HIV in viremic patients continues to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="782">
                    <text>It is observed that HD CD4+ T cells specific for HIV in viremic patients continues to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in phase G0/G1.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="783">
                    <text>It is observed that HIV-specific CD4+ T cells in viremic patients continues to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="784">
                    <text>It is observed that HIV-specific CD4+ T cells in viremic patients continues to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in phase G0/G1.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="785">
                    <text>It is observed that HIV-specific T cells CCD4+ in viremic patients continues to proliferate in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="786">
                    <text>It is observed that HIV-specific T cells CCD4+ in viremic patients continues to proliferate strongly in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in phase G0/G1.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="787">
                    <text>It is observed that HSC continues to proliferate in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="788">
                    <text>It is observed that HSC continues to proliferate in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="789">
                    <text>It is observed that HSC continues to proliferate in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="790">
                    <text>It is observed that HSC continues to proliferate in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="791">
                    <text>It is observed that HSC continues to proliferate in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="792">
                    <text>It is observed that HSC continues to proliferate in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="793">
                    <text>It is observed that HSC continues to proliferate in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="794">
                    <text>It is observed that HSC continues to proliferate strongly in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in phase G0/G1.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="795">
                    <text>It is observed that HSC continues to proliferate strongly in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in phase G0/G1.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="796">
                    <text>It is observed that HSC continues to proliferate strongly in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in phase G0/G1.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="797">
                    <text>It is observed that HSC continues to proliferate strongly in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in phase G0/G1.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="798">
                    <text>It is observed that HSC continues to proliferate strongly in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in phase G0/G1.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="799">
                    <text>It is observed that HSC continues to proliferate strongly in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in phase G0/G1.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="800">
                    <text>It is observed that HSC continues to proliferate strongly in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tended to be in phase G0/G1.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="801">
                    <text>It is observed that Stat5ab-/-peripheral T cells regains the ability to proliferate after the introduction of Stat5a of full-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="802">
                    <text>It is observed that Stat5ab-/-peripheral T cells regains the ability to proliferate after the introduction of the Stat5a type of complete wild size (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="803">
                    <text>It is observed that Stat5ab-/-peripheral T cells regains the ability to proliferate after the introduction of the full-length wild type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="804">
                    <text>It is observed that Stat5ab-/-peripheral T cells regains the ability to proliferate after the introduction of wild body stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="805">
                    <text>It is observed that Stat5ab-/-peripheral T cells regains the ability to proliferate indefinitely after the introduction of Stat5a of full-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="806">
                    <text>It is observed that Stat5ab-/-peripheral T cells regains the ability to proliferate indefinitely after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="807">
                    <text>It is observed that Stat5ab-/-peripheral T cells regains the ability to proliferate indefinitely after the introduction of the Stat5a type of complete wild size (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="808">
                    <text>It is observed that Stat5ab-/-peripheral T cells regains the ability to proliferate indefinitely after the introduction of the full-length wild type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="809">
                    <text>It is observed that Stat5ab/-peripheral T cells regains the ability to proliferate after the introduction of the Stat5a complete-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="810">
                    <text>It is observed that Stat5ab/-peripheral T cells regains the ability to proliferate indefinitely after the introduction of the Stat5a complete-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="811">
                    <text>It is observed that Stat5ab/-peripheral regains the ability to proliferate after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="812">
                    <text>It is observed that Stat5ab/-peripheral regains the ability to proliferate indefinitely after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="813">
                    <text>It is observed that adult T cells regains the ability to proliferate indefinitely when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="814">
                    <text>It is observed that adult T cells regains the ability to proliferate when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="815">
                    <text>It is observed that adult naive T cells regains the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="816">
                    <text>It is observed that adult naive T cells regains the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="817">
                    <text>It is observed that endothelial cells regains the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="818">
                    <text>It is observed that endothelial cells regains the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="819">
                    <text>It is observed that ingenue T cells of adults regains the ability to proliferate indefinitely when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="820">
                    <text>It is observed that ingenue T cells of adults regains the ability to proliferate when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="821">
                    <text>It is observed that stat5ab-/-peripheral T cells regains the ability to proliferate after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="822">
                    <text>It is observed that stat5ab-/-peripheral T cells regains the ability to proliferate after the introduction of the full wild-length Stat5a type (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="823">
                    <text>It is observed that stat5ab-/-peripheral T cells regains the ability to proliferate indefinitely after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="824">
                    <text>It is observed that stat5ab-/-peripheral T cells regains the ability to proliferate indefinitely after the introduction of the full wild-length Stat5a type (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="825">
                    <text>It is observed that stat5ab/-peripheral T cells regains the ability to proliferate after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="826">
                    <text>It is observed that stat5ab/-peripheral T cells regains the ability to proliferate indefinitely after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="827">
                    <text>It is observed that stat5ab/peripheral T cells regains the ability to proliferate after the introduction of the completely length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="828">
                    <text>It is observed that stat5ab/peripheral T cells regains the ability to proliferate after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="829">
                    <text>It is observed that stat5ab/peripheral T cells regains the ability to proliferate after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="830">
                    <text>It is observed that stat5ab/peripheral T cells regains the ability to proliferate indefinitely after the introduction of the completely length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="831">
                    <text>It is observed that stat5ab/peripheral T cells regains the ability to proliferate indefinitely after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="832">
                    <text>It is observed that stat5ab/peripheral T cells regains the ability to proliferate indefinitely after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="833">
                    <text>It is observed that the human placenta regains the ability to proliferate along gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="834">
                    <text>It is observed that the human placenta regains the ability to proliferate indefinitely along gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="835">
                    <text>It is proliferate that Stat5ab-/-peripheral T cells regains the undefined proliferation capability after the introduction of Stat5a of full-length wild type (image 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="836">
                    <text>It is proliferate that Stat5ab-/-peripheral T cells regains the undefined proliferation capability after the introduction of Stat5a stulation (image 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="837">
                    <text>It is proliferate that Stat5ab-/-peripheral T cells regains the undefined proliferation capability after the introduction of the Stat5a type of complete wild size (image 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="838">
                    <text>It is proliferate that Stat5ab-/-peripheral T cells regains the undefined proliferation capability after the introduction of the full-length wild type Stat5a (image 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="839">
                    <text>It is proliferate that Stat5ab-/-peripheral T cells regains the undefined proliferation capability after the introduction of wild body stat5a (image 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="840">
                    <text>It is proliferate that Stat5ab/-peripheral T cells regains the undefined proliferation capability after the introduction of the Stat5a complete-length wild type (image 6B).</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="841">
                    <text>It is proliferate that Stat5ab/-peripheral regains the undefined proliferation capability after the introduction of Stat5a stulation (image 6B).</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="842">
                    <text>It is proliferate that adult T cells regains the undefined proliferation capability when transferred to lymphonic hosts (image 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="843">
                    <text>It is proliferate that adult naive T cells regains the undefined proliferation capability when transferred to lymphopenic hosts (image 6B).</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="844">
                    <text>It is proliferate that endothelial cells regains the undefined proliferation capability when exposed to FGF2 (image 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="845">
                    <text>It is proliferate that ingenue T cells of adults regains the undefined proliferation capability when transferred to lymphonic hosts (image 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="846">
                    <text>It is proliferate that stat5ab-/-peripheral T cells regains the undefined proliferation capability after the introduction of the full wild-length Stat5a (image 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="847">
                    <text>It is proliferate that stat5ab-/-peripheral T cells regains the undefined proliferation capability after the introduction of the full wild-length Stat5a type (image 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="848">
                    <text>It is proliferate that stat5ab/peripheral T cells regains the undefined proliferation capability after the introduction of the completely length wild-type Stat5a (image 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="849">
                    <text>It is proliferate that stat5ab/peripheral T cells regains the undefined proliferation capability after the introduction of the full wild-length Stat5a (image 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="850">
                    <text>It is proliferate that stat5ab/peripheral T cells regains the undefined proliferation capability after the introduction of the full wild-length state5a (image 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="851">
                    <text>It is proliferate that the human placenta regains the undefined proliferation capability along gestation (image 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="852">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells can be endowed with biochemical machinery to proliferate after the introduction of Stat5a of full-length wild type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="853">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells can be endowed with biochemical machinery to proliferate after the introduction of Stat5a stulation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="854">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells can be endowed with biochemical machinery to proliferate after the introduction of the Stat5a type of complete wild size, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="855">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells can be endowed with biochemical machinery to proliferate after the introduction of the full-length wild type Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="856">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells can be endowed with biochemical machinery to proliferate after the introduction of wild body stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="857">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells can be endowed with biochemical machinery to proliferate indefinitely after the introduction of Stat5a of full-length wild type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="858">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells can be endowed with biochemical machinery to proliferate indefinitely after the introduction of Stat5a stulation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="859">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells can be endowed with biochemical machinery to proliferate indefinitely after the introduction of the Stat5a type of complete wild size, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="860">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells can be endowed with biochemical machinery to proliferate indefinitely after the introduction of the full-length wild type Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="861">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells can be endowed with biochemical machinery to proliferate indefinitely after the introduction of wild body stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="862">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells could have been endowed with biochemical machinery to proliferate indefinitely after the introduction of Stat5a of full-length wild type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="863">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells could have been endowed with biochemical machinery to proliferate indefinitely after the introduction of Stat5a stulation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="864">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells could have been endowed with biochemical machinery to proliferate indefinitely after the introduction of the Stat5a type of complete wild size, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="865">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells could have been endowed with biochemical machinery to proliferate indefinitely after the introduction of the full-length wild type Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="866">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells could have been endowed with biochemical machinery to proliferate indefinitely after the introduction of wild body stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="867">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells has been endowed with biochemical machinery to proliferate indefinitely after the introduction of Stat5a of full-length wild type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="868">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells has been endowed with biochemical machinery to proliferate indefinitely after the introduction of Stat5a stulation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="869">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells has been endowed with biochemical machinery to proliferate indefinitely after the introduction of the Stat5a type of complete wild size, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="870">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells has been endowed with biochemical machinery to proliferate indefinitely after the introduction of the full-length wild type Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="871">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells has been endowed with biochemical machinery to proliferate indefinitely after the introduction of wild body stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="872">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells is endowed with biochemical machinery to proliferate indefinitely after the introduction of Stat5a of full-length wild type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="873">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells is endowed with biochemical machinery to proliferate indefinitely after the introduction of Stat5a stulation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="874">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells is endowed with biochemical machinery to proliferate indefinitely after the introduction of the Stat5a type of complete wild size, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="875">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells is endowed with biochemical machinery to proliferate indefinitely after the introduction of the full-length wild type Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="876">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells is endowed with biochemical machinery to proliferate indefinitely after the introduction of wild body stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="877">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells was endowed with biochemical machinery to proliferate after the introduction of Stat5a of full-length wild type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="878">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells was endowed with biochemical machinery to proliferate after the introduction of Stat5a stulation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="879">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells was endowed with biochemical machinery to proliferate after the introduction of the Stat5a type of complete wild size, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="880">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells was endowed with biochemical machinery to proliferate after the introduction of the full-length wild type Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="881">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells was endowed with biochemical machinery to proliferate after the introduction of wild body stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="882">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells was endowed with biochemical machinery to proliferate indefinitely after the introduction of Stat5a of full-length wild type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="883">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells was endowed with biochemical machinery to proliferate indefinitely after the introduction of Stat5a stulation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="884">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells was endowed with biochemical machinery to proliferate indefinitely after the introduction of the Stat5a type of complete wild size, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="885">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells was endowed with biochemical machinery to proliferate indefinitely after the introduction of the full-length wild type Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="886">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells was endowed with biochemical machinery to proliferate indefinitely after the introduction of wild body stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="887">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells will be endowed with biochemical machinery to proliferate indefinitely after the introduction of Stat5a of full-length wild type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="888">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells will be endowed with biochemical machinery to proliferate indefinitely after the introduction of Stat5a stulation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="889">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells will be endowed with biochemical machinery to proliferate indefinitely after the introduction of the Stat5a type of complete wild size, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="890">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells will be endowed with biochemical machinery to proliferate indefinitely after the introduction of the full-length wild type Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="891">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells will be endowed with biochemical machinery to proliferate indefinitely after the introduction of wild body stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="892">
                    <text>Our observations illustrate that Stat5ab/-peripheral T cells can be endowed with biochemical machinery to proliferate after the introduction of the Stat5a complete-length wild type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="893">
                    <text>Our observations illustrate that Stat5ab/-peripheral T cells can be endowed with biochemical machinery to proliferate indefinitely after the introduction of the Stat5a complete-length wild type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="894">
                    <text>Our observations illustrate that Stat5ab/-peripheral T cells could have been endowed with biochemical machinery to proliferate indefinitely after the introduction of the Stat5a complete-length wild type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="895">
                    <text>Our observations illustrate that Stat5ab/-peripheral T cells has been endowed with biochemical machinery to proliferate indefinitely after the introduction of the Stat5a complete-length wild type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="896">
                    <text>Our observations illustrate that Stat5ab/-peripheral T cells is endowed with biochemical machinery to proliferate indefinitely after the introduction of the Stat5a complete-length wild type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="897">
                    <text>Our observations illustrate that Stat5ab/-peripheral T cells was endowed with biochemical machinery to proliferate after the introduction of the Stat5a complete-length wild type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="898">
                    <text>Our observations illustrate that Stat5ab/-peripheral T cells was endowed with biochemical machinery to proliferate indefinitely after the introduction of the Stat5a complete-length wild type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="899">
                    <text>Our observations illustrate that Stat5ab/-peripheral T cells will be endowed with biochemical machinery to proliferate indefinitely after the introduction of the Stat5a complete-length wild type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="900">
                    <text>Our observations illustrate that Stat5ab/-peripheral can be endowed with biochemical machinery to proliferate after the introduction of Stat5a stulation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="901">
                    <text>Our observations illustrate that Stat5ab/-peripheral can be endowed with biochemical machinery to proliferate indefinitely after the introduction of Stat5a stulation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="902">
                    <text>Our observations illustrate that Stat5ab/-peripheral could have been endowed with biochemical machinery to proliferate indefinitely after the introduction of Stat5a stulation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="903">
                    <text>Our observations illustrate that Stat5ab/-peripheral has been endowed with biochemical machinery to proliferate indefinitely after the introduction of Stat5a stulation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="904">
                    <text>Our observations illustrate that Stat5ab/-peripheral is endowed with biochemical machinery to proliferate indefinitely after the introduction of Stat5a stulation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="905">
                    <text>Our observations illustrate that Stat5ab/-peripheral was endowed with biochemical machinery to proliferate after the introduction of Stat5a stulation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="906">
                    <text>Our observations illustrate that Stat5ab/-peripheral was endowed with biochemical machinery to proliferate indefinitely after the introduction of Stat5a stulation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="907">
                    <text>Our observations illustrate that Stat5ab/-peripheral will be endowed with biochemical machinery to proliferate indefinitely after the introduction of Stat5a stulation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="908">
                    <text>Our observations illustrate that adult T cells can be endowed with biochemical machinery to proliferate indefinitely when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="909">
                    <text>Our observations illustrate that adult T cells can be endowed with biochemical machinery to proliferate when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="910">
                    <text>Our observations illustrate that adult T cells could have been endowed with biochemical machinery to proliferate indefinitely when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="911">
                    <text>Our observations illustrate that adult T cells has been endowed with biochemical machinery to proliferate indefinitely when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="912">
                    <text>Our observations illustrate that adult T cells is endowed with biochemical machinery to proliferate indefinitely when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="913">
                    <text>Our observations illustrate that adult T cells was endowed with biochemical machinery to proliferate indefinitely when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="914">
                    <text>Our observations illustrate that adult T cells was endowed with biochemical machinery to proliferate when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="915">
                    <text>Our observations illustrate that adult T cells will be endowed with biochemical machinery to proliferate indefinitely when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="916">
                    <text>Our observations illustrate that adult naive T cells can be endowed with biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="917">
                    <text>Our observations illustrate that adult naive T cells can be endowed with biochemical machinery to proliferate when transferred to lymphopenic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="918">
                    <text>Our observations illustrate that adult naive T cells could have been endowed with biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="919">
                    <text>Our observations illustrate that adult naive T cells has been endowed with biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="920">
                    <text>Our observations illustrate that adult naive T cells is endowed with biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="921">
                    <text>Our observations illustrate that adult naive T cells was endowed with biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="922">
                    <text>Our observations illustrate that adult naive T cells was endowed with biochemical machinery to proliferate when transferred to lymphopenic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="923">
                    <text>Our observations illustrate that adult naive T cells will be endowed with biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="924">
                    <text>Our observations illustrate that endothelial cells can be endowed with biochemical machinery to proliferate indefinitely when exposed to FGF2, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="925">
                    <text>Our observations illustrate that endothelial cells can be endowed with biochemical machinery to proliferate when exposed to FGF2, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="926">
                    <text>Our observations illustrate that endothelial cells could have been endowed with biochemical machinery to proliferate indefinitely when exposed to FGF2, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="927">
                    <text>Our observations illustrate that endothelial cells has been endowed with biochemical machinery to proliferate indefinitely when exposed to FGF2, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="928">
                    <text>Our observations illustrate that endothelial cells is endowed with biochemical machinery to proliferate indefinitely when exposed to FGF2, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="929">
                    <text>Our observations illustrate that endothelial cells was endowed with biochemical machinery to proliferate indefinitely when exposed to FGF2, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="930">
                    <text>Our observations illustrate that endothelial cells was endowed with biochemical machinery to proliferate when exposed to FGF2, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="931">
                    <text>Our observations illustrate that endothelial cells will be endowed with biochemical machinery to proliferate indefinitely when exposed to FGF2, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="932">
                    <text>Our observations illustrate that ingenue T cells of adults can be endowed with biochemical machinery to proliferate indefinitely when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="933">
                    <text>Our observations illustrate that ingenue T cells of adults can be endowed with biochemical machinery to proliferate when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="934">
                    <text>Our observations illustrate that ingenue T cells of adults could have been endowed with biochemical machinery to proliferate indefinitely when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="935">
                    <text>Our observations illustrate that ingenue T cells of adults has been endowed with biochemical machinery to proliferate indefinitely when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="936">
                    <text>Our observations illustrate that ingenue T cells of adults is endowed with biochemical machinery to proliferate indefinitely when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="937">
                    <text>Our observations illustrate that ingenue T cells of adults was endowed with biochemical machinery to proliferate indefinitely when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="938">
                    <text>Our observations illustrate that ingenue T cells of adults was endowed with biochemical machinery to proliferate when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="939">
                    <text>Our observations illustrate that ingenue T cells of adults will be endowed with biochemical machinery to proliferate indefinitely when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="940">
                    <text>Our observations illustrate that stat5ab-/-peripheral T cells can be endowed with biochemical machinery to proliferate after the introduction of the full wild-length Stat5a type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="941">
                    <text>Our observations illustrate that stat5ab-/-peripheral T cells can be endowed with biochemical machinery to proliferate after the introduction of the full wild-length Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="942">
                    <text>Our observations illustrate that stat5ab-/-peripheral T cells can be endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length Stat5a type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="943">
                    <text>Our observations illustrate that stat5ab-/-peripheral T cells can be endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="944">
                    <text>Our observations illustrate that stat5ab-/-peripheral T cells could have been endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length Stat5a type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="945">
                    <text>Our observations illustrate that stat5ab-/-peripheral T cells could have been endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="946">
                    <text>Our observations illustrate that stat5ab-/-peripheral T cells has been endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length Stat5a type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="947">
                    <text>Our observations illustrate that stat5ab-/-peripheral T cells has been endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="948">
                    <text>Our observations illustrate that stat5ab-/-peripheral T cells is endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length Stat5a type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="949">
                    <text>Our observations illustrate that stat5ab-/-peripheral T cells is endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="950">
                    <text>Our observations illustrate that stat5ab-/-peripheral T cells was endowed with biochemical machinery to proliferate after the introduction of the full wild-length Stat5a type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="951">
                    <text>Our observations illustrate that stat5ab-/-peripheral T cells was endowed with biochemical machinery to proliferate after the introduction of the full wild-length Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="952">
                    <text>Our observations illustrate that stat5ab-/-peripheral T cells was endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length Stat5a type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="953">
                    <text>Our observations illustrate that stat5ab-/-peripheral T cells was endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="954">
                    <text>Our observations illustrate that stat5ab-/-peripheral T cells will be endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length Stat5a type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="955">
                    <text>Our observations illustrate that stat5ab-/-peripheral T cells will be endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="956">
                    <text>Our observations illustrate that stat5ab/-peripheral T cells can be endowed with biochemical machinery to proliferate after the introduction of the full wild-length state5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="957">
                    <text>Our observations illustrate that stat5ab/-peripheral T cells can be endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length state5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="958">
                    <text>Our observations illustrate that stat5ab/-peripheral T cells could have been endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length state5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="959">
                    <text>Our observations illustrate that stat5ab/-peripheral T cells has been endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length state5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="960">
                    <text>Our observations illustrate that stat5ab/-peripheral T cells is endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length state5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="961">
                    <text>Our observations illustrate that stat5ab/-peripheral T cells was endowed with biochemical machinery to proliferate after the introduction of the full wild-length state5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="962">
                    <text>Our observations illustrate that stat5ab/-peripheral T cells was endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length state5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="963">
                    <text>Our observations illustrate that stat5ab/-peripheral T cells will be endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length state5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="964">
                    <text>Our observations illustrate that stat5ab/peripheral T cells can be endowed with biochemical machinery to proliferate after the introduction of the completely length wild-type Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="965">
                    <text>Our observations illustrate that stat5ab/peripheral T cells can be endowed with biochemical machinery to proliferate after the introduction of the full wild-length Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="966">
                    <text>Our observations illustrate that stat5ab/peripheral T cells can be endowed with biochemical machinery to proliferate after the introduction of the full wild-length state5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="967">
                    <text>Our observations illustrate that stat5ab/peripheral T cells can be endowed with biochemical machinery to proliferate indefinitely after the introduction of the completely length wild-type Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="968">
                    <text>Our observations illustrate that stat5ab/peripheral T cells can be endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="969">
                    <text>Our observations illustrate that stat5ab/peripheral T cells can be endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length state5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="970">
                    <text>Our observations illustrate that stat5ab/peripheral T cells could have been endowed with biochemical machinery to proliferate indefinitely after the introduction of the completely length wild-type Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="971">
                    <text>Our observations illustrate that stat5ab/peripheral T cells could have been endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="972">
                    <text>Our observations illustrate that stat5ab/peripheral T cells could have been endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length state5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="973">
                    <text>Our observations illustrate that stat5ab/peripheral T cells has been endowed with biochemical machinery to proliferate indefinitely after the introduction of the completely length wild-type Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="974">
                    <text>Our observations illustrate that stat5ab/peripheral T cells has been endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="975">
                    <text>Our observations illustrate that stat5ab/peripheral T cells has been endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length state5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="976">
                    <text>Our observations illustrate that stat5ab/peripheral T cells is endowed with biochemical machinery to proliferate indefinitely after the introduction of the completely length wild-type Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="977">
                    <text>Our observations illustrate that stat5ab/peripheral T cells is endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="978">
                    <text>Our observations illustrate that stat5ab/peripheral T cells is endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length state5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="979">
                    <text>Our observations illustrate that stat5ab/peripheral T cells was endowed with biochemical machinery to proliferate after the introduction of the completely length wild-type Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="980">
                    <text>Our observations illustrate that stat5ab/peripheral T cells was endowed with biochemical machinery to proliferate after the introduction of the full wild-length Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="981">
                    <text>Our observations illustrate that stat5ab/peripheral T cells was endowed with biochemical machinery to proliferate after the introduction of the full wild-length state5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="982">
                    <text>Our observations illustrate that stat5ab/peripheral T cells was endowed with biochemical machinery to proliferate indefinitely after the introduction of the completely length wild-type Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="983">
                    <text>Our observations illustrate that stat5ab/peripheral T cells was endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="984">
                    <text>Our observations illustrate that stat5ab/peripheral T cells was endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length state5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="985">
                    <text>Our observations illustrate that stat5ab/peripheral T cells will be endowed with biochemical machinery to proliferate indefinitely after the introduction of the completely length wild-type Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="986">
                    <text>Our observations illustrate that stat5ab/peripheral T cells will be endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="987">
                    <text>Our observations illustrate that stat5ab/peripheral T cells will be endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length state5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="988">
                    <text>Stat5ab-/-peripheral T cells can regain the ability to proliferate after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="989">
                    <text>Stat5ab-/-peripheral T cells can regain the ability to proliferate after the introduction of the Stat5a type of complete wild size (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="990">
                    <text>Stat5ab-/-peripheral T cells can regain the ability to proliferate after the introduction of the full-length wild type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="991">
                    <text>Stat5ab-/-peripheral T cells can regain the ability to proliferate after the introduction of wild body stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="992">
                    <text>Stat5ab-/-peripheral T cells can regain the ability to proliferate indefinitely after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="993">
                    <text>Stat5ab-/-peripheral T cells can regain the ability to proliferate indefinitely after the introduction of the Stat5a type of complete wild size (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="994">
                    <text>Stat5ab-/-peripheral T cells can regain the ability to proliferate indefinitely after the introduction of the full-length wild type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="995">
                    <text>Stat5ab-/-peripheral T cells can regain the ability to proliferate indefinitely after the introduction of wild body stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="996">
                    <text>Stat5ab-/-peripheral T cells has regained the ability to proliferate after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="997">
                    <text>Stat5ab-/-peripheral T cells has regained the ability to proliferate after the introduction of the Stat5a type of complete wild size (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="998">
                    <text>Stat5ab-/-peripheral T cells has regained the ability to proliferate after the introduction of the full-length wild type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="999">
                    <text>Stat5ab-/-peripheral T cells has regained the ability to proliferate after the introduction of wild body stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1000">
                    <text>Stat5ab-/-peripheral T cells has the probability of recovering the ability to proliferate after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1001">
                    <text>Stat5ab-/-peripheral T cells has the probability of recovering the ability to proliferate after the introduction of the Stat5a type of complete wild size (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1002">
                    <text>Stat5ab-/-peripheral T cells has the probability of recovering the ability to proliferate after the introduction of the full-length wild type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1003">
                    <text>Stat5ab-/-peripheral T cells has the probability of recovering the ability to proliferate after the introduction of wild body stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1004">
                    <text>Stat5ab-/-peripheral T cells has the probability of recovering the ability to proliferate indefinitely after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1005">
                    <text>Stat5ab-/-peripheral T cells has the probability of recovering the ability to proliferate indefinitely after the introduction of the Stat5a type of complete wild size (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1006">
                    <text>Stat5ab-/-peripheral T cells has the probability of recovering the ability to proliferate indefinitely after the introduction of the full-length wild type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1007">
                    <text>Stat5ab-/-peripheral T cells has the probability of recovering the ability to proliferate indefinitely after the introduction of wild body stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1008">
                    <text>Stat5ab-/-peripheral T cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1009">
                    <text>Stat5ab-/-peripheral T cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1010">
                    <text>Stat5ab-/-peripheral T cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1011">
                    <text>Stat5ab-/-peripheral T cells is likely to proliferate the undefined proliferation capacity after the introduction of Stat5a of full-length wild type (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1012">
                    <text>Stat5ab-/-peripheral T cells is likely to proliferate the undefined proliferation capacity after the introduction of Stat5a stulation (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1013">
                    <text>Stat5ab-/-peripheral T cells is likely to proliferate the undefined proliferation capacity after the introduction of the Stat5a type of complete wild size (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1014">
                    <text>Stat5ab-/-peripheral T cells is likely to proliferate the undefined proliferation capacity after the introduction of the full-length wild type Stat5a (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1015">
                    <text>Stat5ab-/-peripheral T cells is likely to proliferate the undefined proliferation capacity after the introduction of wild body stat5a (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1016">
                    <text>Stat5ab-/-peripheral T cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1017">
                    <text>Stat5ab-/-peripheral T cells may have regained the ability to proliferate after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1018">
                    <text>Stat5ab-/-peripheral T cells may have regained the ability to proliferate after the introduction of the Stat5a type of complete wild size (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1019">
                    <text>Stat5ab-/-peripheral T cells may have regained the ability to proliferate after the introduction of the full-length wild type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1020">
                    <text>Stat5ab-/-peripheral T cells may have regained the ability to proliferate after the introduction of wild body stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1021">
                    <text>Stat5ab-/-peripheral T cells may have regained the ability to proliferate indefinitely after the introduction of Stat5a of full-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1022">
                    <text>Stat5ab-/-peripheral T cells may have regained the ability to proliferate indefinitely after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1023">
                    <text>Stat5ab-/-peripheral T cells may have regained the ability to proliferate indefinitely after the introduction of the Stat5a type of complete wild size (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1024">
                    <text>Stat5ab-/-peripheral T cells may have regained the ability to proliferate indefinitely after the introduction of wild body stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1025">
                    <text>Stat5ab-/-peripheral T cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1026">
                    <text>Stat5ab-/-peripheral T cells may proliferate recovered the undefined proliferation capacity after the introduction of Stat5a of full-length wild type (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1027">
                    <text>Stat5ab-/-peripheral T cells may proliferate recovered the undefined proliferation capacity after the introduction of Stat5a stulation (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1028">
                    <text>Stat5ab-/-peripheral T cells may proliferate recovered the undefined proliferation capacity after the introduction of the Stat5a type of complete wild size (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1029">
                    <text>Stat5ab-/-peripheral T cells may proliferate recovered the undefined proliferation capacity after the introduction of the full-length wild type Stat5a (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1030">
                    <text>Stat5ab-/-peripheral T cells may proliferate recovered the undefined proliferation capacity after the introduction of wild body stat5a (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1031">
                    <text>Stat5ab-/-peripheral T cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1032">
                    <text>Stat5ab-/-peripheral T cells may proliferate the undefined proliferation capacity after the introduction of Stat5a of full-length wild type (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1033">
                    <text>Stat5ab-/-peripheral T cells may proliferate the undefined proliferation capacity after the introduction of Stat5a stulation (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1034">
                    <text>Stat5ab-/-peripheral T cells may proliferate the undefined proliferation capacity after the introduction of the Stat5a type of complete wild size (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1035">
                    <text>Stat5ab-/-peripheral T cells may proliferate the undefined proliferation capacity after the introduction of the full-length wild type Stat5a (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1036">
                    <text>Stat5ab-/-peripheral T cells may proliferate the undefined proliferation capacity after the introduction of wild body stat5a (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1037">
                    <text>Stat5ab-/-peripheral T cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1038">
                    <text>Stat5ab-/-peripheral T cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1039">
                    <text>Stat5ab-/-peripheral T cells proliferate the undefined proliferation capacity after the introduction of Stat5a of full-length wild type (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1040">
                    <text>Stat5ab-/-peripheral T cells proliferate the undefined proliferation capacity after the introduction of Stat5a stulation (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1041">
                    <text>Stat5ab-/-peripheral T cells proliferate the undefined proliferation capacity after the introduction of the Stat5a type of complete wild size (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1042">
                    <text>Stat5ab-/-peripheral T cells proliferate the undefined proliferation capacity after the introduction of the full-length wild type Stat5a (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1043">
                    <text>Stat5ab-/-peripheral T cells proliferate the undefined proliferation capacity after the introduction of wild body stat5a (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1044">
                    <text>Stat5ab-/-peripheral T cells recovered the ability to proliferate after the introduction of Stat5a of full-length wild type (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1045">
                    <text>Stat5ab-/-peripheral T cells recovered the ability to proliferate after the introduction of Stat5a stulation (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1046">
                    <text>Stat5ab-/-peripheral T cells recovered the ability to proliferate after the introduction of the Stat5a type of complete wild size (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1047">
                    <text>Stat5ab-/-peripheral T cells recovered the ability to proliferate after the introduction of the full-length wild type Stat5a (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1048">
                    <text>Stat5ab-/-peripheral T cells recovered the ability to proliferate after the introduction of wild body stat5a (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1049">
                    <text>Stat5ab-/-peripheral T cells regained the ability to proliferate indefinitely after the introduction of Stat5a of full-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1050">
                    <text>Stat5ab-/-peripheral T cells regained the ability to proliferate indefinitely after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1051">
                    <text>Stat5ab-/-peripheral T cells regained the ability to proliferate indefinitely after the introduction of the Stat5a type of complete wild size (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1052">
                    <text>Stat5ab-/-peripheral T cells regained the ability to proliferate indefinitely after the introduction of wild body stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1053">
                    <text>Stat5ab-/-peripheral T cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1054">
                    <text>Stat5ab-/-peripheral T cells will proliferate the undefined proliferation capability after the introduction of Stat5a of full-length wild type (image 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1055">
                    <text>Stat5ab-/-peripheral T cells will proliferate the undefined proliferation capability after the introduction of Stat5a stulation (image 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1056">
                    <text>Stat5ab-/-peripheral T cells will proliferate the undefined proliferation capability after the introduction of the Stat5a type of complete wild size (image 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1057">
                    <text>Stat5ab-/-peripheral T cells will proliferate the undefined proliferation capability after the introduction of the full-length wild type Stat5a (image 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1058">
                    <text>Stat5ab-/-peripheral T cells will proliferate the undefined proliferation capability after the introduction of wild body stat5a (image 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1059">
                    <text>Stat5ab-/-peripheral T cells will regain the ability to proliferate after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1060">
                    <text>Stat5ab-/-peripheral T cells will regain the ability to proliferate after the introduction of the Stat5a type of complete wild size (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1061">
                    <text>Stat5ab-/-peripheral T cells will regain the ability to proliferate after the introduction of the full-length wild type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1062">
                    <text>Stat5ab-/-peripheral T cells will regain the ability to proliferate after the introduction of wild body stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1063">
                    <text>Stat5ab-/-peripheral T cells will regain the ability to proliferate indefinitely after the introduction of Stat5a of full-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1064">
                    <text>Stat5ab-/-peripheral T cells will regain the ability to proliferate indefinitely after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1065">
                    <text>Stat5ab-/-peripheral T cells will regain the ability to proliferate indefinitely after the introduction of the full-length wild type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1066">
                    <text>Stat5ab-/-peripheral T cells will regain the ability to proliferate indefinitely after the introduction of wild body stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1067">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, are observed to proliferate after the introduction of Stat5a of full-length wild type.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1068">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, are observed to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1069">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, are observed to proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1070">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, are observed to proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1071">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, are observed to proliferate after the introduction of wild body stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1072">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, have the ability to proliferate after the introduction of Stat5a of full-length wild type.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1073">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, have the ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1074">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, have the ability to proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1075">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, have the ability to proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1076">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, have the ability to proliferate after the introduction of wild body stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1077">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, will proliferate after the introduction of Stat5a of full-length wild type.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1078">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, will proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1079">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, will proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1080">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, will proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1081">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, will proliferate after the introduction of wild body stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1082">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, are able to proliferate after the introduction of Stat5a of full-length wild type.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1083">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, are able to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1084">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, are able to proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1085">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, are able to proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1086">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, are able to proliferate after the introduction of wild body stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1087">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, are able to proliferate strongly after the introduction of Stat5a of full-length wild type.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1088">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, are able to proliferate strongly after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1089">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, are able to proliferate strongly after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1090">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, are able to proliferate strongly after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1091">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, are able to proliferate strongly after the introduction of wild body stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1092">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, are observed to strongly proliferate after the introduction of Stat5a of full-length wild type.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1093">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, are observed to strongly proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1094">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, are observed to strongly proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1095">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, are observed to strongly proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1096">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, are observed to strongly proliferate after the introduction of wild body stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1097">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, can proliferate after the introduction of Stat5a of full-length wild type.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1098">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, can proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1099">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, can proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1100">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, can proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1101">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, can proliferate after the introduction of wild body stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1102">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, will proliferate after the introduction of Stat5a of full-length wild type.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1103">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, will proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1104">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, will proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1105">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, will proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1106">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, will proliferate after the introduction of wild body stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1107">
                    <text>Stat5ab/-peripheral T cells can regain the ability to proliferate after the introduction of the Stat5a complete-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1108">
                    <text>Stat5ab/-peripheral T cells can regain the ability to proliferate indefinitely after the introduction of the Stat5a complete-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1109">
                    <text>Stat5ab/-peripheral T cells has regained the ability to proliferate after the introduction of the Stat5a complete-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1110">
                    <text>Stat5ab/-peripheral T cells has the probability of recovering the ability to proliferate after the introduction of the Stat5a complete-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1111">
                    <text>Stat5ab/-peripheral T cells has the probability of recovering the ability to proliferate indefinitely after the introduction of the Stat5a complete-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1112">
                    <text>Stat5ab/-peripheral T cells is likely to proliferate the undefined proliferation capacity after the introduction of the Stat5a complete-length wild type (picture 6B).</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1113">
                    <text>Stat5ab/-peripheral T cells may have regained the ability to proliferate after the introduction of the Stat5a complete-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1114">
                    <text>Stat5ab/-peripheral T cells may have regained the ability to proliferate indefinitely after the introduction of the Stat5a complete-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1115">
                    <text>Stat5ab/-peripheral T cells may proliferate recovered the undefined proliferation capacity after the introduction of the Stat5a complete-length wild type (picture 6B).</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1116">
                    <text>Stat5ab/-peripheral T cells may proliferate the undefined proliferation capacity after the introduction of the Stat5a complete-length wild type (picture 6B).</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1117">
                    <text>Stat5ab/-peripheral T cells proliferate the undefined proliferation capacity after the introduction of the Stat5a complete-length wild type (picture 6B).</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1118">
                    <text>Stat5ab/-peripheral T cells recovered the ability to proliferate after the introduction of the Stat5a complete-length wild type (picture 6B).</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1119">
                    <text>Stat5ab/-peripheral T cells regained the ability to proliferate indefinitely after the introduction of the Stat5a complete-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1120">
                    <text>Stat5ab/-peripheral T cells will proliferate the undefined proliferation capability after the introduction of the Stat5a complete-length wild type (image 6B).</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1121">
                    <text>Stat5ab/-peripheral T cells will regain the ability to proliferate after the introduction of the Stat5a complete-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1122">
                    <text>Stat5ab/-peripheral T cells will regain the ability to proliferate indefinitely after the introduction of the Stat5a complete-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1123">
                    <text>Stat5ab/-peripheral T cells, which are at rest in normal conditions, are observed to proliferate after the introduction of the Stat5a complete-length wild type.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1124">
                    <text>Stat5ab/-peripheral T cells, which are at rest in normal conditions, have the ability to proliferate after the introduction of the Stat5a complete-length wild type.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1125">
                    <text>Stat5ab/-peripheral T cells, which are at rest in normal conditions, will proliferate after the introduction of the Stat5a complete-length wild type.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1126">
                    <text>Stat5ab/-peripheral T cells, which are at rest under normal conditions, are able to proliferate after the introduction of the Stat5a complete-length wild type.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1127">
                    <text>Stat5ab/-peripheral T cells, which are at rest under normal conditions, are able to proliferate strongly after the introduction of the Stat5a complete-length wild type.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1128">
                    <text>Stat5ab/-peripheral T cells, which are at rest under normal conditions, are observed to strongly proliferate after the introduction of the Stat5a complete-length wild type.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1129">
                    <text>Stat5ab/-peripheral T cells, which are at rest under normal conditions, can proliferate after the introduction of the Stat5a complete-length wild type.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1130">
                    <text>Stat5ab/-peripheral T cells, which are at rest under normal conditions, will proliferate after the introduction of the Stat5a complete-length wild type.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1131">
                    <text>Stat5ab/-peripheral can regain the ability to proliferate after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1132">
                    <text>Stat5ab/-peripheral can regain the ability to proliferate indefinitely after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1133">
                    <text>Stat5ab/-peripheral has regained the ability to proliferate after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1134">
                    <text>Stat5ab/-peripheral has the probability of recovering the ability to proliferate after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1135">
                    <text>Stat5ab/-peripheral has the probability of recovering the ability to proliferate indefinitely after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1136">
                    <text>Stat5ab/-peripheral is likely to proliferate the undefined proliferation capacity after the introduction of Stat5a stulation (picture 6B).</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1137">
                    <text>Stat5ab/-peripheral may have regained the ability to proliferate after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1138">
                    <text>Stat5ab/-peripheral may have regained the ability to proliferate indefinitely after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1139">
                    <text>Stat5ab/-peripheral may proliferate recovered the undefined proliferation capacity after the introduction of Stat5a stulation (picture 6B).</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1140">
                    <text>Stat5ab/-peripheral may proliferate the undefined proliferation capacity after the introduction of Stat5a stulation (picture 6B).</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1141">
                    <text>Stat5ab/-peripheral proliferate the undefined proliferation capacity after the introduction of Stat5a stulation (picture 6B).</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1142">
                    <text>Stat5ab/-peripheral recovered the ability to proliferate after the introduction of Stat5a stulation (picture 6B).</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1143">
                    <text>Stat5ab/-peripheral regained the ability to proliferate indefinitely after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1144">
                    <text>Stat5ab/-peripheral will proliferate the undefined proliferation capability after the introduction of Stat5a stulation (image 6B).</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1145">
                    <text>Stat5ab/-peripheral will regain the ability to proliferate after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1146">
                    <text>Stat5ab/-peripheral will regain the ability to proliferate indefinitely after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1147">
                    <text>Stat5ab/-peripheral, which are at rest in normal conditions, are observed to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1148">
                    <text>Stat5ab/-peripheral, which are at rest in normal conditions, have the ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1149">
                    <text>Stat5ab/-peripheral, which are at rest in normal conditions, will proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1150">
                    <text>Stat5ab/-peripheral, which are at rest under normal conditions, are able to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1151">
                    <text>Stat5ab/-peripheral, which are at rest under normal conditions, are able to proliferate strongly after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1152">
                    <text>Stat5ab/-peripheral, which are at rest under normal conditions, are observed to strongly proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1153">
                    <text>Stat5ab/-peripheral, which are at rest under normal conditions, can proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1154">
                    <text>Stat5ab/-peripheral, which are at rest under normal conditions, will proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1155">
                    <text>T A0 cells are able to proliferate the undefined proliferation capacity after the introduction of Stat5a wild body stulation (picture 6B).</text>
                    <arg n="1">after the introduction of Stat5a wild body stulation</arg>
                </example>
                <example src="PERMUTATE" no="1156">
                    <text>T A0 cells are able to proliferate the undefined proliferation capacity transferred to lymph nodes (picture 6B).</text>
                    <arg n="1">transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="1157">
                    <text>T A0 cells are able to proliferate the undefined proliferation capacity transferred to lymphonic hosts (picture 6B).</text>
                    <arg n="1">transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1158">
                    <text>T A0 cells are able to proliferate the undefined proliferation capacity when transferred to lymph nodes (picture 6B).</text>
                    <arg n="1">when transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="1159">
                    <text>T A0 cells are able to proliferate the undefined proliferation capacity when transferred to lymphocytic hosts (picture 6B).</text>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1160">
                    <text>T A0 cells are able to proliferate the undefined proliferation capacity when transferred to lymphonic hosts (picture 6B).</text>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1161">
                    <text>T cells Stat5ab-/-peripheral T cells are able to recover the ability to proliferate after the introduction of Stat5a of full-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1162">
                    <text>T cells Stat5ab-/-peripheral T cells are able to recover the ability to proliferate after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1163">
                    <text>T cells Stat5ab-/-peripheral T cells are able to recover the ability to proliferate after the introduction of the Stat5a type of complete wild size (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1164">
                    <text>T cells Stat5ab-/-peripheral T cells are able to recover the ability to proliferate after the introduction of the full-length wild type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1165">
                    <text>T cells Stat5ab-/-peripheral T cells are able to recover the ability to proliferate after the introduction of wild body stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1166">
                    <text>T cells Stat5ab/-peripheral T cells are able to recover the ability to proliferate after the introduction of the Stat5a complete-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1167">
                    <text>T cells adult T cells are able to recover the ability to proliferate when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1168">
                    <text>T cells adult naive T cells are able to recover the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1169">
                    <text>T cells endothelial cells are able to recover the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="1170">
                    <text>T cells ingenue T cells of adults are able to recover the ability to proliferate when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1171">
                    <text>T cells stat5ab-/-peripheral T cells are able to recover the ability to proliferate after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1172">
                    <text>T cells stat5ab-/-peripheral T cells are able to recover the ability to proliferate after the introduction of the full wild-length Stat5a type (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="1173">
                    <text>T cells stat5ab/-peripheral T cells are able to recover the ability to proliferate after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1174">
                    <text>T cells stat5ab/peripheral T cells are able to recover the ability to proliferate after the introduction of the completely length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1175">
                    <text>T cells stat5ab/peripheral T cells are able to recover the ability to proliferate after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1176">
                    <text>T cells stat5ab/peripheral T cells are able to recover the ability to proliferate after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1177">
                    <text>T cells the human placenta are able to recover the ability to proliferate along gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="1178">
                    <text>The A0 capacity (BT cells) that may have proliferated in vitro was examined by injection of 3? 106 LVTE cells into the muscle of the calf of 3 immunocompromised mice.</text>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1179">
                    <text>The BI cells capacity that can proliferate in vivo was examined by injection of 3? 106 LVTE cells into the muscle of the calf of 3 immunocompromised mice.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1180">
                    <text>The BI cells capacity that proliferated in vivo was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1181">
                    <text>The BI cells capacity that will proliferate strongly in vivo has been examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1182">
                    <text>The CCD4+ HIV-specific T cells of viremic patients capacity that can proliferate in vitro was examined by injection of 3? 106 LVTE cells into the muscle of the calf of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1183">
                    <text>The CCD4+ HIV-specific T cells of viremic patients capacity that proliferated in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1184">
                    <text>The CCD4+ HIV-specific T cells of viremic patients capacity that will proliferate strongly in vitro has been examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1185">
                    <text>The CCD4+ HIV-specific cells of viremic patients capacity that can proliferate in vitro was examined by injection of 3? 106 LVTE cells into the muscle of the calf of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1186">
                    <text>The CCD4+ HIV-specific cells of viremic patients capacity that proliferated in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1187">
                    <text>The CCD4+ HIV-specific cells of viremic patients capacity that will proliferate strongly in vitro has been examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1188">
                    <text>The EBD cells capacity that can proliferate in vivo was examined by injection of 3? 106 LVTE cells into the muscle of the calf of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1189">
                    <text>The EBD cells capacity that proliferated in vivo was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1190">
                    <text>The EBD cells capacity that will proliferate strongly in vivo has been examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1191">
                    <text>The HD CD4+ T cells specific for HIV in viremic patients capacity that can proliferate in vitro was examined by injection of 3? 106 LVTE cells into the muscle of the calf of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1192">
                    <text>The HD CD4+ T cells specific for HIV in viremic patients capacity that proliferated in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1193">
                    <text>The HD CD4+ T cells specific for HIV in viremic patients capacity that will proliferate strongly in vitro has been examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1194">
                    <text>The HD CD4+ T cells specific to HIV in viremics patients capacity that can proliferate in vitro was examined by injection of 3? 106 LVTE cells into the muscle of the calf of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1195">
                    <text>The HD CD4+ T cells specific to HIV in viremics patients capacity that proliferated in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1196">
                    <text>The HD CD4+ T cells specific to HIV in viremics patients capacity that will proliferate strongly in vitro has been examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1197">
                    <text>The HD-specific T CD4+ cells for HIV in viremic patients capacity that can proliferate in vitro was examined by injection of 3? 106 LVTE cells into the muscle of the calf of 3 immunocompromised mice.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1198">
                    <text>The HD-specific T CD4+ cells for HIV in viremic patients capacity that proliferated in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1199">
                    <text>The HD-specific T CD4+ cells for HIV in viremic patients capacity that will proliferate strongly in vitro has been examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1200">
                    <text>The HDCD4+ T cells specific to HIV in viremics patients capacity that can proliferate in vitro was examined by injection of 3? 106 LVTE cells into the muscle of the calf of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1201">
                    <text>The HDCD4+ T cells specific to HIV in viremics patients capacity that proliferated in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1202">
                    <text>The HDCD4+ T cells specific to HIV in viremics patients capacity that will proliferate strongly in vitro has been examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1203">
                    <text>The HIV-specific T-cells CCD4+ in viraemic patients capacity that can proliferate in vitro was examined by injection of 3? 106 LVTE cells into the muscle of the calf of 3 immunocompromised mice.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1204">
                    <text>The HIV-specific T-cells CCD4+ in viraemic patients capacity that proliferated in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1205">
                    <text>The HIV-specific T-cells CCD4+ in viraemic patients capacity that will proliferate strongly in vitro has been examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1206">
                    <text>The Stat5ab-/-peripheral T cells regained the ability to proliferate the after the introduction of Stat5a of full-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1207">
                    <text>The Stat5ab-/-peripheral T cells regained the ability to proliferate the after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1208">
                    <text>The Stat5ab-/-peripheral T cells regained the ability to proliferate the after the introduction of the Stat5a type of complete wild size (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1209">
                    <text>The Stat5ab-/-peripheral T cells regained the ability to proliferate the after the introduction of the full-length wild type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1210">
                    <text>The Stat5ab-/-peripheral T cells regained the ability to proliferate the after the introduction of wild body stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1211">
                    <text>The Stat5ab/-peripheral regained the ability to proliferate the after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1212">
                    <text>The ability of A0 cells (BT) observed to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells into the muscle of the calf of 3 immunocompromised mice.</text>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1213">
                    <text>The ability of A0 cells (BT) to have the ability to proliferate strongly in vitro was examined by injection of 3? 106 CVC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1214">
                    <text>The ability of A0 cells (BT) to proliferate in vitro was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1215">
                    <text>The ability of A0 cells (BT) to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1216">
                    <text>The ability of A0 cells (BT) to proliferated strongly in vitro was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1217">
                    <text>The ability of A0 cells (EBD) proliferating to in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1218">
                    <text>The ability of A0 cells (EBD) that have the ability to proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1219">
                    <text>The ability of A0 cells (EBD) that have the ability to proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1220">
                    <text>The ability of A0 cells (EBD) to proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1221">
                    <text>The ability of BI cells that can proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1222">
                    <text>The ability of BI cells that can proliferate strongly in vivo was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1223">
                    <text>The ability of BI cells that can strongly proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1224">
                    <text>The ability of BI cells that have proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1225">
                    <text>The ability of BI cells that have strongly proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1226">
                    <text>The ability of BI cells that have the ability to proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1227">
                    <text>The ability of BI cells that is able to proliferate strongly in vivo was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1228">
                    <text>The ability of BI cells that is capable of proliferating in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1229">
                    <text>The ability of BI cells that is capable of strongly proliferating in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1230">
                    <text>The ability of BI cells that may have proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1231">
                    <text>The ability of BI cells that may have strongly proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1232">
                    <text>The ability of BI cells that proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1233">
                    <text>The ability of BI cells that was observed to proliferate strongly in vivo was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1234">
                    <text>The ability of BI cells to proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1235">
                    <text>The ability of BI cells to proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1236">
                    <text>The ability of BT cells that can proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1237">
                    <text>The ability of BT cells that can strongly proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1238">
                    <text>The ability of BT cells that have proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1239">
                    <text>The ability of BT cells that have strongly proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1240">
                    <text>The ability of BT cells that have the ability to proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1241">
                    <text>The ability of BT cells that is capable of proliferating in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1242">
                    <text>The ability of BT cells that is capable of strongly proliferating in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1243">
                    <text>The ability of BT cells that may have proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1244">
                    <text>The ability of BT cells that may have strongly proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1245">
                    <text>The ability of BT cells that proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1246">
                    <text>The ability of BT cells to proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1247">
                    <text>The ability of BT cells to proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1248">
                    <text>The ability of BT cells to proliferated in vivo was examined by injection of 3? 106 LVTE into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1249">
                    <text>The ability of CCD4+ HIV-specific T cells of viremic patients that can proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1250">
                    <text>The ability of CCD4+ HIV-specific T cells of viremic patients that can proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1251">
                    <text>The ability of CCD4+ HIV-specific T cells of viremic patients that can strongly proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1252">
                    <text>The ability of CCD4+ HIV-specific T cells of viremic patients that have proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1253">
                    <text>The ability of CCD4+ HIV-specific T cells of viremic patients that have strongly proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1254">
                    <text>The ability of CCD4+ HIV-specific T cells of viremic patients that have the ability to proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1255">
                    <text>The ability of CCD4+ HIV-specific T cells of viremic patients that is able to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1256">
                    <text>The ability of CCD4+ HIV-specific T cells of viremic patients that is capable of proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1257">
                    <text>The ability of CCD4+ HIV-specific T cells of viremic patients that is capable of strongly proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1258">
                    <text>The ability of CCD4+ HIV-specific T cells of viremic patients that may have proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1259">
                    <text>The ability of CCD4+ HIV-specific T cells of viremic patients that may have strongly proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1260">
                    <text>The ability of CCD4+ HIV-specific T cells of viremic patients that proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1261">
                    <text>The ability of CCD4+ HIV-specific T cells of viremic patients that was observed to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1262">
                    <text>The ability of CCD4+ HIV-specific T cells of viremic patients to proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1263">
                    <text>The ability of CCD4+ HIV-specific T cells of viremic patients to proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1264">
                    <text>The ability of CCD4+ HIV-specific T cells of viremic patients to proliferated in vitro was examined by injection of 3? 106 LVTE into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1265">
                    <text>The ability of CCD4+ HIV-specific cells of viremic patients that can proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1266">
                    <text>The ability of CCD4+ HIV-specific cells of viremic patients that can proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1267">
                    <text>The ability of CCD4+ HIV-specific cells of viremic patients that can strongly proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1268">
                    <text>The ability of CCD4+ HIV-specific cells of viremic patients that have proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1269">
                    <text>The ability of CCD4+ HIV-specific cells of viremic patients that have strongly proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1270">
                    <text>The ability of CCD4+ HIV-specific cells of viremic patients that have the ability to proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1271">
                    <text>The ability of CCD4+ HIV-specific cells of viremic patients that is able to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1272">
                    <text>The ability of CCD4+ HIV-specific cells of viremic patients that is capable of proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1273">
                    <text>The ability of CCD4+ HIV-specific cells of viremic patients that is capable of strongly proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1274">
                    <text>The ability of CCD4+ HIV-specific cells of viremic patients that may have proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1275">
                    <text>The ability of CCD4+ HIV-specific cells of viremic patients that may have strongly proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1276">
                    <text>The ability of CCD4+ HIV-specific cells of viremic patients that proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1277">
                    <text>The ability of CCD4+ HIV-specific cells of viremic patients that was observed to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1278">
                    <text>The ability of CCD4+ HIV-specific cells of viremic patients to proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1279">
                    <text>The ability of CCD4+ HIV-specific cells of viremic patients to proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1280">
                    <text>The ability of CCD4+ HIV-specific cells of viremic patients to proliferated in vitro was examined by injection of 3? 106 LVTE into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1281">
                    <text>The ability of EBD cells that can proliferate strongly in vivo was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1282">
                    <text>The ability of EBD cells that is able to proliferate strongly in vivo was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1283">
                    <text>The ability of EBD cells that was observed to proliferate strongly in vivo was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1284">
                    <text>The ability of EBD cells to proliferated in vivo was examined by injection of 3? 106 LVTE into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1285">
                    <text>The ability of HD CD4+ T cells specific for HIV in viremic patients that can proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1286">
                    <text>The ability of HD CD4+ T cells specific for HIV in viremic patients that can proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1287">
                    <text>The ability of HD CD4+ T cells specific for HIV in viremic patients that can strongly proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1288">
                    <text>The ability of HD CD4+ T cells specific for HIV in viremic patients that have proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1289">
                    <text>The ability of HD CD4+ T cells specific for HIV in viremic patients that have strongly proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1290">
                    <text>The ability of HD CD4+ T cells specific for HIV in viremic patients that have the ability to proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1291">
                    <text>The ability of HD CD4+ T cells specific for HIV in viremic patients that is able to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1292">
                    <text>The ability of HD CD4+ T cells specific for HIV in viremic patients that is capable of proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1293">
                    <text>The ability of HD CD4+ T cells specific for HIV in viremic patients that is capable of strongly proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1294">
                    <text>The ability of HD CD4+ T cells specific for HIV in viremic patients that may have proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1295">
                    <text>The ability of HD CD4+ T cells specific for HIV in viremic patients that may have strongly proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1296">
                    <text>The ability of HD CD4+ T cells specific for HIV in viremic patients that proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1297">
                    <text>The ability of HD CD4+ T cells specific for HIV in viremic patients that was observed to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1298">
                    <text>The ability of HD CD4+ T cells specific for HIV in viremic patients to proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1299">
                    <text>The ability of HD CD4+ T cells specific for HIV in viremic patients to proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1300">
                    <text>The ability of HD CD4+ T cells specific for HIV in viremic patients to proliferated in vitro was examined by injection of 3? 106 LVTE into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1301">
                    <text>The ability of HD CD4+ T cells specific to HIV in viremics patients that can proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1302">
                    <text>The ability of HD CD4+ T cells specific to HIV in viremics patients that can proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1303">
                    <text>The ability of HD CD4+ T cells specific to HIV in viremics patients that can strongly proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1304">
                    <text>The ability of HD CD4+ T cells specific to HIV in viremics patients that have proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1305">
                    <text>The ability of HD CD4+ T cells specific to HIV in viremics patients that have strongly proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1306">
                    <text>The ability of HD CD4+ T cells specific to HIV in viremics patients that have the ability to proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1307">
                    <text>The ability of HD CD4+ T cells specific to HIV in viremics patients that is able to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1308">
                    <text>The ability of HD CD4+ T cells specific to HIV in viremics patients that is capable of proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1309">
                    <text>The ability of HD CD4+ T cells specific to HIV in viremics patients that is capable of strongly proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1310">
                    <text>The ability of HD CD4+ T cells specific to HIV in viremics patients that may have proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1311">
                    <text>The ability of HD CD4+ T cells specific to HIV in viremics patients that may have strongly proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1312">
                    <text>The ability of HD CD4+ T cells specific to HIV in viremics patients that proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1313">
                    <text>The ability of HD CD4+ T cells specific to HIV in viremics patients that was observed to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1314">
                    <text>The ability of HD CD4+ T cells specific to HIV in viremics patients to proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1315">
                    <text>The ability of HD CD4+ T cells specific to HIV in viremics patients to proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1316">
                    <text>The ability of HD CD4+ T cells specific to HIV in viremics patients to proliferated in vitro was examined by injection of 3? 106 LVTE into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1317">
                    <text>The ability of HD-specific T CD4+ cells for HIV in viremic patients that can proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1318">
                    <text>The ability of HD-specific T CD4+ cells for HIV in viremic patients that can proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1319">
                    <text>The ability of HD-specific T CD4+ cells for HIV in viremic patients that can strongly proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1320">
                    <text>The ability of HD-specific T CD4+ cells for HIV in viremic patients that have proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1321">
                    <text>The ability of HD-specific T CD4+ cells for HIV in viremic patients that have strongly proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1322">
                    <text>The ability of HD-specific T CD4+ cells for HIV in viremic patients that have the ability to proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1323">
                    <text>The ability of HD-specific T CD4+ cells for HIV in viremic patients that is able to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1324">
                    <text>The ability of HD-specific T CD4+ cells for HIV in viremic patients that is capable of proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1325">
                    <text>The ability of HD-specific T CD4+ cells for HIV in viremic patients that is capable of strongly proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1326">
                    <text>The ability of HD-specific T CD4+ cells for HIV in viremic patients that may have proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1327">
                    <text>The ability of HD-specific T CD4+ cells for HIV in viremic patients that may have strongly proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1328">
                    <text>The ability of HD-specific T CD4+ cells for HIV in viremic patients that proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1329">
                    <text>The ability of HD-specific T CD4+ cells for HIV in viremic patients that was observed to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1330">
                    <text>The ability of HD-specific T CD4+ cells for HIV in viremic patients to proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1331">
                    <text>The ability of HD-specific T CD4+ cells for HIV in viremic patients to proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1332">
                    <text>The ability of HD-specific T CD4+ cells for HIV in viremic patients to proliferated in vitro was examined by injection of 3? 106 LVTE into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1333">
                    <text>The ability of HDCD4+ T cells specific to HIV in viremics patients that can proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1334">
                    <text>The ability of HDCD4+ T cells specific to HIV in viremics patients that can proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1335">
                    <text>The ability of HDCD4+ T cells specific to HIV in viremics patients that can strongly proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1336">
                    <text>The ability of HDCD4+ T cells specific to HIV in viremics patients that have proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1337">
                    <text>The ability of HDCD4+ T cells specific to HIV in viremics patients that have strongly proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1338">
                    <text>The ability of HDCD4+ T cells specific to HIV in viremics patients that have the ability to proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1339">
                    <text>The ability of HDCD4+ T cells specific to HIV in viremics patients that is able to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1340">
                    <text>The ability of HDCD4+ T cells specific to HIV in viremics patients that is capable of proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1341">
                    <text>The ability of HDCD4+ T cells specific to HIV in viremics patients that is capable of strongly proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1342">
                    <text>The ability of HDCD4+ T cells specific to HIV in viremics patients that may have proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1343">
                    <text>The ability of HDCD4+ T cells specific to HIV in viremics patients that may have strongly proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1344">
                    <text>The ability of HDCD4+ T cells specific to HIV in viremics patients that proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1345">
                    <text>The ability of HDCD4+ T cells specific to HIV in viremics patients that was observed to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1346">
                    <text>The ability of HDCD4+ T cells specific to HIV in viremics patients to proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1347">
                    <text>The ability of HDCD4+ T cells specific to HIV in viremics patients to proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1348">
                    <text>The ability of HDCD4+ T cells specific to HIV in viremics patients to proliferated in vitro was examined by injection of 3? 106 LVTE into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1349">
                    <text>The ability of HIV-specific T-cells CCD4+ in viraemic patients that can proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1350">
                    <text>The ability of HIV-specific T-cells CCD4+ in viraemic patients that can proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1351">
                    <text>The ability of HIV-specific T-cells CCD4+ in viraemic patients that can strongly proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1352">
                    <text>The ability of HIV-specific T-cells CCD4+ in viraemic patients that have proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1353">
                    <text>The ability of HIV-specific T-cells CCD4+ in viraemic patients that have strongly proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1354">
                    <text>The ability of HIV-specific T-cells CCD4+ in viraemic patients that have the ability to proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1355">
                    <text>The ability of HIV-specific T-cells CCD4+ in viraemic patients that is able to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1356">
                    <text>The ability of HIV-specific T-cells CCD4+ in viraemic patients that is capable of proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1357">
                    <text>The ability of HIV-specific T-cells CCD4+ in viraemic patients that is capable of strongly proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1358">
                    <text>The ability of HIV-specific T-cells CCD4+ in viraemic patients that may have proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1359">
                    <text>The ability of HIV-specific T-cells CCD4+ in viraemic patients that may have strongly proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1360">
                    <text>The ability of HIV-specific T-cells CCD4+ in viraemic patients that proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1361">
                    <text>The ability of HIV-specific T-cells CCD4+ in viraemic patients that was observed to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1362">
                    <text>The ability of HIV-specific T-cells CCD4+ in viraemic patients to proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1363">
                    <text>The ability of HIV-specific T-cells CCD4+ in viraemic patients to proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1364">
                    <text>The ability of HIV-specific T-cells CCD4+ in viraemic patients to proliferated in vitro was examined by injection of 3? 106 LVTE into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1365">
                    <text>The ability to proliferate in vitro has been examined by injection of 3? 106 LVTE cells into the veil muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1366">
                    <text>The ability to proliferate in vitro was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1367">
                    <text>The ability to proliferate strongly in vitro was examined by injection of 3? 106 CVC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1368">
                    <text>The adult T cells regained the ability to proliferate the when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1369">
                    <text>The adult naive T cells regained the ability to proliferate the when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1370">
                    <text>The capacity of BI cells proliferating in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1371">
                    <text>The capacity of BI cells that may have proliferated strongly in vivo was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1372">
                    <text>The capacity of BT cells proliferating in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1373">
                    <text>The capacity of CCD4+ HIV-specific T cells of viremic patients proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1374">
                    <text>The capacity of CCD4+ HIV-specific T cells of viremic patients that may have proliferated strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1375">
                    <text>The capacity of CCD4+ HIV-specific cells of viremic patients proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1376">
                    <text>The capacity of CCD4+ HIV-specific cells of viremic patients that may have proliferated strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1377">
                    <text>The capacity of EBD cells that may have proliferated strongly in vivo was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="1378">
                    <text>The capacity of HD CD4+ T cells specific for HIV in viremic patients proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1379">
                    <text>The capacity of HD CD4+ T cells specific for HIV in viremic patients that may have proliferated strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1380">
                    <text>The capacity of HD CD4+ T cells specific to HIV in viremics patients proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1381">
                    <text>The capacity of HD CD4+ T cells specific to HIV in viremics patients that may have proliferated strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1382">
                    <text>The capacity of HD-specific T CD4+ cells for HIV in viremic patients proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1383">
                    <text>The capacity of HD-specific T CD4+ cells for HIV in viremic patients that may have proliferated strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1384">
                    <text>The capacity of HDCD4+ T cells specific to HIV in viremics patients proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1385">
                    <text>The capacity of HDCD4+ T cells specific to HIV in viremics patients that may have proliferated strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1386">
                    <text>The capacity of HIV-specific T-cells CCD4+ in viraemic patients proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1387">
                    <text>The capacity of HIV-specific T-cells CCD4+ in viraemic patients that may have proliferated strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="1388">
                    <text>The endothelial cells regained the ability to proliferate the when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="1389">
                    <text>The ingenue T cells of adults regained the ability to proliferate the when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1390">
                    <text>The stat5ab-/-peripheral T cells regained the ability to proliferate the after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1391">
                    <text>The stat5ab-/-peripheral T cells regained the ability to proliferate the after the introduction of the full wild-length Stat5a type (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="1392">
                    <text>The stat5ab/-peripheral T cells regained the ability to proliferate the after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1393">
                    <text>The stat5ab/peripheral T cells regained the ability to proliferate the after the introduction of the completely length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1394">
                    <text>The stat5ab/peripheral T cells regained the ability to proliferate the after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1395">
                    <text>The stat5ab/peripheral T cells regained the ability to proliferate the after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1396">
                    <text>The the human placenta regained the ability to proliferate the along gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="1397">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate after the introduction of Stat5a of full-length wild type.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1398">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1399">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1400">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1401">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate after the introduction of wild body stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1402">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1403">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate after the introduction of Stat5a of full-length wild type.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1404">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1405">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1406">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1407">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate after the introduction of wild body stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1408">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate after the introduction of Stat5a of full-length wild type.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1409">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1410">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1411">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1412">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate after the introduction of wild body stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1413">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate after the introduction of Stat5a of full-length wild type.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1414">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1415">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1416">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1417">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate after the introduction of wild body stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1418">
                    <text>The treatment of Stat5ab/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate after the introduction of the Stat5a complete-length wild type.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1419">
                    <text>The treatment of Stat5ab/-peripheral T cells of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate after the introduction of the Stat5a complete-length wild type.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1420">
                    <text>The treatment of Stat5ab/-peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate after the introduction of the Stat5a complete-length wild type.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1421">
                    <text>The treatment of Stat5ab/-peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate after the introduction of the Stat5a complete-length wild type.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1422">
                    <text>The treatment of Stat5ab/-peripheral of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1423">
                    <text>The treatment of Stat5ab/-peripheral of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1424">
                    <text>The treatment of Stat5ab/-peripheral of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1425">
                    <text>The treatment of Stat5ab/-peripheral of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1426">
                    <text>The treatment of adult T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1427">
                    <text>The treatment of adult T cells of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1428">
                    <text>The treatment of adult T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1429">
                    <text>The treatment of adult T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1430">
                    <text>The treatment of adult naive T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1431">
                    <text>The treatment of adult naive T cells of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1432">
                    <text>The treatment of adult naive T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1433">
                    <text>The treatment of adult naive T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1434">
                    <text>The treatment of allergen prostate cancer cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1435">
                    <text>The treatment of androgen prostate cancer cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1436">
                    <text>The treatment of androgen tumour cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="1437">
                    <text>The treatment of androgen-responsive prostate cancer cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1438">
                    <text>The treatment of androgenic responsive prostate cancer cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1439">
                    <text>The treatment of cancer cells from the androgen prostate of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1440">
                    <text>The treatment of cancer cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1441">
                    <text>The treatment of cancer cells of the androgen prostate of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1442">
                    <text>The treatment of carcinogenic cells of the prostate that respond to the androgen of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="1443">
                    <text>The treatment of ingenue T cells of adults of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1444">
                    <text>The treatment of ingenue T cells of adults of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1445">
                    <text>The treatment of ingenue T cells of adults of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1446">
                    <text>The treatment of ingenue T cells of adults of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1447">
                    <text>The treatment of prostate cancer cells respond to androgen of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1448">
                    <text>The treatment of prostate cancer cells responding to androgen of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1449">
                    <text>The treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate after the introduction of the full wild-length Stat5a type.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="1450">
                    <text>The treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1451">
                    <text>The treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1452">
                    <text>The treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate after the introduction of the full wild-length Stat5a type.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="1453">
                    <text>The treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1454">
                    <text>The treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate after the introduction of the full wild-length Stat5a type.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="1455">
                    <text>The treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1456">
                    <text>The treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate after the introduction of the full wild-length Stat5a type.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="1457">
                    <text>The treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1458">
                    <text>The treatment of stat5ab/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1459">
                    <text>The treatment of stat5ab/-peripheral T cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1460">
                    <text>The treatment of stat5ab/-peripheral T cells of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1461">
                    <text>The treatment of stat5ab/-peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1462">
                    <text>The treatment of stat5ab/-peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1463">
                    <text>The treatment of stat5ab/peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate after the introduction of the completely length wild-type Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1464">
                    <text>The treatment of stat5ab/peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1465">
                    <text>The treatment of stat5ab/peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1466">
                    <text>The treatment of stat5ab/peripheral T cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1467">
                    <text>The treatment of stat5ab/peripheral T cells of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate after the introduction of the completely length wild-type Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1468">
                    <text>The treatment of stat5ab/peripheral T cells of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1469">
                    <text>The treatment of stat5ab/peripheral T cells of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1470">
                    <text>The treatment of stat5ab/peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate after the introduction of the completely length wild-type Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1471">
                    <text>The treatment of stat5ab/peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1472">
                    <text>The treatment of stat5ab/peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1473">
                    <text>The treatment of stat5ab/peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate after the introduction of the completely length wild-type Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1474">
                    <text>The treatment of stat5ab/peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1475">
                    <text>The treatment of stat5ab/peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1476">
                    <text>The treatment of the human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate along gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="1477">
                    <text>The treatment of the human placenta of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate along gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="1478">
                    <text>The treatment of the human placenta of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate along gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="1479">
                    <text>The treatment of the human placenta of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate along gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="1480">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1481">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1482">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1483">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate after the introduction of Stat5a of full-length wild type.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1484">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1485">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1486">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1487">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate after the introduction of wild body stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1488">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate after the introduction of Stat5a of full-length wild type.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1489">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1490">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1491">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1492">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate after the introduction of wild body stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1493">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate after the introduction of Stat5a of full-length wild type.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1494">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1495">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1496">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1497">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate after the introduction of wild body stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1498">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1499">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate after the introduction of Stat5a of full-length wild type.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1500">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1501">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1502">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1503">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate after the introduction of wild body stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1504">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate after the introduction of Stat5a of full-length wild type.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1505">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1506">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1507">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1508">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate after the introduction of wild body stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1509">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate after the introduction of Stat5a of full-length wild type.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1510">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1511">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1512">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1513">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate after the introduction of wild body stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1514">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate after the introduction of Stat5a of full-length wild type.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1515">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1516">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1517">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1518">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate after the introduction of wild body stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1519">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate after the introduction of Stat5a of full-length wild type.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1520">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1521">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="1522">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1523">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate after the introduction of wild body stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1524">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1525">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1526">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1527">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1528">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1529">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1530">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1531">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1532">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1533">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1534">
                    <text>Treatment of Stat5ab/-peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate after the introduction of the Stat5a complete-length wild type.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1535">
                    <text>Treatment of Stat5ab/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate after the introduction of the Stat5a complete-length wild type.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1536">
                    <text>Treatment of Stat5ab/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate after the introduction of the Stat5a complete-length wild type.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1537">
                    <text>Treatment of Stat5ab/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate after the introduction of the Stat5a complete-length wild type.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1538">
                    <text>Treatment of Stat5ab/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate after the introduction of the Stat5a complete-length wild type.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1539">
                    <text>Treatment of Stat5ab/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate after the introduction of the Stat5a complete-length wild type.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1540">
                    <text>Treatment of Stat5ab/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate after the introduction of the Stat5a complete-length wild type.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1541">
                    <text>Treatment of Stat5ab/-peripheral T cells of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate after the introduction of the Stat5a complete-length wild type.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="1542">
                    <text>Treatment of Stat5ab/-peripheral of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1543">
                    <text>Treatment of Stat5ab/-peripheral of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1544">
                    <text>Treatment of Stat5ab/-peripheral of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1545">
                    <text>Treatment of Stat5ab/-peripheral of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1546">
                    <text>Treatment of Stat5ab/-peripheral of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1547">
                    <text>Treatment of Stat5ab/-peripheral of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1548">
                    <text>Treatment of Stat5ab/-peripheral of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1549">
                    <text>Treatment of Stat5ab/-peripheral of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="1550">
                    <text>Treatment of adult T cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1551">
                    <text>Treatment of adult T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1552">
                    <text>Treatment of adult T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1553">
                    <text>Treatment of adult T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1554">
                    <text>Treatment of adult T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1555">
                    <text>Treatment of adult T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1556">
                    <text>Treatment of adult T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1557">
                    <text>Treatment of adult T cells of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1558">
                    <text>Treatment of adult naive T cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1559">
                    <text>Treatment of adult naive T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1560">
                    <text>Treatment of adult naive T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1561">
                    <text>Treatment of adult naive T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1562">
                    <text>Treatment of adult naive T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1563">
                    <text>Treatment of adult naive T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1564">
                    <text>Treatment of adult naive T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1565">
                    <text>Treatment of adult naive T cells of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1566">
                    <text>Treatment of allergen prostate cancer cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1567">
                    <text>Treatment of allergen prostate cancer cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1568">
                    <text>Treatment of allergen prostate cancer cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1569">
                    <text>Treatment of allergen prostate cancer cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1570">
                    <text>Treatment of allergen prostate cancer cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1571">
                    <text>Treatment of allergen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1572">
                    <text>Treatment of allergen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1573">
                    <text>Treatment of allergen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1574">
                    <text>Treatment of allergen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1575">
                    <text>Treatment of allergen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1576">
                    <text>Treatment of allergen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1577">
                    <text>Treatment of allergen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1578">
                    <text>Treatment of allergen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1579">
                    <text>Treatment of allergen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1580">
                    <text>Treatment of androgen prostate cancer cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1581">
                    <text>Treatment of androgen prostate cancer cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1582">
                    <text>Treatment of androgen prostate cancer cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1583">
                    <text>Treatment of androgen prostate cancer cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1584">
                    <text>Treatment of androgen prostate cancer cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1585">
                    <text>Treatment of androgen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1586">
                    <text>Treatment of androgen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1587">
                    <text>Treatment of androgen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1588">
                    <text>Treatment of androgen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1589">
                    <text>Treatment of androgen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1590">
                    <text>Treatment of androgen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1591">
                    <text>Treatment of androgen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1592">
                    <text>Treatment of androgen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1593">
                    <text>Treatment of androgen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1594">
                    <text>Treatment of androgen tumour cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="1595">
                    <text>Treatment of androgen tumour cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="1596">
                    <text>Treatment of androgen tumour cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="1597">
                    <text>Treatment of androgen tumour cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="1598">
                    <text>Treatment of androgen tumour cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="1599">
                    <text>Treatment of androgen tumour cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="1600">
                    <text>Treatment of androgen tumour cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="1601">
                    <text>Treatment of androgen tumour cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="1602">
                    <text>Treatment of androgen tumour cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="1603">
                    <text>Treatment of androgen tumour cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="1604">
                    <text>Treatment of androgen tumour cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="1605">
                    <text>Treatment of androgen tumour cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="1606">
                    <text>Treatment of androgen tumour cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="1607">
                    <text>Treatment of androgen tumour cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="1608">
                    <text>Treatment of androgen-responsive prostate cancer cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1609">
                    <text>Treatment of androgen-responsive prostate cancer cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1610">
                    <text>Treatment of androgen-responsive prostate cancer cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1611">
                    <text>Treatment of androgen-responsive prostate cancer cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1612">
                    <text>Treatment of androgen-responsive prostate cancer cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1613">
                    <text>Treatment of androgen-responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1614">
                    <text>Treatment of androgen-responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1615">
                    <text>Treatment of androgen-responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1616">
                    <text>Treatment of androgen-responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1617">
                    <text>Treatment of androgen-responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1618">
                    <text>Treatment of androgen-responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1619">
                    <text>Treatment of androgen-responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1620">
                    <text>Treatment of androgen-responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1621">
                    <text>Treatment of androgen-responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1622">
                    <text>Treatment of androgenic responsive prostate cancer cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1623">
                    <text>Treatment of androgenic responsive prostate cancer cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1624">
                    <text>Treatment of androgenic responsive prostate cancer cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1625">
                    <text>Treatment of androgenic responsive prostate cancer cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1626">
                    <text>Treatment of androgenic responsive prostate cancer cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1627">
                    <text>Treatment of androgenic responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1628">
                    <text>Treatment of androgenic responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1629">
                    <text>Treatment of androgenic responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1630">
                    <text>Treatment of androgenic responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1631">
                    <text>Treatment of androgenic responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1632">
                    <text>Treatment of androgenic responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1633">
                    <text>Treatment of androgenic responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1634">
                    <text>Treatment of androgenic responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1635">
                    <text>Treatment of androgenic responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1636">
                    <text>Treatment of cancer cells from the androgen prostate of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1637">
                    <text>Treatment of cancer cells from the androgen prostate of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1638">
                    <text>Treatment of cancer cells from the androgen prostate of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1639">
                    <text>Treatment of cancer cells from the androgen prostate of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1640">
                    <text>Treatment of cancer cells from the androgen prostate of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1641">
                    <text>Treatment of cancer cells from the androgen prostate of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1642">
                    <text>Treatment of cancer cells from the androgen prostate of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1643">
                    <text>Treatment of cancer cells from the androgen prostate of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1644">
                    <text>Treatment of cancer cells from the androgen prostate of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1645">
                    <text>Treatment of cancer cells from the androgen prostate of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1646">
                    <text>Treatment of cancer cells from the androgen prostate of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1647">
                    <text>Treatment of cancer cells from the androgen prostate of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1648">
                    <text>Treatment of cancer cells from the androgen prostate of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1649">
                    <text>Treatment of cancer cells from the androgen prostate of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1650">
                    <text>Treatment of cancer cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1651">
                    <text>Treatment of cancer cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1652">
                    <text>Treatment of cancer cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1653">
                    <text>Treatment of cancer cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1654">
                    <text>Treatment of cancer cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1655">
                    <text>Treatment of cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1656">
                    <text>Treatment of cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1657">
                    <text>Treatment of cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1658">
                    <text>Treatment of cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1659">
                    <text>Treatment of cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1660">
                    <text>Treatment of cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1661">
                    <text>Treatment of cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1662">
                    <text>Treatment of cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1663">
                    <text>Treatment of cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1664">
                    <text>Treatment of cancer cells of the androgen prostate of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1665">
                    <text>Treatment of cancer cells of the androgen prostate of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1666">
                    <text>Treatment of cancer cells of the androgen prostate of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1667">
                    <text>Treatment of cancer cells of the androgen prostate of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1668">
                    <text>Treatment of cancer cells of the androgen prostate of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1669">
                    <text>Treatment of cancer cells of the androgen prostate of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1670">
                    <text>Treatment of cancer cells of the androgen prostate of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1671">
                    <text>Treatment of cancer cells of the androgen prostate of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1672">
                    <text>Treatment of cancer cells of the androgen prostate of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1673">
                    <text>Treatment of cancer cells of the androgen prostate of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1674">
                    <text>Treatment of cancer cells of the androgen prostate of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1675">
                    <text>Treatment of cancer cells of the androgen prostate of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1676">
                    <text>Treatment of cancer cells of the androgen prostate of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1677">
                    <text>Treatment of cancer cells of the androgen prostate of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1678">
                    <text>Treatment of carcinogenic cells of the prostate that respond to the androgen of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="1679">
                    <text>Treatment of carcinogenic cells of the prostate that respond to the androgen of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="1680">
                    <text>Treatment of carcinogenic cells of the prostate that respond to the androgen of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="1681">
                    <text>Treatment of carcinogenic cells of the prostate that respond to the androgen of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="1682">
                    <text>Treatment of carcinogenic cells of the prostate that respond to the androgen of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="1683">
                    <text>Treatment of carcinogenic cells of the prostate that respond to the androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="1684">
                    <text>Treatment of carcinogenic cells of the prostate that respond to the androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="1685">
                    <text>Treatment of carcinogenic cells of the prostate that respond to the androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="1686">
                    <text>Treatment of carcinogenic cells of the prostate that respond to the androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="1687">
                    <text>Treatment of carcinogenic cells of the prostate that respond to the androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="1688">
                    <text>Treatment of carcinogenic cells of the prostate that respond to the androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="1689">
                    <text>Treatment of carcinogenic cells of the prostate that respond to the androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="1690">
                    <text>Treatment of carcinogenic cells of the prostate that respond to the androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="1691">
                    <text>Treatment of carcinogenic cells of the prostate that respond to the androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="1692">
                    <text>Treatment of ingenue T cells of adults of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1693">
                    <text>Treatment of ingenue T cells of adults of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1694">
                    <text>Treatment of ingenue T cells of adults of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1695">
                    <text>Treatment of ingenue T cells of adults of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1696">
                    <text>Treatment of ingenue T cells of adults of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1697">
                    <text>Treatment of ingenue T cells of adults of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1698">
                    <text>Treatment of ingenue T cells of adults of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1699">
                    <text>Treatment of ingenue T cells of adults of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1700">
                    <text>Treatment of prostate cancer cells respond to androgen of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1701">
                    <text>Treatment of prostate cancer cells respond to androgen of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1702">
                    <text>Treatment of prostate cancer cells respond to androgen of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1703">
                    <text>Treatment of prostate cancer cells respond to androgen of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1704">
                    <text>Treatment of prostate cancer cells respond to androgen of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1705">
                    <text>Treatment of prostate cancer cells respond to androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1706">
                    <text>Treatment of prostate cancer cells respond to androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1707">
                    <text>Treatment of prostate cancer cells respond to androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1708">
                    <text>Treatment of prostate cancer cells respond to androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1709">
                    <text>Treatment of prostate cancer cells respond to androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1710">
                    <text>Treatment of prostate cancer cells respond to androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1711">
                    <text>Treatment of prostate cancer cells respond to androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1712">
                    <text>Treatment of prostate cancer cells respond to androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1713">
                    <text>Treatment of prostate cancer cells respond to androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1714">
                    <text>Treatment of prostate cancer cells responding to androgen of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1715">
                    <text>Treatment of prostate cancer cells responding to androgen of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1716">
                    <text>Treatment of prostate cancer cells responding to androgen of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1717">
                    <text>Treatment of prostate cancer cells responding to androgen of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1718">
                    <text>Treatment of prostate cancer cells responding to androgen of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1719">
                    <text>Treatment of prostate cancer cells responding to androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1720">
                    <text>Treatment of prostate cancer cells responding to androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1721">
                    <text>Treatment of prostate cancer cells responding to androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1722">
                    <text>Treatment of prostate cancer cells responding to androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1723">
                    <text>Treatment of prostate cancer cells responding to androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1724">
                    <text>Treatment of prostate cancer cells responding to androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1725">
                    <text>Treatment of prostate cancer cells responding to androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1726">
                    <text>Treatment of prostate cancer cells responding to androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1727">
                    <text>Treatment of prostate cancer cells responding to androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="1728">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1729">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1730">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1731">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate after the introduction of the full wild-length Stat5a type.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="1732">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1733">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate after the introduction of the full wild-length Stat5a type.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="1734">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1735">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate after the introduction of the full wild-length Stat5a type.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="1736">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1737">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1738">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate after the introduction of the full wild-length Stat5a type.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="1739">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1740">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate after the introduction of the full wild-length Stat5a type.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="1741">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1742">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate after the introduction of the full wild-length Stat5a type.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="1743">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1744">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate after the introduction of the full wild-length Stat5a type.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="1745">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1746">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate after the introduction of the full wild-length Stat5a type.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="1747">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1748">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1749">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1750">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1751">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1752">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1753">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1754">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1755">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1756">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1757">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1758">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1759">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1760">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1761">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1762">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1763">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1764">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1765">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1766">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1767">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1768">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1769">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1770">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1771">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1772">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1773">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1774">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1775">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1776">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1777">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1778">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1779">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1780">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1781">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1782">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1783">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate after the introduction of the completely length wild-type Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1784">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1785">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1786">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate after the introduction of the completely length wild-type Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1787">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1788">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1789">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate after the introduction of the completely length wild-type Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1790">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1791">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1792">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1793">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate after the introduction of the completely length wild-type Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1794">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1795">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1796">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate after the introduction of the completely length wild-type Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1797">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1798">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1799">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate after the introduction of the completely length wild-type Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1800">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1801">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1802">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate after the introduction of the completely length wild-type Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1803">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1804">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1805">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate after the introduction of the completely length wild-type Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1806">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="1807">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="1808">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1809">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1810">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1811">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1812">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1813">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1814">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1815">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1816">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1817">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1818">
                    <text>Treatment of the human placenta of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate along gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="1819">
                    <text>Treatment of the human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate along gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="1820">
                    <text>Treatment of the human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate along gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="1821">
                    <text>Treatment of the human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate along gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="1822">
                    <text>Treatment of the human placenta of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate along gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="1823">
                    <text>Treatment of the human placenta of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate along gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="1824">
                    <text>Treatment of the human placenta of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate along gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="1825">
                    <text>Treatment of the human placenta of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate along gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="1826">
                    <text>adult T cells can regain the ability to proliferate indefinitely when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1827">
                    <text>adult T cells can regain the ability to proliferate when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1828">
                    <text>adult T cells has regained the ability to proliferate when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1829">
                    <text>adult T cells has the probability of recovering the ability to proliferate indefinitely when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1830">
                    <text>adult T cells has the probability of recovering the ability to proliferate when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1831">
                    <text>adult T cells is likely to proliferate the undefined proliferation capacity when transferred to lymphonic hosts (picture 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1832">
                    <text>adult T cells may have regained the ability to proliferate indefinitely when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1833">
                    <text>adult T cells may have regained the ability to proliferate when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1834">
                    <text>adult T cells may proliferate recovered the undefined proliferation capacity when transferred to lymphonic hosts (picture 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1835">
                    <text>adult T cells may proliferate the undefined proliferation capacity when transferred to lymphonic hosts (picture 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1836">
                    <text>adult T cells proliferate the undefined proliferation capacity when transferred to lymphonic hosts (picture 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1837">
                    <text>adult T cells recovered the ability to proliferate when transferred to lymphonic hosts (picture 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1838">
                    <text>adult T cells regained the ability to proliferate indefinitely when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1839">
                    <text>adult T cells will proliferate the undefined proliferation capability when transferred to lymphonic hosts (image 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1840">
                    <text>adult T cells will regain the ability to proliferate indefinitely when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1841">
                    <text>adult T cells will regain the ability to proliferate when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1842">
                    <text>adult T cells, which are at rest in normal conditions, will proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1843">
                    <text>adult T cells, which are at rest under normal conditions, are able to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1844">
                    <text>adult T cells, which are at rest under normal conditions, will proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1845">
                    <text>adult naive T cells can regain the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1846">
                    <text>adult naive T cells can regain the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1847">
                    <text>adult naive T cells has regained the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1848">
                    <text>adult naive T cells has the probability of recovering the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1849">
                    <text>adult naive T cells has the probability of recovering the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1850">
                    <text>adult naive T cells is likely to proliferate the undefined proliferation capacity when transferred to lymphopenic hosts (picture 6B).</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1851">
                    <text>adult naive T cells may have regained the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1852">
                    <text>adult naive T cells may have regained the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1853">
                    <text>adult naive T cells may proliferate recovered the undefined proliferation capacity when transferred to lymphopenic hosts (picture 6B).</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1854">
                    <text>adult naive T cells may proliferate the undefined proliferation capacity when transferred to lymphopenic hosts (picture 6B).</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1855">
                    <text>adult naive T cells proliferate the undefined proliferation capacity when transferred to lymphopenic hosts (picture 6B).</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1856">
                    <text>adult naive T cells recovered the ability to proliferate when transferred to lymphopenic hosts (picture 6B).</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1857">
                    <text>adult naive T cells regained the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1858">
                    <text>adult naive T cells will proliferate the undefined proliferation capability when transferred to lymphopenic hosts (image 6B).</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1859">
                    <text>adult naive T cells will regain the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1860">
                    <text>adult naive T cells will regain the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1861">
                    <text>adult naive T cells, which are at rest in normal conditions, are observed to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1862">
                    <text>adult naive T cells, which are at rest in normal conditions, have the ability to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1863">
                    <text>adult naive T cells, which are at rest in normal conditions, will proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1864">
                    <text>adult naive T cells, which are at rest under normal conditions, are observed to strongly proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1865">
                    <text>adult naive T cells, which are at rest under normal conditions, can proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1866">
                    <text>allergen prostate cancer cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1867">
                    <text>allergen prostate cancer cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1868">
                    <text>allergen prostate cancer cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1869">
                    <text>allergen prostate cancer cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1870">
                    <text>allergen prostate cancer cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1871">
                    <text>allergen prostate cancer cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1872">
                    <text>allergen prostate cancer cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1873">
                    <text>allergen prostate cancer cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1874">
                    <text>allergen prostate cancer cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1875">
                    <text>allergen prostate cancer cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1876">
                    <text>androgen prostate cancer cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1877">
                    <text>androgen prostate cancer cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1878">
                    <text>androgen prostate cancer cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1879">
                    <text>androgen prostate cancer cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1880">
                    <text>androgen prostate cancer cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1881">
                    <text>androgen prostate cancer cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1882">
                    <text>androgen prostate cancer cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1883">
                    <text>androgen prostate cancer cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1884">
                    <text>androgen prostate cancer cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1885">
                    <text>androgen prostate cancer cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1886">
                    <text>androgen tumour cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="1887">
                    <text>androgen tumour cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="1888">
                    <text>androgen tumour cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="1889">
                    <text>androgen tumour cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="1890">
                    <text>androgen tumour cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="1891">
                    <text>androgen tumour cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="1892">
                    <text>androgen tumour cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="1893">
                    <text>androgen tumour cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="1894">
                    <text>androgen tumour cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="1895">
                    <text>androgen tumour cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="1896">
                    <text>androgen-responsive prostate cancer cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1897">
                    <text>androgen-responsive prostate cancer cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1898">
                    <text>androgen-responsive prostate cancer cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1899">
                    <text>androgen-responsive prostate cancer cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1900">
                    <text>androgen-responsive prostate cancer cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1901">
                    <text>androgen-responsive prostate cancer cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1902">
                    <text>androgen-responsive prostate cancer cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1903">
                    <text>androgen-responsive prostate cancer cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1904">
                    <text>androgen-responsive prostate cancer cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1905">
                    <text>androgen-responsive prostate cancer cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1906">
                    <text>androgenic responsive prostate cancer cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1907">
                    <text>androgenic responsive prostate cancer cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1908">
                    <text>androgenic responsive prostate cancer cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1909">
                    <text>androgenic responsive prostate cancer cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1910">
                    <text>androgenic responsive prostate cancer cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1911">
                    <text>androgenic responsive prostate cancer cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1912">
                    <text>androgenic responsive prostate cancer cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1913">
                    <text>androgenic responsive prostate cancer cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1914">
                    <text>androgenic responsive prostate cancer cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1915">
                    <text>androgenic responsive prostate cancer cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1916">
                    <text>cancer cells from the androgen prostate has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1917">
                    <text>cancer cells from the androgen prostate is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1918">
                    <text>cancer cells from the androgen prostate is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1919">
                    <text>cancer cells from the androgen prostate is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1920">
                    <text>cancer cells from the androgen prostate is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1921">
                    <text>cancer cells from the androgen prostate may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1922">
                    <text>cancer cells from the androgen prostate may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1923">
                    <text>cancer cells from the androgen prostate proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1924">
                    <text>cancer cells from the androgen prostate proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1925">
                    <text>cancer cells from the androgen prostate will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1926">
                    <text>cancer cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1927">
                    <text>cancer cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1928">
                    <text>cancer cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1929">
                    <text>cancer cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1930">
                    <text>cancer cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1931">
                    <text>cancer cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1932">
                    <text>cancer cells of the androgen prostate has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1933">
                    <text>cancer cells of the androgen prostate is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1934">
                    <text>cancer cells of the androgen prostate is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1935">
                    <text>cancer cells of the androgen prostate is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1936">
                    <text>cancer cells of the androgen prostate is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1937">
                    <text>cancer cells of the androgen prostate may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1938">
                    <text>cancer cells of the androgen prostate may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1939">
                    <text>cancer cells of the androgen prostate proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1940">
                    <text>cancer cells of the androgen prostate proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1941">
                    <text>cancer cells of the androgen prostate will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="1942">
                    <text>cancer cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1943">
                    <text>cancer cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1944">
                    <text>cancer cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="1945">
                    <text>carcinogenic cells of the prostate that respond to the androgen has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="1946">
                    <text>carcinogenic cells of the prostate that respond to the androgen is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="1947">
                    <text>carcinogenic cells of the prostate that respond to the androgen is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="1948">
                    <text>carcinogenic cells of the prostate that respond to the androgen is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="1949">
                    <text>carcinogenic cells of the prostate that respond to the androgen is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="1950">
                    <text>carcinogenic cells of the prostate that respond to the androgen may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="1951">
                    <text>carcinogenic cells of the prostate that respond to the androgen may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="1952">
                    <text>carcinogenic cells of the prostate that respond to the androgen proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="1953">
                    <text>carcinogenic cells of the prostate that respond to the androgen proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="1954">
                    <text>carcinogenic cells of the prostate that respond to the androgen will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="1955">
                    <text>endothelial cells can regain the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="1956">
                    <text>endothelial cells can regain the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="1957">
                    <text>endothelial cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="1958">
                    <text>endothelial cells has regained the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="1959">
                    <text>endothelial cells has the probability of recovering the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="1960">
                    <text>endothelial cells has the probability of recovering the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="1961">
                    <text>endothelial cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="1962">
                    <text>endothelial cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="1963">
                    <text>endothelial cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="1964">
                    <text>endothelial cells is likely to proliferate the undefined proliferation capacity when exposed to FGF2 (picture 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="1965">
                    <text>endothelial cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="1966">
                    <text>endothelial cells may have regained the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="1967">
                    <text>endothelial cells may have regained the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="1968">
                    <text>endothelial cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="1969">
                    <text>endothelial cells may proliferate recovered the undefined proliferation capacity when exposed to FGF2 (picture 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="1970">
                    <text>endothelial cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="1971">
                    <text>endothelial cells may proliferate the undefined proliferation capacity when exposed to FGF2 (picture 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="1972">
                    <text>endothelial cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="1973">
                    <text>endothelial cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="1974">
                    <text>endothelial cells proliferate the undefined proliferation capacity when exposed to FGF2 (picture 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="1975">
                    <text>endothelial cells recovered the ability to proliferate when exposed to FGF2 (picture 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="1976">
                    <text>endothelial cells regained the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="1977">
                    <text>endothelial cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="1978">
                    <text>endothelial cells will proliferate the undefined proliferation capability when exposed to FGF2 (image 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="1979">
                    <text>endothelial cells will regain the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="1980">
                    <text>endothelial cells will regain the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="1981">
                    <text>endothelial cells, which are at rest in normal conditions, are observed to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="1982">
                    <text>endothelial cells, which are at rest in normal conditions, have the ability to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="1983">
                    <text>endothelial cells, which are at rest in normal conditions, will proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="1984">
                    <text>endothelial cells, which are at rest under normal conditions, are able to proliferate strongly when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="1985">
                    <text>endothelial cells, which are at rest under normal conditions, are able to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="1986">
                    <text>endothelial cells, which are at rest under normal conditions, are observed to strongly proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="1987">
                    <text>endothelial cells, which are at rest under normal conditions, can proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="1988">
                    <text>endothelial cells, which are at rest under normal conditions, will proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="1989">
                    <text>ingenue T cells of adults can regain the ability to proliferate indefinitely when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1990">
                    <text>ingenue T cells of adults can regain the ability to proliferate when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1991">
                    <text>ingenue T cells of adults has regained the ability to proliferate when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1992">
                    <text>ingenue T cells of adults has the probability of recovering the ability to proliferate indefinitely when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1993">
                    <text>ingenue T cells of adults has the probability of recovering the ability to proliferate when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1994">
                    <text>ingenue T cells of adults is likely to proliferate the undefined proliferation capacity when transferred to lymphonic hosts (picture 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1995">
                    <text>ingenue T cells of adults may have regained the ability to proliferate indefinitely when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1996">
                    <text>ingenue T cells of adults may have regained the ability to proliferate when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1997">
                    <text>ingenue T cells of adults may proliferate recovered the undefined proliferation capacity when transferred to lymphonic hosts (picture 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1998">
                    <text>ingenue T cells of adults may proliferate the undefined proliferation capacity when transferred to lymphonic hosts (picture 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1999">
                    <text>ingenue T cells of adults proliferate the undefined proliferation capacity when transferred to lymphonic hosts (picture 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="2000">
                    <text>ingenue T cells of adults recovered the ability to proliferate when transferred to lymphonic hosts (picture 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="2001">
                    <text>ingenue T cells of adults regained the ability to proliferate indefinitely when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="2002">
                    <text>ingenue T cells of adults will proliferate the undefined proliferation capability when transferred to lymphonic hosts (image 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="2003">
                    <text>ingenue T cells of adults will regain the ability to proliferate indefinitely when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="2004">
                    <text>ingenue T cells of adults will regain the ability to proliferate when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="2005">
                    <text>ingenue T cells of adults, which are at rest in normal conditions, are observed to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="2006">
                    <text>ingenue T cells of adults, which are at rest in normal conditions, have the ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="2007">
                    <text>ingenue T cells of adults, which are at rest under normal conditions, are able to proliferate strongly when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="2008">
                    <text>ingenue T cells of adults, which are at rest under normal conditions, are observed to strongly proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="2009">
                    <text>ingenue T cells of adults, which are at rest under normal conditions, will proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="2010">
                    <text>prostate cancer cells respond to androgen has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="2011">
                    <text>prostate cancer cells respond to androgen is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="2012">
                    <text>prostate cancer cells respond to androgen is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="2013">
                    <text>prostate cancer cells respond to androgen is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="2014">
                    <text>prostate cancer cells respond to androgen is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="2015">
                    <text>prostate cancer cells respond to androgen may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="2016">
                    <text>prostate cancer cells respond to androgen may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="2017">
                    <text>prostate cancer cells respond to androgen proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="2018">
                    <text>prostate cancer cells respond to androgen proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="2019">
                    <text>prostate cancer cells respond to androgen will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="2020">
                    <text>prostate cancer cells responding to androgen has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="2021">
                    <text>prostate cancer cells responding to androgen is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="2022">
                    <text>prostate cancer cells responding to androgen is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="2023">
                    <text>prostate cancer cells responding to androgen is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="2024">
                    <text>prostate cancer cells responding to androgen is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="2025">
                    <text>prostate cancer cells responding to androgen may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="2026">
                    <text>prostate cancer cells responding to androgen may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="2027">
                    <text>prostate cancer cells responding to androgen proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="2028">
                    <text>prostate cancer cells responding to androgen proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="2029">
                    <text>prostate cancer cells responding to androgen will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="2030">
                    <text>stat5ab-/-peripheral T cells can regain the ability to proliferate after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2031">
                    <text>stat5ab-/-peripheral T cells can regain the ability to proliferate after the introduction of the full wild-length Stat5a type (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="2032">
                    <text>stat5ab-/-peripheral T cells can regain the ability to proliferate indefinitely after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2033">
                    <text>stat5ab-/-peripheral T cells can regain the ability to proliferate indefinitely after the introduction of the full wild-length Stat5a type (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="2034">
                    <text>stat5ab-/-peripheral T cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="2035">
                    <text>stat5ab-/-peripheral T cells has regained the ability to proliferate after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2036">
                    <text>stat5ab-/-peripheral T cells has regained the ability to proliferate after the introduction of the full wild-length Stat5a type (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="2037">
                    <text>stat5ab-/-peripheral T cells has the probability of recovering the ability to proliferate after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2038">
                    <text>stat5ab-/-peripheral T cells has the probability of recovering the ability to proliferate after the introduction of the full wild-length Stat5a type (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="2039">
                    <text>stat5ab-/-peripheral T cells has the probability of recovering the ability to proliferate indefinitely after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2040">
                    <text>stat5ab-/-peripheral T cells has the probability of recovering the ability to proliferate indefinitely after the introduction of the full wild-length Stat5a type (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="2041">
                    <text>stat5ab-/-peripheral T cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="2042">
                    <text>stat5ab-/-peripheral T cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="2043">
                    <text>stat5ab-/-peripheral T cells is likely to proliferate the undefined proliferation capacity after the introduction of the full wild-length Stat5a (picture 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2044">
                    <text>stat5ab-/-peripheral T cells is likely to proliferate the undefined proliferation capacity after the introduction of the full wild-length Stat5a type (picture 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="2045">
                    <text>stat5ab-/-peripheral T cells may have regained the ability to proliferate after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2046">
                    <text>stat5ab-/-peripheral T cells may have regained the ability to proliferate after the introduction of the full wild-length Stat5a type (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="2047">
                    <text>stat5ab-/-peripheral T cells may have regained the ability to proliferate indefinitely after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2048">
                    <text>stat5ab-/-peripheral T cells may have regained the ability to proliferate indefinitely after the introduction of the full wild-length Stat5a type (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="2049">
                    <text>stat5ab-/-peripheral T cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="2050">
                    <text>stat5ab-/-peripheral T cells may proliferate recovered the undefined proliferation capacity after the introduction of the full wild-length Stat5a (picture 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2051">
                    <text>stat5ab-/-peripheral T cells may proliferate the undefined proliferation capacity after the introduction of the full wild-length Stat5a type (picture 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="2052">
                    <text>stat5ab-/-peripheral T cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="2053">
                    <text>stat5ab-/-peripheral T cells proliferate the undefined proliferation capacity after the introduction of the full wild-length Stat5a (picture 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2054">
                    <text>stat5ab-/-peripheral T cells recovered the ability to proliferate after the introduction of the full wild-length Stat5a (picture 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2055">
                    <text>stat5ab-/-peripheral T cells recovered the ability to proliferate after the introduction of the full wild-length Stat5a type (picture 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="2056">
                    <text>stat5ab-/-peripheral T cells regained the ability to proliferate indefinitely after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2057">
                    <text>stat5ab-/-peripheral T cells regained the ability to proliferate indefinitely after the introduction of the full wild-length Stat5a type (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="2058">
                    <text>stat5ab-/-peripheral T cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="2059">
                    <text>stat5ab-/-peripheral T cells will proliferate the undefined proliferation capability after the introduction of the full wild-length Stat5a (image 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2060">
                    <text>stat5ab-/-peripheral T cells will proliferate the undefined proliferation capability after the introduction of the full wild-length Stat5a type (image 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="2061">
                    <text>stat5ab-/-peripheral T cells will regain the ability to proliferate after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2062">
                    <text>stat5ab-/-peripheral T cells will regain the ability to proliferate after the introduction of the full wild-length Stat5a type (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="2063">
                    <text>stat5ab-/-peripheral T cells will regain the ability to proliferate indefinitely after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2064">
                    <text>stat5ab-/-peripheral T cells will regain the ability to proliferate indefinitely after the introduction of the full wild-length Stat5a type (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="2065">
                    <text>stat5ab-/-peripheral T cells, which are at rest in normal conditions, are observed to proliferate after the introduction of the full wild-length Stat5a type.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="2066">
                    <text>stat5ab-/-peripheral T cells, which are at rest in normal conditions, are observed to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2067">
                    <text>stat5ab-/-peripheral T cells, which are at rest in normal conditions, have the ability to proliferate after the introduction of the full wild-length Stat5a type.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="2068">
                    <text>stat5ab-/-peripheral T cells, which are at rest in normal conditions, have the ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2069">
                    <text>stat5ab-/-peripheral T cells, which are at rest in normal conditions, will proliferate after the introduction of the full wild-length Stat5a type.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="2070">
                    <text>stat5ab-/-peripheral T cells, which are at rest in normal conditions, will proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2071">
                    <text>stat5ab-/-peripheral T cells, which are at rest under normal conditions, are able to proliferate after the introduction of the full wild-length Stat5a type.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="2072">
                    <text>stat5ab-/-peripheral T cells, which are at rest under normal conditions, are able to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2073">
                    <text>stat5ab-/-peripheral T cells, which are at rest under normal conditions, are able to proliferate strongly after the introduction of the full wild-length Stat5a type.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="2074">
                    <text>stat5ab-/-peripheral T cells, which are at rest under normal conditions, are able to proliferate strongly after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2075">
                    <text>stat5ab-/-peripheral T cells, which are at rest under normal conditions, are observed to strongly proliferate after the introduction of the full wild-length Stat5a type.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="2076">
                    <text>stat5ab-/-peripheral T cells, which are at rest under normal conditions, are observed to strongly proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2077">
                    <text>stat5ab-/-peripheral T cells, which are at rest under normal conditions, can proliferate after the introduction of the full wild-length Stat5a type.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="2078">
                    <text>stat5ab-/-peripheral T cells, which are at rest under normal conditions, can proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2079">
                    <text>stat5ab-/-peripheral T cells, which are at rest under normal conditions, will proliferate after the introduction of the full wild-length Stat5a type.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="2080">
                    <text>stat5ab-/-peripheral T cells, which are at rest under normal conditions, will proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2081">
                    <text>stat5ab/-peripheral T cells can regain the ability to proliferate after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2082">
                    <text>stat5ab/-peripheral T cells can regain the ability to proliferate indefinitely after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2083">
                    <text>stat5ab/-peripheral T cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="2084">
                    <text>stat5ab/-peripheral T cells has regained the ability to proliferate after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2085">
                    <text>stat5ab/-peripheral T cells has the probability of recovering the ability to proliferate after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2086">
                    <text>stat5ab/-peripheral T cells has the probability of recovering the ability to proliferate indefinitely after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2087">
                    <text>stat5ab/-peripheral T cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="2088">
                    <text>stat5ab/-peripheral T cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="2089">
                    <text>stat5ab/-peripheral T cells is likely to proliferate the undefined proliferation capacity after the introduction of the full wild-length state5a (picture 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2090">
                    <text>stat5ab/-peripheral T cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="2091">
                    <text>stat5ab/-peripheral T cells may have regained the ability to proliferate after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2092">
                    <text>stat5ab/-peripheral T cells may have regained the ability to proliferate indefinitely after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2093">
                    <text>stat5ab/-peripheral T cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="2094">
                    <text>stat5ab/-peripheral T cells may proliferate recovered the undefined proliferation capacity after the introduction of the full wild-length state5a (picture 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2095">
                    <text>stat5ab/-peripheral T cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="2096">
                    <text>stat5ab/-peripheral T cells may proliferate the undefined proliferation capacity after the introduction of the full wild-length state5a (picture 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2097">
                    <text>stat5ab/-peripheral T cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="2098">
                    <text>stat5ab/-peripheral T cells proliferate the undefined proliferation capacity after the introduction of the full wild-length state5a (picture 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2099">
                    <text>stat5ab/-peripheral T cells recovered the ability to proliferate after the introduction of the full wild-length state5a (picture 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2100">
                    <text>stat5ab/-peripheral T cells regained the ability to proliferate indefinitely after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2101">
                    <text>stat5ab/-peripheral T cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="2102">
                    <text>stat5ab/-peripheral T cells will proliferate the undefined proliferation capability after the introduction of the full wild-length state5a (image 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2103">
                    <text>stat5ab/-peripheral T cells will regain the ability to proliferate after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2104">
                    <text>stat5ab/-peripheral T cells will regain the ability to proliferate indefinitely after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2105">
                    <text>stat5ab/-peripheral T cells, which are at rest in normal conditions, are observed to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2106">
                    <text>stat5ab/-peripheral T cells, which are at rest in normal conditions, have the ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2107">
                    <text>stat5ab/-peripheral T cells, which are at rest in normal conditions, will proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2108">
                    <text>stat5ab/-peripheral T cells, which are at rest under normal conditions, are able to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2109">
                    <text>stat5ab/-peripheral T cells, which are at rest under normal conditions, are able to proliferate strongly after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2110">
                    <text>stat5ab/-peripheral T cells, which are at rest under normal conditions, are observed to strongly proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2111">
                    <text>stat5ab/-peripheral T cells, which are at rest under normal conditions, can proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2112">
                    <text>stat5ab/-peripheral T cells, which are at rest under normal conditions, will proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2113">
                    <text>stat5ab/peripheral T cells can regain the ability to proliferate after the introduction of the completely length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2114">
                    <text>stat5ab/peripheral T cells can regain the ability to proliferate after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2115">
                    <text>stat5ab/peripheral T cells can regain the ability to proliferate after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2116">
                    <text>stat5ab/peripheral T cells can regain the ability to proliferate indefinitely after the introduction of the completely length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2117">
                    <text>stat5ab/peripheral T cells can regain the ability to proliferate indefinitely after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2118">
                    <text>stat5ab/peripheral T cells can regain the ability to proliferate indefinitely after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2119">
                    <text>stat5ab/peripheral T cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="2120">
                    <text>stat5ab/peripheral T cells has regained the ability to proliferate after the introduction of the completely length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2121">
                    <text>stat5ab/peripheral T cells has regained the ability to proliferate after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2122">
                    <text>stat5ab/peripheral T cells has regained the ability to proliferate after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2123">
                    <text>stat5ab/peripheral T cells has the probability of recovering the ability to proliferate after the introduction of the completely length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2124">
                    <text>stat5ab/peripheral T cells has the probability of recovering the ability to proliferate after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2125">
                    <text>stat5ab/peripheral T cells has the probability of recovering the ability to proliferate after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2126">
                    <text>stat5ab/peripheral T cells has the probability of recovering the ability to proliferate indefinitely after the introduction of the completely length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2127">
                    <text>stat5ab/peripheral T cells has the probability of recovering the ability to proliferate indefinitely after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2128">
                    <text>stat5ab/peripheral T cells has the probability of recovering the ability to proliferate indefinitely after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2129">
                    <text>stat5ab/peripheral T cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="2130">
                    <text>stat5ab/peripheral T cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="2131">
                    <text>stat5ab/peripheral T cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="2132">
                    <text>stat5ab/peripheral T cells is likely to proliferate the undefined proliferation capacity after the introduction of the completely length wild-type Stat5a (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2133">
                    <text>stat5ab/peripheral T cells is likely to proliferate the undefined proliferation capacity after the introduction of the full wild-length state5a (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2134">
                    <text>stat5ab/peripheral T cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="2135">
                    <text>stat5ab/peripheral T cells may have regained the ability to proliferate after the introduction of the completely length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2136">
                    <text>stat5ab/peripheral T cells may have regained the ability to proliferate after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2137">
                    <text>stat5ab/peripheral T cells may have regained the ability to proliferate after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2138">
                    <text>stat5ab/peripheral T cells may have regained the ability to proliferate indefinitely after the introduction of the completely length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2139">
                    <text>stat5ab/peripheral T cells may have regained the ability to proliferate indefinitely after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2140">
                    <text>stat5ab/peripheral T cells may have regained the ability to proliferate indefinitely after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2141">
                    <text>stat5ab/peripheral T cells may proliferate recovered the undefined proliferation capacity after the introduction of the completely length wild-type Stat5a (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2142">
                    <text>stat5ab/peripheral T cells may proliferate recovered the undefined proliferation capacity after the introduction of the full wild-length Stat5a (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2143">
                    <text>stat5ab/peripheral T cells may proliferate recovered the undefined proliferation capacity after the introduction of the full wild-length state5a (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2144">
                    <text>stat5ab/peripheral T cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="2145">
                    <text>stat5ab/peripheral T cells may proliferate the undefined proliferation capacity after the introduction of the completely length wild-type Stat5a (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2146">
                    <text>stat5ab/peripheral T cells may proliferate the undefined proliferation capacity after the introduction of the full wild-length Stat5a (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2147">
                    <text>stat5ab/peripheral T cells may proliferate the undefined proliferation capacity after the introduction of the full wild-length state5a (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2148">
                    <text>stat5ab/peripheral T cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="2149">
                    <text>stat5ab/peripheral T cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="2150">
                    <text>stat5ab/peripheral T cells proliferate the undefined proliferation capacity after the introduction of the completely length wild-type Stat5a (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2151">
                    <text>stat5ab/peripheral T cells proliferate the undefined proliferation capacity after the introduction of the full wild-length Stat5a (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2152">
                    <text>stat5ab/peripheral T cells proliferate the undefined proliferation capacity after the introduction of the full wild-length state5a (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2153">
                    <text>stat5ab/peripheral T cells recovered the ability to proliferate after the introduction of the full wild-length Stat5a (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2154">
                    <text>stat5ab/peripheral T cells recovered the ability to proliferate after the introduction of the full wild-length state5a (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2155">
                    <text>stat5ab/peripheral T cells regained the ability to proliferate indefinitely after the introduction of the completely length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2156">
                    <text>stat5ab/peripheral T cells regained the ability to proliferate indefinitely after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2157">
                    <text>stat5ab/peripheral T cells regained the ability to proliferate indefinitely after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2158">
                    <text>stat5ab/peripheral T cells will proliferate the undefined proliferation capability after the introduction of the completely length wild-type Stat5a (image 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2159">
                    <text>stat5ab/peripheral T cells will proliferate the undefined proliferation capability after the introduction of the full wild-length Stat5a (image 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2160">
                    <text>stat5ab/peripheral T cells will regain the ability to proliferate after the introduction of the completely length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2161">
                    <text>stat5ab/peripheral T cells will regain the ability to proliferate after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2162">
                    <text>stat5ab/peripheral T cells will regain the ability to proliferate after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2163">
                    <text>stat5ab/peripheral T cells will regain the ability to proliferate indefinitely after the introduction of the completely length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2164">
                    <text>stat5ab/peripheral T cells will regain the ability to proliferate indefinitely after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2165">
                    <text>stat5ab/peripheral T cells will regain the ability to proliferate indefinitely after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2166">
                    <text>stat5ab/peripheral T cells, which are at rest in normal conditions, are observed to proliferate after the introduction of the completely length wild-type Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2167">
                    <text>stat5ab/peripheral T cells, which are at rest in normal conditions, are observed to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2168">
                    <text>stat5ab/peripheral T cells, which are at rest in normal conditions, are observed to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2169">
                    <text>stat5ab/peripheral T cells, which are at rest in normal conditions, have the ability to proliferate after the introduction of the completely length wild-type Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2170">
                    <text>stat5ab/peripheral T cells, which are at rest in normal conditions, have the ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2171">
                    <text>stat5ab/peripheral T cells, which are at rest in normal conditions, have the ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2172">
                    <text>stat5ab/peripheral T cells, which are at rest in normal conditions, will proliferate after the introduction of the completely length wild-type Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2173">
                    <text>stat5ab/peripheral T cells, which are at rest in normal conditions, will proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2174">
                    <text>stat5ab/peripheral T cells, which are at rest in normal conditions, will proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2175">
                    <text>stat5ab/peripheral T cells, which are at rest under normal conditions, are able to proliferate after the introduction of the completely length wild-type Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2176">
                    <text>stat5ab/peripheral T cells, which are at rest under normal conditions, are able to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2177">
                    <text>stat5ab/peripheral T cells, which are at rest under normal conditions, are able to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2178">
                    <text>stat5ab/peripheral T cells, which are at rest under normal conditions, are able to proliferate strongly after the introduction of the completely length wild-type Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2179">
                    <text>stat5ab/peripheral T cells, which are at rest under normal conditions, are able to proliferate strongly after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2180">
                    <text>stat5ab/peripheral T cells, which are at rest under normal conditions, are able to proliferate strongly after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2181">
                    <text>stat5ab/peripheral T cells, which are at rest under normal conditions, are observed to strongly proliferate after the introduction of the completely length wild-type Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2182">
                    <text>stat5ab/peripheral T cells, which are at rest under normal conditions, are observed to strongly proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2183">
                    <text>stat5ab/peripheral T cells, which are at rest under normal conditions, are observed to strongly proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2184">
                    <text>stat5ab/peripheral T cells, which are at rest under normal conditions, can proliferate after the introduction of the completely length wild-type Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2185">
                    <text>stat5ab/peripheral T cells, which are at rest under normal conditions, can proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2186">
                    <text>stat5ab/peripheral T cells, which are at rest under normal conditions, can proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2187">
                    <text>stat5ab/peripheral T cells, which are at rest under normal conditions, will proliferate after the introduction of the completely length wild-type Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2188">
                    <text>stat5ab/peripheral T cells, which are at rest under normal conditions, will proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="2189">
                    <text>stat5ab/peripheral T cells, which are at rest under normal conditions, will proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="2190">
                    <text>the human placenta can regain the ability to proliferate along gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="2191">
                    <text>the human placenta can regain the ability to proliferate indefinitely along gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="2192">
                    <text>the human placenta has regained the ability to proliferate along gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="2193">
                    <text>the human placenta has the probability of recovering the ability to proliferate along gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="2194">
                    <text>the human placenta has the probability of recovering the ability to proliferate indefinitely along gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="2195">
                    <text>the human placenta is likely to proliferate the undefined proliferation capacity along gestation (picture 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="2196">
                    <text>the human placenta may have regained the ability to proliferate along gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="2197">
                    <text>the human placenta may have regained the ability to proliferate indefinitely along gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="2198">
                    <text>the human placenta may proliferate recovered the undefined proliferation capacity along gestation (picture 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="2199">
                    <text>the human placenta may proliferate the undefined proliferation capacity along gestation (picture 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="2200">
                    <text>the human placenta proliferate the undefined proliferation capacity along gestation (picture 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="2201">
                    <text>the human placenta recovered the ability to proliferate along gestation (picture 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="2202">
                    <text>the human placenta regained the ability to proliferate indefinitely along gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="2203">
                    <text>the human placenta will proliferate the undefined proliferation capability along gestation (image 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="2204">
                    <text>the human placenta will regain the ability to proliferate along gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="2205">
                    <text>the human placenta will regain the ability to proliferate indefinitely along gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="2206">
                    <text>the human placenta, which are at rest in normal conditions, are observed to proliferate along gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="2207">
                    <text>the human placenta, which are at rest in normal conditions, have the ability to proliferate along gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="2208">
                    <text>the human placenta, which are at rest in normal conditions, will proliferate along gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="2209">
                    <text>the human placenta, which are at rest under normal conditions, are able to proliferate along gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="2210">
                    <text>the human placenta, which are at rest under normal conditions, are able to proliferate strongly along gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="2211">
                    <text>the human placenta, which are at rest under normal conditions, are observed to strongly proliferate along gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="2212">
                    <text>the human placenta, which are at rest under normal conditions, can proliferate along gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="2213">
                    <text>the human placenta, which are at rest under normal conditions, will proliferate along gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>After androgen withdrawal and angiogen treatment, CD4+ HIV T cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>After androgen withdrawal and angiogen treatment, CD4+ HIV T cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>After androgen withdrawal and angiogen treatment, CD4+ HIV T cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>After androgen withdrawal and angiogen treatment, CD4+ HIV T cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>After androgen withdrawal and angiogen treatment, CD4+ HIV T cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>After androgen withdrawal and angiogen treatment, CD4+ HIV T cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>After androgen withdrawal and angiogen treatment, EBD cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>After androgen withdrawal and angiogen treatment, EBD cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>After androgen withdrawal and angiogen treatment, EBD cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>After androgen withdrawal and angiogen treatment, EBD cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>After androgen withdrawal and angiogen treatment, EBD cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>After androgen withdrawal and angiogen treatment, EBD cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>After androgen withdrawal and angiogen treatment, HD CD4+ T cells specific to HIV in viremics patients able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>After androgen withdrawal and angiogen treatment, HD CD4+ T cells specific to HIV in viremics patients may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>After androgen withdrawal and angiogen treatment, HD CD4+ T cells specific to HIV in viremics patients was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>After androgen withdrawal and angiogen treatment, HD CD4+ T cells specific to HIV in viremics patients which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>After androgen withdrawal and angiogen treatment, HD CD4+ T cells specific to HIV in viremics patients which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>After androgen withdrawal and angiogen treatment, HD CD4+ T cells specific to HIV in viremics patients will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>After androgen withdrawal and angiogen treatment, TBI cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>After androgen withdrawal and angiogen treatment, TBI cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>After androgen withdrawal and angiogen treatment, TBI cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>After androgen withdrawal and angiogen treatment, TBI cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>After androgen withdrawal and angiogen treatment, TBI cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>After androgen withdrawal and angiogen treatment, TBI cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>After androgen withdrawal and angiogen treatment, adult T cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>After androgen withdrawal and angiogen treatment, adult T cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>After androgen withdrawal and angiogen treatment, adult T cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>After androgen withdrawal and angiogen treatment, adult T cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>After androgen withdrawal and angiogen treatment, adult T cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>After androgen withdrawal and angiogen treatment, adult T cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>After androgen withdrawal and angiogen treatment, androgen cancer cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>After androgen withdrawal and angiogen treatment, androgen cancer cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>After androgen withdrawal and angiogen treatment, androgen cancer cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>After androgen withdrawal and angiogen treatment, androgen cancer cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>After androgen withdrawal and angiogen treatment, androgen cancer cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>After androgen withdrawal and angiogen treatment, androgen cancer cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>After androgen withdrawal and angiogen treatment, androgens responsive prostate cancer cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="38">
                    <text>After androgen withdrawal and angiogen treatment, androgens responsive prostate cancer cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="39">
                    <text>After androgen withdrawal and angiogen treatment, androgens responsive prostate cancer cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="40">
                    <text>After androgen withdrawal and angiogen treatment, androgens responsive prostate cancer cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="41">
                    <text>After androgen withdrawal and angiogen treatment, androgens responsive prostate cancer cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="42">
                    <text>After androgen withdrawal and angiogen treatment, androgens responsive prostate cancer cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="43">
                    <text>After androgen withdrawal and angiogen treatment, angiogen prostate cancer cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="44">
                    <text>After androgen withdrawal and angiogen treatment, angiogen prostate cancer cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="45">
                    <text>After androgen withdrawal and angiogen treatment, angiogen prostate cancer cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="46">
                    <text>After androgen withdrawal and angiogen treatment, angiogen prostate cancer cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="47">
                    <text>After androgen withdrawal and angiogen treatment, angiogen prostate cancer cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="48">
                    <text>After androgen withdrawal and angiogen treatment, angiogen prostate cancer cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="49">
                    <text>After androgen withdrawal and angiogen treatment, feet cells transplanted intra-splintly able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="50">
                    <text>After androgen withdrawal and angiogen treatment, feet cells transplanted intra-splintly may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="51">
                    <text>After androgen withdrawal and angiogen treatment, feet cells transplanted intra-splintly was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="52">
                    <text>After androgen withdrawal and angiogen treatment, feet cells transplanted intra-splintly which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="53">
                    <text>After androgen withdrawal and angiogen treatment, feet cells transplanted intra-splintly which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="54">
                    <text>After androgen withdrawal and angiogen treatment, feet cells transplanted intra-splintly will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="55">
                    <text>After androgen withdrawal and angiogen treatment, feet cells transplanted intrasplenically able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="56">
                    <text>After androgen withdrawal and angiogen treatment, feet cells transplanted intrasplenically may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="57">
                    <text>After androgen withdrawal and angiogen treatment, feet cells transplanted intrasplenically was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="58">
                    <text>After androgen withdrawal and angiogen treatment, feet cells transplanted intrasplenically which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="59">
                    <text>After androgen withdrawal and angiogen treatment, feet cells transplanted intrasplenically which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="60">
                    <text>After androgen withdrawal and angiogen treatment, feet cells transplanted intrasplenically will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="61">
                    <text>After androgen withdrawal and angiogen treatment, feet cells transplanted intrasplentically able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="62">
                    <text>After androgen withdrawal and angiogen treatment, feet cells transplanted intrasplentically may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="63">
                    <text>After androgen withdrawal and angiogen treatment, feet cells transplanted intrasplentically was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="64">
                    <text>After androgen withdrawal and angiogen treatment, feet cells transplanted intrasplentically which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="65">
                    <text>After androgen withdrawal and angiogen treatment, feet cells transplanted intrasplentically which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="66">
                    <text>After androgen withdrawal and angiogen treatment, feet cells transplanted intrasplentically will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="67">
                    <text>After androgen withdrawal and angiogen treatment, fetal liver cells transplanted intrasplenically able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="68">
                    <text>After androgen withdrawal and angiogen treatment, fetal liver cells transplanted intrasplenically may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="69">
                    <text>After androgen withdrawal and angiogen treatment, fetal liver cells transplanted intrasplenically was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="70">
                    <text>After androgen withdrawal and angiogen treatment, fetal liver cells transplanted intrasplenically which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="71">
                    <text>After androgen withdrawal and angiogen treatment, fetal liver cells transplanted intrasplenically which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="72">
                    <text>After androgen withdrawal and angiogen treatment, fetal liver cells transplanted intrasplenically will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="73">
                    <text>After androgen withdrawal and angiogen treatment, human placenta able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="74">
                    <text>After androgen withdrawal and angiogen treatment, human placenta may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="75">
                    <text>After androgen withdrawal and angiogen treatment, human placenta was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="76">
                    <text>After androgen withdrawal and angiogen treatment, human placenta which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="77">
                    <text>After androgen withdrawal and angiogen treatment, human placenta which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="78">
                    <text>After androgen withdrawal and angiogen treatment, human placenta will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="79">
                    <text>After androgen withdrawal and angiogen treatment, ingenue T cells for adults able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="80">
                    <text>After androgen withdrawal and angiogen treatment, ingenue T cells for adults may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="81">
                    <text>After androgen withdrawal and angiogen treatment, ingenue T cells for adults was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="82">
                    <text>After androgen withdrawal and angiogen treatment, ingenue T cells for adults which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="83">
                    <text>After androgen withdrawal and angiogen treatment, ingenue T cells for adults which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="84">
                    <text>After androgen withdrawal and angiogen treatment, ingenue T cells for adults will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="85">
                    <text>After androgen withdrawal and angiogen treatment, ingenue T cells of adults able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="86">
                    <text>After androgen withdrawal and angiogen treatment, ingenue T cells of adults may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="87">
                    <text>After androgen withdrawal and angiogen treatment, ingenue T cells of adults was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="88">
                    <text>After androgen withdrawal and angiogen treatment, ingenue T cells of adults which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="89">
                    <text>After androgen withdrawal and angiogen treatment, ingenue T cells of adults which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="90">
                    <text>After androgen withdrawal and angiogen treatment, ingenue T cells of adults will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="91">
                    <text>After androgen withdrawal and angiogen treatment, intra-splate transplant feet cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="92">
                    <text>After androgen withdrawal and angiogen treatment, intra-splate transplant feet cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="93">
                    <text>After androgen withdrawal and angiogen treatment, intra-splate transplant feet cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="94">
                    <text>After androgen withdrawal and angiogen treatment, intra-splate transplant feet cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="95">
                    <text>After androgen withdrawal and angiogen treatment, intra-splate transplant feet cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="96">
                    <text>After androgen withdrawal and angiogen treatment, intra-splate transplant feet cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="97">
                    <text>After androgen withdrawal and angiogen treatment, intra-splenic transplant fetal cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="98">
                    <text>After androgen withdrawal and angiogen treatment, intra-splenic transplant fetal cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="99">
                    <text>After androgen withdrawal and angiogen treatment, intra-splenic transplant fetal cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="100">
                    <text>After androgen withdrawal and angiogen treatment, intra-splenic transplant fetal cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="101">
                    <text>After androgen withdrawal and angiogen treatment, intra-splenic transplant fetal cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="102">
                    <text>After androgen withdrawal and angiogen treatment, intra-splenic transplant fetal cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="103">
                    <text>After androgen withdrawal and angiogen treatment, intra-splintly transplanted fetal shapes able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="104">
                    <text>After androgen withdrawal and angiogen treatment, intra-splintly transplanted fetal shapes may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="105">
                    <text>After androgen withdrawal and angiogen treatment, intra-splintly transplanted fetal shapes was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="106">
                    <text>After androgen withdrawal and angiogen treatment, intra-splintly transplanted fetal shapes which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="107">
                    <text>After androgen withdrawal and angiogen treatment, intra-splintly transplanted fetal shapes which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="108">
                    <text>After androgen withdrawal and angiogen treatment, intra-splintly transplanted fetal shapes will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="109">
                    <text>After androgen withdrawal and angiogen treatment, intrasplens transplanted liver cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="110">
                    <text>After androgen withdrawal and angiogen treatment, intrasplens transplanted liver cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="111">
                    <text>After androgen withdrawal and angiogen treatment, intrasplens transplanted liver cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="112">
                    <text>After androgen withdrawal and angiogen treatment, intrasplens transplanted liver cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="113">
                    <text>After androgen withdrawal and angiogen treatment, intrasplens transplanted liver cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="114">
                    <text>After androgen withdrawal and angiogen treatment, intrasplens transplanted liver cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="115">
                    <text>After androgen withdrawal and angiogen treatment, intrasplensally transplanted fetal cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="116">
                    <text>After androgen withdrawal and angiogen treatment, intrasplensally transplanted fetal cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="117">
                    <text>After androgen withdrawal and angiogen treatment, intrasplensally transplanted fetal cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="118">
                    <text>After androgen withdrawal and angiogen treatment, intrasplensally transplanted fetal cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="119">
                    <text>After androgen withdrawal and angiogen treatment, intrasplensally transplanted fetal cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="120">
                    <text>After androgen withdrawal and angiogen treatment, intrasplensally transplanted fetal cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="121">
                    <text>After androgen withdrawal and angiogen treatment, intrasplensally transplanted liver cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="122">
                    <text>After androgen withdrawal and angiogen treatment, intrasplensally transplanted liver cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="123">
                    <text>After androgen withdrawal and angiogen treatment, intrasplensally transplanted liver cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="124">
                    <text>After androgen withdrawal and angiogen treatment, intrasplensally transplanted liver cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="125">
                    <text>After androgen withdrawal and angiogen treatment, intrasplensally transplanted liver cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="126">
                    <text>After androgen withdrawal and angiogen treatment, intrasplensally transplanted liver cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="127">
                    <text>After androgen withdrawal and angiogen treatment, intrasplintly transplanted fetal cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="128">
                    <text>After androgen withdrawal and angiogen treatment, intrasplintly transplanted fetal cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="129">
                    <text>After androgen withdrawal and angiogen treatment, intrasplintly transplanted fetal cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="130">
                    <text>After androgen withdrawal and angiogen treatment, intrasplintly transplanted fetal cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="131">
                    <text>After androgen withdrawal and angiogen treatment, intrasplintly transplanted fetal cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="132">
                    <text>After androgen withdrawal and angiogen treatment, intrasplintly transplanted fetal cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="133">
                    <text>After androgen withdrawal and angiogen treatment, intrasponntically transplanted fetal cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="134">
                    <text>After androgen withdrawal and angiogen treatment, intrasponntically transplanted fetal cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="135">
                    <text>After androgen withdrawal and angiogen treatment, intrasponntically transplanted fetal cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="136">
                    <text>After androgen withdrawal and angiogen treatment, intrasponntically transplanted fetal cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="137">
                    <text>After androgen withdrawal and angiogen treatment, intrasponntically transplanted fetal cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="138">
                    <text>After androgen withdrawal and angiogen treatment, intrasponntically transplanted fetal cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="139">
                    <text>After androgen withdrawal and angiogen treatment, intraspontically transplanted fetal cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="140">
                    <text>After androgen withdrawal and angiogen treatment, intraspontically transplanted fetal cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="141">
                    <text>After androgen withdrawal and angiogen treatment, intraspontically transplanted fetal cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="142">
                    <text>After androgen withdrawal and angiogen treatment, intraspontically transplanted fetal cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="143">
                    <text>After androgen withdrawal and angiogen treatment, intraspontically transplanted fetal cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="144">
                    <text>After androgen withdrawal and angiogen treatment, intraspontically transplanted fetal cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="145">
                    <text>After androgen withdrawal and angiogen treatment, the human placenta able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="146">
                    <text>After androgen withdrawal and angiogen treatment, the human placenta may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="147">
                    <text>After androgen withdrawal and angiogen treatment, the human placenta was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="148">
                    <text>After androgen withdrawal and angiogen treatment, the human placenta which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="149">
                    <text>After androgen withdrawal and angiogen treatment, the human placenta which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="150">
                    <text>After androgen withdrawal and angiogen treatment, the human placenta will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="151">
                    <text>After androgen withdrawal and angiogen treatment, transplant feet cells intrasplenomegaly able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="152">
                    <text>After androgen withdrawal and angiogen treatment, transplant feet cells intrasplenomegaly may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="153">
                    <text>After androgen withdrawal and angiogen treatment, transplant feet cells intrasplenomegaly was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="154">
                    <text>After androgen withdrawal and angiogen treatment, transplant feet cells intrasplenomegaly which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="155">
                    <text>After androgen withdrawal and angiogen treatment, transplant feet cells intrasplenomegaly which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="156">
                    <text>After androgen withdrawal and angiogen treatment, transplant feet cells intrasplenomegaly will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="157">
                    <text>After androgen withdrawal and anti-androgen treatment, CD4+ HIV T cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="158">
                    <text>After androgen withdrawal and anti-androgen treatment, CD4+ HIV T cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="159">
                    <text>After androgen withdrawal and anti-androgen treatment, CD4+ HIV T cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="160">
                    <text>After androgen withdrawal and anti-androgen treatment, CD4+ HIV T cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="161">
                    <text>After androgen withdrawal and anti-androgen treatment, CD4+ HIV T cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="162">
                    <text>After androgen withdrawal and anti-androgen treatment, CD4+ HIV T cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="163">
                    <text>After androgen withdrawal and anti-androgen treatment, CD4+ HIV T cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="164">
                    <text>After androgen withdrawal and anti-androgen treatment, CD4+ HIV T cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="165">
                    <text>After androgen withdrawal and anti-androgen treatment, CD4+ HIV T cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="166">
                    <text>After androgen withdrawal and anti-androgen treatment, EBD cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="167">
                    <text>After androgen withdrawal and anti-androgen treatment, EBD cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="168">
                    <text>After androgen withdrawal and anti-androgen treatment, EBD cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="169">
                    <text>After androgen withdrawal and anti-androgen treatment, EBD cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="170">
                    <text>After androgen withdrawal and anti-androgen treatment, EBD cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="171">
                    <text>After androgen withdrawal and anti-androgen treatment, EBD cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="172">
                    <text>After androgen withdrawal and anti-androgen treatment, EBD cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="173">
                    <text>After androgen withdrawal and anti-androgen treatment, EBD cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="174">
                    <text>After androgen withdrawal and anti-androgen treatment, EBD cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="175">
                    <text>After androgen withdrawal and anti-androgen treatment, HD CD4+ T cells specific to HIV in viremics patients ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="176">
                    <text>After androgen withdrawal and anti-androgen treatment, HD CD4+ T cells specific to HIV in viremics patients ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="177">
                    <text>After androgen withdrawal and anti-androgen treatment, HD CD4+ T cells specific to HIV in viremics patients failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="178">
                    <text>After androgen withdrawal and anti-androgen treatment, HD CD4+ T cells specific to HIV in viremics patients has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="179">
                    <text>After androgen withdrawal and anti-androgen treatment, HD CD4+ T cells specific to HIV in viremics patients is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="180">
                    <text>After androgen withdrawal and anti-androgen treatment, HD CD4+ T cells specific to HIV in viremics patients may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="181">
                    <text>After androgen withdrawal and anti-androgen treatment, HD CD4+ T cells specific to HIV in viremics patients which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="182">
                    <text>After androgen withdrawal and anti-androgen treatment, HD CD4+ T cells specific to HIV in viremics patients which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="183">
                    <text>After androgen withdrawal and anti-androgen treatment, HD CD4+ T cells specific to HIV in viremics patients will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="184">
                    <text>After androgen withdrawal and anti-androgen treatment, TBI cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="185">
                    <text>After androgen withdrawal and anti-androgen treatment, TBI cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="186">
                    <text>After androgen withdrawal and anti-androgen treatment, TBI cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="187">
                    <text>After androgen withdrawal and anti-androgen treatment, TBI cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="188">
                    <text>After androgen withdrawal and anti-androgen treatment, TBI cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="189">
                    <text>After androgen withdrawal and anti-androgen treatment, TBI cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="190">
                    <text>After androgen withdrawal and anti-androgen treatment, TBI cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="191">
                    <text>After androgen withdrawal and anti-androgen treatment, TBI cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="192">
                    <text>After androgen withdrawal and anti-androgen treatment, TBI cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="193">
                    <text>After androgen withdrawal and anti-androgen treatment, adult T cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="194">
                    <text>After androgen withdrawal and anti-androgen treatment, adult T cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="195">
                    <text>After androgen withdrawal and anti-androgen treatment, adult T cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="196">
                    <text>After androgen withdrawal and anti-androgen treatment, adult T cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="197">
                    <text>After androgen withdrawal and anti-androgen treatment, adult T cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="198">
                    <text>After androgen withdrawal and anti-androgen treatment, adult T cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="199">
                    <text>After androgen withdrawal and anti-androgen treatment, adult T cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="200">
                    <text>After androgen withdrawal and anti-androgen treatment, adult T cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="201">
                    <text>After androgen withdrawal and anti-androgen treatment, adult T cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="202">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen cancer cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="203">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen cancer cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="204">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen cancer cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="205">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen cancer cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="206">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen cancer cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="207">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen cancer cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="208">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen cancer cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="209">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen cancer cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="210">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen cancer cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="211">
                    <text>After androgen withdrawal and anti-androgen treatment, androgens responsive prostate cancer cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="212">
                    <text>After androgen withdrawal and anti-androgen treatment, androgens responsive prostate cancer cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="213">
                    <text>After androgen withdrawal and anti-androgen treatment, androgens responsive prostate cancer cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="214">
                    <text>After androgen withdrawal and anti-androgen treatment, androgens responsive prostate cancer cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="215">
                    <text>After androgen withdrawal and anti-androgen treatment, androgens responsive prostate cancer cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="216">
                    <text>After androgen withdrawal and anti-androgen treatment, androgens responsive prostate cancer cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="217">
                    <text>After androgen withdrawal and anti-androgen treatment, androgens responsive prostate cancer cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="218">
                    <text>After androgen withdrawal and anti-androgen treatment, androgens responsive prostate cancer cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="219">
                    <text>After androgen withdrawal and anti-androgen treatment, androgens responsive prostate cancer cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="220">
                    <text>After androgen withdrawal and anti-androgen treatment, angiogen prostate cancer cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="221">
                    <text>After androgen withdrawal and anti-androgen treatment, angiogen prostate cancer cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="222">
                    <text>After androgen withdrawal and anti-androgen treatment, angiogen prostate cancer cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="223">
                    <text>After androgen withdrawal and anti-androgen treatment, angiogen prostate cancer cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="224">
                    <text>After androgen withdrawal and anti-androgen treatment, angiogen prostate cancer cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="225">
                    <text>After androgen withdrawal and anti-androgen treatment, angiogen prostate cancer cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="226">
                    <text>After androgen withdrawal and anti-androgen treatment, angiogen prostate cancer cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="227">
                    <text>After androgen withdrawal and anti-androgen treatment, angiogen prostate cancer cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="228">
                    <text>After androgen withdrawal and anti-androgen treatment, angiogen prostate cancer cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="229">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intra-splintly ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="230">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intra-splintly ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="231">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intra-splintly failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="232">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intra-splintly has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="233">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intra-splintly is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="234">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intra-splintly may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="235">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intra-splintly which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="236">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intra-splintly which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="237">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intra-splintly will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="238">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intrasplenically ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="239">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intrasplenically ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="240">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intrasplenically failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="241">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intrasplenically has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="242">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intrasplenically is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="243">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intrasplenically may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="244">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intrasplenically which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="245">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intrasplenically which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="246">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intrasplenically will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="247">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intrasplentically ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="248">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intrasplentically ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="249">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intrasplentically failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="250">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intrasplentically has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="251">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intrasplentically is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="252">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intrasplentically may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="253">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intrasplentically which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="254">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intrasplentically which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="255">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intrasplentically will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="256">
                    <text>After androgen withdrawal and anti-androgen treatment, fetal liver cells transplanted intrasplenically ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="257">
                    <text>After androgen withdrawal and anti-androgen treatment, fetal liver cells transplanted intrasplenically ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="258">
                    <text>After androgen withdrawal and anti-androgen treatment, fetal liver cells transplanted intrasplenically failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="259">
                    <text>After androgen withdrawal and anti-androgen treatment, fetal liver cells transplanted intrasplenically has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="260">
                    <text>After androgen withdrawal and anti-androgen treatment, fetal liver cells transplanted intrasplenically is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="261">
                    <text>After androgen withdrawal and anti-androgen treatment, fetal liver cells transplanted intrasplenically may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="262">
                    <text>After androgen withdrawal and anti-androgen treatment, fetal liver cells transplanted intrasplenically which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="263">
                    <text>After androgen withdrawal and anti-androgen treatment, fetal liver cells transplanted intrasplenically which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="264">
                    <text>After androgen withdrawal and anti-androgen treatment, fetal liver cells transplanted intrasplenically will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="265">
                    <text>After androgen withdrawal and anti-androgen treatment, human placenta ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="266">
                    <text>After androgen withdrawal and anti-androgen treatment, human placenta ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="267">
                    <text>After androgen withdrawal and anti-androgen treatment, human placenta failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="268">
                    <text>After androgen withdrawal and anti-androgen treatment, human placenta has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="269">
                    <text>After androgen withdrawal and anti-androgen treatment, human placenta is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="270">
                    <text>After androgen withdrawal and anti-androgen treatment, human placenta may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="271">
                    <text>After androgen withdrawal and anti-androgen treatment, human placenta which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="272">
                    <text>After androgen withdrawal and anti-androgen treatment, human placenta which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="273">
                    <text>After androgen withdrawal and anti-androgen treatment, human placenta will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="274">
                    <text>After androgen withdrawal and anti-androgen treatment, ingenue T cells for adults ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="275">
                    <text>After androgen withdrawal and anti-androgen treatment, ingenue T cells for adults ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="276">
                    <text>After androgen withdrawal and anti-androgen treatment, ingenue T cells for adults failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="277">
                    <text>After androgen withdrawal and anti-androgen treatment, ingenue T cells for adults has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="278">
                    <text>After androgen withdrawal and anti-androgen treatment, ingenue T cells for adults is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="279">
                    <text>After androgen withdrawal and anti-androgen treatment, ingenue T cells for adults may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="280">
                    <text>After androgen withdrawal and anti-androgen treatment, ingenue T cells for adults which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="281">
                    <text>After androgen withdrawal and anti-androgen treatment, ingenue T cells for adults which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="282">
                    <text>After androgen withdrawal and anti-androgen treatment, ingenue T cells for adults will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="283">
                    <text>After androgen withdrawal and anti-androgen treatment, ingenue T cells of adults ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="284">
                    <text>After androgen withdrawal and anti-androgen treatment, ingenue T cells of adults ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="285">
                    <text>After androgen withdrawal and anti-androgen treatment, ingenue T cells of adults failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="286">
                    <text>After androgen withdrawal and anti-androgen treatment, ingenue T cells of adults has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="287">
                    <text>After androgen withdrawal and anti-androgen treatment, ingenue T cells of adults is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="288">
                    <text>After androgen withdrawal and anti-androgen treatment, ingenue T cells of adults may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="289">
                    <text>After androgen withdrawal and anti-androgen treatment, ingenue T cells of adults which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="290">
                    <text>After androgen withdrawal and anti-androgen treatment, ingenue T cells of adults which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="291">
                    <text>After androgen withdrawal and anti-androgen treatment, ingenue T cells of adults will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="292">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splate transplant feet cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="293">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splate transplant feet cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="294">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splate transplant feet cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="295">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splate transplant feet cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="296">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splate transplant feet cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="297">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splate transplant feet cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="298">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splate transplant feet cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="299">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splate transplant feet cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="300">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splate transplant feet cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="301">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splenic transplant fetal cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="302">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splenic transplant fetal cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="303">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splenic transplant fetal cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="304">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splenic transplant fetal cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="305">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splenic transplant fetal cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="306">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splenic transplant fetal cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="307">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splenic transplant fetal cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="308">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splenic transplant fetal cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="309">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splenic transplant fetal cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="310">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splintly transplanted fetal shapes ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="311">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splintly transplanted fetal shapes ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="312">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splintly transplanted fetal shapes failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="313">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splintly transplanted fetal shapes has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="314">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splintly transplanted fetal shapes is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="315">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splintly transplanted fetal shapes may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="316">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splintly transplanted fetal shapes which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="317">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splintly transplanted fetal shapes which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="318">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splintly transplanted fetal shapes will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="319">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplens transplanted liver cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="320">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplens transplanted liver cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="321">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplens transplanted liver cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="322">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplens transplanted liver cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="323">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplens transplanted liver cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="324">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplens transplanted liver cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="325">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplens transplanted liver cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="326">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplens transplanted liver cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="327">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplens transplanted liver cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="328">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplensally transplanted fetal cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="329">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplensally transplanted fetal cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="330">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplensally transplanted fetal cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="331">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplensally transplanted fetal cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="332">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplensally transplanted fetal cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="333">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplensally transplanted fetal cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="334">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplensally transplanted fetal cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="335">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplensally transplanted fetal cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="336">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplensally transplanted fetal cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="337">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplensally transplanted liver cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="338">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplensally transplanted liver cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="339">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplensally transplanted liver cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="340">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplensally transplanted liver cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="341">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplensally transplanted liver cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="342">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplensally transplanted liver cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="343">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplensally transplanted liver cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="344">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplensally transplanted liver cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="345">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplensally transplanted liver cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="346">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplintly transplanted fetal cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="347">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplintly transplanted fetal cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="348">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplintly transplanted fetal cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="349">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplintly transplanted fetal cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="350">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplintly transplanted fetal cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="351">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplintly transplanted fetal cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="352">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplintly transplanted fetal cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="353">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplintly transplanted fetal cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="354">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplintly transplanted fetal cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="355">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasponntically transplanted fetal cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="356">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasponntically transplanted fetal cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="357">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasponntically transplanted fetal cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="358">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasponntically transplanted fetal cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="359">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasponntically transplanted fetal cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="360">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasponntically transplanted fetal cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="361">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasponntically transplanted fetal cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="362">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasponntically transplanted fetal cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="363">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasponntically transplanted fetal cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="364">
                    <text>After androgen withdrawal and anti-androgen treatment, intraspontically transplanted fetal cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="365">
                    <text>After androgen withdrawal and anti-androgen treatment, intraspontically transplanted fetal cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="366">
                    <text>After androgen withdrawal and anti-androgen treatment, intraspontically transplanted fetal cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="367">
                    <text>After androgen withdrawal and anti-androgen treatment, intraspontically transplanted fetal cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="368">
                    <text>After androgen withdrawal and anti-androgen treatment, intraspontically transplanted fetal cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="369">
                    <text>After androgen withdrawal and anti-androgen treatment, intraspontically transplanted fetal cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="370">
                    <text>After androgen withdrawal and anti-androgen treatment, intraspontically transplanted fetal cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="371">
                    <text>After androgen withdrawal and anti-androgen treatment, intraspontically transplanted fetal cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="372">
                    <text>After androgen withdrawal and anti-androgen treatment, intraspontically transplanted fetal cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="373">
                    <text>After androgen withdrawal and anti-androgen treatment, the human placenta ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="374">
                    <text>After androgen withdrawal and anti-androgen treatment, the human placenta ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="375">
                    <text>After androgen withdrawal and anti-androgen treatment, the human placenta failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="376">
                    <text>After androgen withdrawal and anti-androgen treatment, the human placenta has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="377">
                    <text>After androgen withdrawal and anti-androgen treatment, the human placenta is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="378">
                    <text>After androgen withdrawal and anti-androgen treatment, the human placenta may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="379">
                    <text>After androgen withdrawal and anti-androgen treatment, the human placenta which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="380">
                    <text>After androgen withdrawal and anti-androgen treatment, the human placenta which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="381">
                    <text>After androgen withdrawal and anti-androgen treatment, the human placenta will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="382">
                    <text>After androgen withdrawal and anti-androgen treatment, transplant feet cells intrasplenomegaly ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="383">
                    <text>After androgen withdrawal and anti-androgen treatment, transplant feet cells intrasplenomegaly ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="384">
                    <text>After androgen withdrawal and anti-androgen treatment, transplant feet cells intrasplenomegaly failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="385">
                    <text>After androgen withdrawal and anti-androgen treatment, transplant feet cells intrasplenomegaly has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="386">
                    <text>After androgen withdrawal and anti-androgen treatment, transplant feet cells intrasplenomegaly is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="387">
                    <text>After androgen withdrawal and anti-androgen treatment, transplant feet cells intrasplenomegaly may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="388">
                    <text>After androgen withdrawal and anti-androgen treatment, transplant feet cells intrasplenomegaly which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="389">
                    <text>After androgen withdrawal and anti-androgen treatment, transplant feet cells intrasplenomegaly which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="390">
                    <text>After androgen withdrawal and anti-androgen treatment, transplant feet cells intrasplenomegaly will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="391">
                    <text>After androgen withdrawal and antiandrogen treatment, CD4+ HIV T cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="392">
                    <text>After androgen withdrawal and antiandrogen treatment, CD4+ HIV T cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="393">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="394">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="395">
                    <text>After androgen withdrawal and antiandrogen treatment, HD CD4+ T cells specific to HIV in viremics patients ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="396">
                    <text>After androgen withdrawal and antiandrogen treatment, HD CD4+ T cells specific to HIV in viremics patients ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="397">
                    <text>After androgen withdrawal and antiandrogen treatment, TBI cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="398">
                    <text>After androgen withdrawal and antiandrogen treatment, TBI cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="399">
                    <text>After androgen withdrawal and antiandrogen treatment, adult T cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="400">
                    <text>After androgen withdrawal and antiandrogen treatment, adult T cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="401">
                    <text>After androgen withdrawal and antiandrogen treatment, androgen cancer cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="402">
                    <text>After androgen withdrawal and antiandrogen treatment, androgen cancer cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="403">
                    <text>After androgen withdrawal and antiandrogen treatment, androgens responsive prostate cancer cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="404">
                    <text>After androgen withdrawal and antiandrogen treatment, androgens responsive prostate cancer cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="405">
                    <text>After androgen withdrawal and antiandrogen treatment, angiogen prostate cancer cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="406">
                    <text>After androgen withdrawal and antiandrogen treatment, angiogen prostate cancer cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="407">
                    <text>After androgen withdrawal and antiandrogen treatment, feet cells transplanted intra-splintly ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="408">
                    <text>After androgen withdrawal and antiandrogen treatment, feet cells transplanted intra-splintly ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="409">
                    <text>After androgen withdrawal and antiandrogen treatment, feet cells transplanted intrasplenically ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="410">
                    <text>After androgen withdrawal and antiandrogen treatment, feet cells transplanted intrasplenically ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="411">
                    <text>After androgen withdrawal and antiandrogen treatment, feet cells transplanted intrasplentically ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="412">
                    <text>After androgen withdrawal and antiandrogen treatment, feet cells transplanted intrasplentically ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="413">
                    <text>After androgen withdrawal and antiandrogen treatment, fetal liver cells transplanted intrasplenically ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="414">
                    <text>After androgen withdrawal and antiandrogen treatment, fetal liver cells transplanted intrasplenically ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="415">
                    <text>After androgen withdrawal and antiandrogen treatment, human placenta ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="416">
                    <text>After androgen withdrawal and antiandrogen treatment, human placenta ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="417">
                    <text>After androgen withdrawal and antiandrogen treatment, ingenue T cells for adults ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="418">
                    <text>After androgen withdrawal and antiandrogen treatment, ingenue T cells for adults ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="419">
                    <text>After androgen withdrawal and antiandrogen treatment, ingenue T cells of adults ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="420">
                    <text>After androgen withdrawal and antiandrogen treatment, ingenue T cells of adults ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="421">
                    <text>After androgen withdrawal and antiandrogen treatment, intra-splate transplant feet cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="422">
                    <text>After androgen withdrawal and antiandrogen treatment, intra-splate transplant feet cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="423">
                    <text>After androgen withdrawal and antiandrogen treatment, intra-splenic transplant fetal cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="424">
                    <text>After androgen withdrawal and antiandrogen treatment, intra-splenic transplant fetal cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="425">
                    <text>After androgen withdrawal and antiandrogen treatment, intra-splintly transplanted fetal shapes ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="426">
                    <text>After androgen withdrawal and antiandrogen treatment, intra-splintly transplanted fetal shapes ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="427">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplens transplanted liver cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="428">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplens transplanted liver cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="429">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplensally transplanted fetal cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="430">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplensally transplanted fetal cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="431">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplensally transplanted liver cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="432">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplensally transplanted liver cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="433">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplintly transplanted fetal cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="434">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplintly transplanted fetal cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="435">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasponntically transplanted fetal cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="436">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasponntically transplanted fetal cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="437">
                    <text>After androgen withdrawal and antiandrogen treatment, intraspontically transplanted fetal cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="438">
                    <text>After androgen withdrawal and antiandrogen treatment, intraspontically transplanted fetal cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="439">
                    <text>After androgen withdrawal and antiandrogen treatment, the human placenta ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="440">
                    <text>After androgen withdrawal and antiandrogen treatment, the human placenta ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="441">
                    <text>After androgen withdrawal and antiandrogen treatment, transplant feet cells intrasplenomegaly ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="442">
                    <text>After androgen withdrawal and antiandrogen treatment, transplant feet cells intrasplenomegaly ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="443">
                    <text>After androgens have been removed and anti-androgen treatment, CD4+ HIV T cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="444">
                    <text>After androgens have been removed and anti-androgen treatment, CD4+ HIV T cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="445">
                    <text>After androgens have been removed and anti-androgen treatment, EBD cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="446">
                    <text>After androgens have been removed and anti-androgen treatment, EBD cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="447">
                    <text>After androgens have been removed and anti-androgen treatment, HD CD4+ T cells specific to HIV in viremics patients that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="448">
                    <text>After androgens have been removed and anti-androgen treatment, HD CD4+ T cells specific to HIV in viremics patients which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="449">
                    <text>After androgens have been removed and anti-androgen treatment, TBI cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="450">
                    <text>After androgens have been removed and anti-androgen treatment, TBI cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="451">
                    <text>After androgens have been removed and anti-androgen treatment, adult T cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="452">
                    <text>After androgens have been removed and anti-androgen treatment, adult T cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="453">
                    <text>After androgens have been removed and anti-androgen treatment, androgen cancer cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="454">
                    <text>After androgens have been removed and anti-androgen treatment, androgen cancer cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="455">
                    <text>After androgens have been removed and anti-androgen treatment, androgens responsive prostate cancer cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="456">
                    <text>After androgens have been removed and anti-androgen treatment, androgens responsive prostate cancer cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="457">
                    <text>After androgens have been removed and anti-androgen treatment, angiogen prostate cancer cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="458">
                    <text>After androgens have been removed and anti-androgen treatment, angiogen prostate cancer cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="459">
                    <text>After androgens have been removed and anti-androgen treatment, feet cells transplanted intra-splintly that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="460">
                    <text>After androgens have been removed and anti-androgen treatment, feet cells transplanted intra-splintly which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="461">
                    <text>After androgens have been removed and anti-androgen treatment, feet cells transplanted intrasplenically that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="462">
                    <text>After androgens have been removed and anti-androgen treatment, feet cells transplanted intrasplenically which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="463">
                    <text>After androgens have been removed and anti-androgen treatment, feet cells transplanted intrasplentically that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="464">
                    <text>After androgens have been removed and anti-androgen treatment, feet cells transplanted intrasplentically which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="465">
                    <text>After androgens have been removed and anti-androgen treatment, fetal liver cells transplanted intrasplenically that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="466">
                    <text>After androgens have been removed and anti-androgen treatment, fetal liver cells transplanted intrasplenically which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="467">
                    <text>After androgens have been removed and anti-androgen treatment, human placenta that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="468">
                    <text>After androgens have been removed and anti-androgen treatment, human placenta which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="469">
                    <text>After androgens have been removed and anti-androgen treatment, ingenue T cells for adults that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="470">
                    <text>After androgens have been removed and anti-androgen treatment, ingenue T cells for adults which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="471">
                    <text>After androgens have been removed and anti-androgen treatment, ingenue T cells of adults that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="472">
                    <text>After androgens have been removed and anti-androgen treatment, ingenue T cells of adults which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="473">
                    <text>After androgens have been removed and anti-androgen treatment, intra-splate transplant feet cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="474">
                    <text>After androgens have been removed and anti-androgen treatment, intra-splate transplant feet cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="475">
                    <text>After androgens have been removed and anti-androgen treatment, intra-splenic transplant fetal cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="476">
                    <text>After androgens have been removed and anti-androgen treatment, intra-splenic transplant fetal cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="477">
                    <text>After androgens have been removed and anti-androgen treatment, intra-splintly transplanted fetal shapes that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="478">
                    <text>After androgens have been removed and anti-androgen treatment, intra-splintly transplanted fetal shapes which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="479">
                    <text>After androgens have been removed and anti-androgen treatment, intrasplens transplanted liver cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="480">
                    <text>After androgens have been removed and anti-androgen treatment, intrasplens transplanted liver cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="481">
                    <text>After androgens have been removed and anti-androgen treatment, intrasplensally transplanted fetal cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="482">
                    <text>After androgens have been removed and anti-androgen treatment, intrasplensally transplanted fetal cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="483">
                    <text>After androgens have been removed and anti-androgen treatment, intrasplensally transplanted liver cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="484">
                    <text>After androgens have been removed and anti-androgen treatment, intrasplensally transplanted liver cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="485">
                    <text>After androgens have been removed and anti-androgen treatment, intrasplintly transplanted fetal cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="486">
                    <text>After androgens have been removed and anti-androgen treatment, intrasplintly transplanted fetal cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="487">
                    <text>After androgens have been removed and anti-androgen treatment, intrasponntically transplanted fetal cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="488">
                    <text>After androgens have been removed and anti-androgen treatment, intrasponntically transplanted fetal cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="489">
                    <text>After androgens have been removed and anti-androgen treatment, intraspontically transplanted fetal cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="490">
                    <text>After androgens have been removed and anti-androgen treatment, intraspontically transplanted fetal cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="491">
                    <text>After androgens have been removed and anti-androgen treatment, the human placenta that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="492">
                    <text>After androgens have been removed and anti-androgen treatment, the human placenta which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="493">
                    <text>After androgens have been removed and anti-androgen treatment, transplant feet cells intrasplenomegaly that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="494">
                    <text>After androgens have been removed and anti-androgen treatment, transplant feet cells intrasplenomegaly which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="495">
                    <text>After the androgen has been withdrawn and angiogen treatment, CD4+ HIV T cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="496">
                    <text>After the androgen has been withdrawn and angiogen treatment, CD4+ HIV T cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="497">
                    <text>After the androgen has been withdrawn and angiogen treatment, CD4+ HIV T cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="498">
                    <text>After the androgen has been withdrawn and angiogen treatment, CD4+ HIV T cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="499">
                    <text>After the androgen has been withdrawn and angiogen treatment, CD4+ HIV T cells will proliferate tumor regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="500">
                    <text>After the androgen has been withdrawn and angiogen treatment, EBD cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="501">
                    <text>After the androgen has been withdrawn and angiogen treatment, EBD cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="502">
                    <text>After the androgen has been withdrawn and angiogen treatment, EBD cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="503">
                    <text>After the androgen has been withdrawn and angiogen treatment, EBD cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="504">
                    <text>After the androgen has been withdrawn and angiogen treatment, EBD cells will proliferate tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="505">
                    <text>After the androgen has been withdrawn and angiogen treatment, HD CD4+ T cells specific to HIV in viremics patients that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="506">
                    <text>After the androgen has been withdrawn and angiogen treatment, HD CD4+ T cells specific to HIV in viremics patients which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="507">
                    <text>After the androgen has been withdrawn and angiogen treatment, HD CD4+ T cells specific to HIV in viremics patients which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="508">
                    <text>After the androgen has been withdrawn and angiogen treatment, HD CD4+ T cells specific to HIV in viremics patients which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="509">
                    <text>After the androgen has been withdrawn and angiogen treatment, HD CD4+ T cells specific to HIV in viremics patients will proliferate tumor regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="510">
                    <text>After the androgen has been withdrawn and angiogen treatment, TBI cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="511">
                    <text>After the androgen has been withdrawn and angiogen treatment, TBI cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="512">
                    <text>After the androgen has been withdrawn and angiogen treatment, TBI cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="513">
                    <text>After the androgen has been withdrawn and angiogen treatment, TBI cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="514">
                    <text>After the androgen has been withdrawn and angiogen treatment, TBI cells will proliferate tumor regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="515">
                    <text>After the androgen has been withdrawn and angiogen treatment, adult T cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="516">
                    <text>After the androgen has been withdrawn and angiogen treatment, adult T cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="517">
                    <text>After the androgen has been withdrawn and angiogen treatment, adult T cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="518">
                    <text>After the androgen has been withdrawn and angiogen treatment, adult T cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="519">
                    <text>After the androgen has been withdrawn and angiogen treatment, adult T cells will proliferate tumor regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="520">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen cancer cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="521">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen cancer cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="522">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen cancer cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="523">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen cancer cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="524">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen cancer cells will proliferate tumor regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="525">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgens responsive prostate cancer cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="526">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgens responsive prostate cancer cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="527">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgens responsive prostate cancer cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="528">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgens responsive prostate cancer cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="529">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgens responsive prostate cancer cells will proliferate tumor regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="530">
                    <text>After the androgen has been withdrawn and angiogen treatment, angiogen prostate cancer cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="531">
                    <text>After the androgen has been withdrawn and angiogen treatment, angiogen prostate cancer cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="532">
                    <text>After the androgen has been withdrawn and angiogen treatment, angiogen prostate cancer cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="533">
                    <text>After the androgen has been withdrawn and angiogen treatment, angiogen prostate cancer cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="534">
                    <text>After the androgen has been withdrawn and angiogen treatment, angiogen prostate cancer cells will proliferate tumor regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="535">
                    <text>After the androgen has been withdrawn and angiogen treatment, feet cells transplanted intra-splintly that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="536">
                    <text>After the androgen has been withdrawn and angiogen treatment, feet cells transplanted intra-splintly which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="537">
                    <text>After the androgen has been withdrawn and angiogen treatment, feet cells transplanted intra-splintly which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="538">
                    <text>After the androgen has been withdrawn and angiogen treatment, feet cells transplanted intra-splintly which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="539">
                    <text>After the androgen has been withdrawn and angiogen treatment, feet cells transplanted intra-splintly will proliferate tumor regression.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="540">
                    <text>After the androgen has been withdrawn and angiogen treatment, feet cells transplanted intrasplenically that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="541">
                    <text>After the androgen has been withdrawn and angiogen treatment, feet cells transplanted intrasplenically which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="542">
                    <text>After the androgen has been withdrawn and angiogen treatment, feet cells transplanted intrasplenically which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="543">
                    <text>After the androgen has been withdrawn and angiogen treatment, feet cells transplanted intrasplenically which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="544">
                    <text>After the androgen has been withdrawn and angiogen treatment, feet cells transplanted intrasplenically will proliferate tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="545">
                    <text>After the androgen has been withdrawn and angiogen treatment, feet cells transplanted intrasplentically that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="546">
                    <text>After the androgen has been withdrawn and angiogen treatment, feet cells transplanted intrasplentically which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="547">
                    <text>After the androgen has been withdrawn and angiogen treatment, feet cells transplanted intrasplentically which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="548">
                    <text>After the androgen has been withdrawn and angiogen treatment, feet cells transplanted intrasplentically which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="549">
                    <text>After the androgen has been withdrawn and angiogen treatment, feet cells transplanted intrasplentically will proliferate tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="550">
                    <text>After the androgen has been withdrawn and angiogen treatment, fetal liver cells transplanted intrasplenically that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="551">
                    <text>After the androgen has been withdrawn and angiogen treatment, fetal liver cells transplanted intrasplenically which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="552">
                    <text>After the androgen has been withdrawn and angiogen treatment, fetal liver cells transplanted intrasplenically which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="553">
                    <text>After the androgen has been withdrawn and angiogen treatment, fetal liver cells transplanted intrasplenically which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="554">
                    <text>After the androgen has been withdrawn and angiogen treatment, fetal liver cells transplanted intrasplenically will proliferate tumor regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="555">
                    <text>After the androgen has been withdrawn and angiogen treatment, human placenta that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="556">
                    <text>After the androgen has been withdrawn and angiogen treatment, human placenta which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="557">
                    <text>After the androgen has been withdrawn and angiogen treatment, human placenta which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="558">
                    <text>After the androgen has been withdrawn and angiogen treatment, human placenta which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="559">
                    <text>After the androgen has been withdrawn and angiogen treatment, human placenta will proliferate tumor regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="560">
                    <text>After the androgen has been withdrawn and angiogen treatment, ingenue T cells for adults that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="561">
                    <text>After the androgen has been withdrawn and angiogen treatment, ingenue T cells for adults which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="562">
                    <text>After the androgen has been withdrawn and angiogen treatment, ingenue T cells for adults which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="563">
                    <text>After the androgen has been withdrawn and angiogen treatment, ingenue T cells for adults which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="564">
                    <text>After the androgen has been withdrawn and angiogen treatment, ingenue T cells for adults will proliferate tumor regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="565">
                    <text>After the androgen has been withdrawn and angiogen treatment, ingenue T cells of adults that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="566">
                    <text>After the androgen has been withdrawn and angiogen treatment, ingenue T cells of adults which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="567">
                    <text>After the androgen has been withdrawn and angiogen treatment, ingenue T cells of adults which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="568">
                    <text>After the androgen has been withdrawn and angiogen treatment, ingenue T cells of adults which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="569">
                    <text>After the androgen has been withdrawn and angiogen treatment, ingenue T cells of adults will proliferate tumor regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="570">
                    <text>After the androgen has been withdrawn and angiogen treatment, intra-splate transplant feet cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="571">
                    <text>After the androgen has been withdrawn and angiogen treatment, intra-splate transplant feet cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="572">
                    <text>After the androgen has been withdrawn and angiogen treatment, intra-splate transplant feet cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="573">
                    <text>After the androgen has been withdrawn and angiogen treatment, intra-splate transplant feet cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="574">
                    <text>After the androgen has been withdrawn and angiogen treatment, intra-splate transplant feet cells will proliferate tumor regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="575">
                    <text>After the androgen has been withdrawn and angiogen treatment, intra-splenic transplant fetal cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="576">
                    <text>After the androgen has been withdrawn and angiogen treatment, intra-splenic transplant fetal cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="577">
                    <text>After the androgen has been withdrawn and angiogen treatment, intra-splenic transplant fetal cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="578">
                    <text>After the androgen has been withdrawn and angiogen treatment, intra-splenic transplant fetal cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="579">
                    <text>After the androgen has been withdrawn and angiogen treatment, intra-splenic transplant fetal cells will proliferate tumor regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="580">
                    <text>After the androgen has been withdrawn and angiogen treatment, intra-splintly transplanted fetal shapes that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="581">
                    <text>After the androgen has been withdrawn and angiogen treatment, intra-splintly transplanted fetal shapes which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="582">
                    <text>After the androgen has been withdrawn and angiogen treatment, intra-splintly transplanted fetal shapes which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="583">
                    <text>After the androgen has been withdrawn and angiogen treatment, intra-splintly transplanted fetal shapes which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="584">
                    <text>After the androgen has been withdrawn and angiogen treatment, intra-splintly transplanted fetal shapes will proliferate tumor regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="585">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasplens transplanted liver cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="586">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasplens transplanted liver cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="587">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasplens transplanted liver cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="588">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasplens transplanted liver cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="589">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasplens transplanted liver cells will proliferate tumor regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="590">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasplensally transplanted fetal cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="591">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasplensally transplanted fetal cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="592">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasplensally transplanted fetal cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="593">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasplensally transplanted fetal cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="594">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasplensally transplanted fetal cells will proliferate tumor regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="595">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasplensally transplanted liver cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="596">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasplensally transplanted liver cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="597">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasplensally transplanted liver cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="598">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasplensally transplanted liver cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="599">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasplensally transplanted liver cells will proliferate tumor regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="600">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasplintly transplanted fetal cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="601">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasplintly transplanted fetal cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="602">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasplintly transplanted fetal cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="603">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasplintly transplanted fetal cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="604">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasplintly transplanted fetal cells will proliferate tumor regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="605">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasponntically transplanted fetal cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="606">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasponntically transplanted fetal cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="607">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasponntically transplanted fetal cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="608">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasponntically transplanted fetal cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="609">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasponntically transplanted fetal cells will proliferate tumor regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="610">
                    <text>After the androgen has been withdrawn and angiogen treatment, intraspontically transplanted fetal cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="611">
                    <text>After the androgen has been withdrawn and angiogen treatment, intraspontically transplanted fetal cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="612">
                    <text>After the androgen has been withdrawn and angiogen treatment, intraspontically transplanted fetal cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="613">
                    <text>After the androgen has been withdrawn and angiogen treatment, intraspontically transplanted fetal cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="614">
                    <text>After the androgen has been withdrawn and angiogen treatment, intraspontically transplanted fetal cells will proliferate tumor regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="615">
                    <text>After the androgen has been withdrawn and angiogen treatment, the human placenta that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="616">
                    <text>After the androgen has been withdrawn and angiogen treatment, the human placenta which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="617">
                    <text>After the androgen has been withdrawn and angiogen treatment, the human placenta which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="618">
                    <text>After the androgen has been withdrawn and angiogen treatment, the human placenta which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="619">
                    <text>After the androgen has been withdrawn and angiogen treatment, the human placenta will proliferate tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="620">
                    <text>After the androgen has been withdrawn and angiogen treatment, transplant feet cells intrasplenomegaly that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="621">
                    <text>After the androgen has been withdrawn and angiogen treatment, transplant feet cells intrasplenomegaly which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="622">
                    <text>After the androgen has been withdrawn and angiogen treatment, transplant feet cells intrasplenomegaly which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="623">
                    <text>After the androgen has been withdrawn and angiogen treatment, transplant feet cells intrasplenomegaly which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="624">
                    <text>After the androgen has been withdrawn and angiogen treatment, transplant feet cells intrasplenomegaly will proliferate tumor regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="625">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, CD4+ HIV T cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="626">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, EBD cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="627">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, HD CD4+ T cells specific to HIV in viremics patients stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="628">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, TBI cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="629">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, adult T cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="630">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, androgen cancer cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="631">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, androgens responsive prostate cancer cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="632">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, angiogen prostate cancer cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="633">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, feet cells transplanted intra-splintly stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="634">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, feet cells transplanted intrasplenically stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="635">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, feet cells transplanted intrasplentically stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="636">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, fetal liver cells transplanted intrasplenically stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="637">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, human placenta stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="638">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, ingenue T cells for adults stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="639">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, ingenue T cells of adults stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="640">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, intra-splate transplant feet cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="641">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, intra-splenic transplant fetal cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="642">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, intra-splintly transplanted fetal shapes stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="643">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, intrasplens transplanted liver cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="644">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, intrasplensally transplanted fetal cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="645">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, intrasplensally transplanted liver cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="646">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, intrasplintly transplanted fetal cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="647">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, intrasponntically transplanted fetal cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="648">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, intraspontically transplanted fetal cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="649">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, the human placenta stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="650">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, transplant feet cells intrasplenomegaly stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="651">
                    <text>CD4+ HIV T cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="652">
                    <text>CD4+ HIV T cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="653">
                    <text>CD4+ HIV T cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="654">
                    <text>CD4+ HIV T cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="655">
                    <text>CD4+ HIV T cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="656">
                    <text>CD4+ HIV T cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="657">
                    <text>CD4+ HIV T cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="658">
                    <text>CD4+ HIV T cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="659">
                    <text>CD4+ HIV T cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="660">
                    <text>CD4+ HIV T cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="661">
                    <text>EBD cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="662">
                    <text>EBD cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="663">
                    <text>EBD cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="664">
                    <text>EBD cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="665">
                    <text>EBD cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="666">
                    <text>EBD cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="667">
                    <text>EBD cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="668">
                    <text>EBD cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="669">
                    <text>EBD cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="670">
                    <text>EBD cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="671">
                    <text>HD CD4+ T cells specific to HIV in viremics patients has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="672">
                    <text>HD CD4+ T cells specific to HIV in viremics patients is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="673">
                    <text>HD CD4+ T cells specific to HIV in viremics patients is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="674">
                    <text>HD CD4+ T cells specific to HIV in viremics patients is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="675">
                    <text>HD CD4+ T cells specific to HIV in viremics patients is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="676">
                    <text>HD CD4+ T cells specific to HIV in viremics patients may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="677">
                    <text>HD CD4+ T cells specific to HIV in viremics patients may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="678">
                    <text>HD CD4+ T cells specific to HIV in viremics patients proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="679">
                    <text>HD CD4+ T cells specific to HIV in viremics patients proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="680">
                    <text>HD CD4+ T cells specific to HIV in viremics patients will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="681">
                    <text>In addition, CD4+ HIV T cells has been found to proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="682">
                    <text>In addition, CD4+ HIV T cells has been found to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="683">
                    <text>In addition, CD4+ HIV T cells has been found to proliferate strongly in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="684">
                    <text>In addition, CD4+ HIV T cells is able to proliferate in response to HIV A1 antigens (when costimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="685">
                    <text>In addition, CD4+ HIV T cells may be observed to proliferate in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="686">
                    <text>In addition, CD4+ HIV T cells proliferated in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="687">
                    <text>In addition, CD4+ HIV T cells was observed to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="688">
                    <text>In addition, it could be shown that CD4+ HIV T cells proliferates in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="689">
                    <text>It is observed that adult T cells regains the ability to proliferate indefinitely when transferred to lymphocytic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="690">
                    <text>It is observed that adult T cells regains the ability to proliferate when transferred to lymphocytic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="691">
                    <text>It is observed that human placenta regains the ability to proliferate during pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="692">
                    <text>It is observed that human placenta regains the ability to proliferate indefinitely during pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="693">
                    <text>It is observed that human placenta regains the ability to proliferate indefinitely pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="694">
                    <text>It is observed that human placenta regains the ability to proliferate pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="695">
                    <text>It is observed that ingenue T cells for adults regains the ability to proliferate indefinitely when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="696">
                    <text>It is observed that ingenue T cells for adults regains the ability to proliferate when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="697">
                    <text>It is observed that the human placenta regains the ability to proliferate during pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="698">
                    <text>It is observed that the human placenta regains the ability to proliferate indefinitely during pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="699">
                    <text>It is observed that the human placenta regains the ability to proliferate indefinitely through pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="700">
                    <text>It is observed that the human placenta regains the ability to proliferate through pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="701">
                    <text>It is proliferate that adult T cells regains the undefined proliferation capability when transferred to lymphocytic hosts (image 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="702">
                    <text>It is proliferate that human placenta regains the undefined proliferation capability during pregnancy (image 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="703">
                    <text>It is proliferate that human placenta regains the undefined proliferation capability pregnancy (image 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="704">
                    <text>It is proliferate that ingenue T cells for adults regains the undefined proliferation capability when transferred to lymphonic hosts (image 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="705">
                    <text>It is proliferate that the human placenta regains the undefined proliferation capability during pregnancy (image 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="706">
                    <text>It is proliferate that the human placenta regains the undefined proliferation capability through pregnancy (image 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="707">
                    <text>Our observations illustrate that adult T cells can be endowed with biochemical machinery to proliferate indefinitely when transferred to lymphocytic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="708">
                    <text>Our observations illustrate that adult T cells can be endowed with biochemical machinery to proliferate when transferred to lymphocytic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="709">
                    <text>Our observations illustrate that adult T cells could have been endowed with biochemical machinery to proliferate indefinitely when transferred to lymphocytic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="710">
                    <text>Our observations illustrate that adult T cells has been endowed with biochemical machinery to proliferate indefinitely when transferred to lymphocytic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="711">
                    <text>Our observations illustrate that adult T cells is endowed with biochemical machinery to proliferate indefinitely when transferred to lymphocytic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="712">
                    <text>Our observations illustrate that adult T cells was endowed with biochemical machinery to proliferate indefinitely when transferred to lymphocytic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="713">
                    <text>Our observations illustrate that adult T cells was endowed with biochemical machinery to proliferate when transferred to lymphocytic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="714">
                    <text>Our observations illustrate that adult T cells will be endowed with biochemical machinery to proliferate indefinitely when transferred to lymphocytic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="715">
                    <text>Our observations illustrate that human placenta can be endowed with biochemical machinery to proliferate during pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="716">
                    <text>Our observations illustrate that human placenta can be endowed with biochemical machinery to proliferate indefinitely during pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="717">
                    <text>Our observations illustrate that human placenta can be endowed with biochemical machinery to proliferate indefinitely pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="718">
                    <text>Our observations illustrate that human placenta can be endowed with biochemical machinery to proliferate pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="719">
                    <text>Our observations illustrate that human placenta could have been endowed with biochemical machinery to proliferate indefinitely during pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="720">
                    <text>Our observations illustrate that human placenta could have been endowed with biochemical machinery to proliferate indefinitely pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="721">
                    <text>Our observations illustrate that human placenta has been endowed with biochemical machinery to proliferate indefinitely during pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="722">
                    <text>Our observations illustrate that human placenta has been endowed with biochemical machinery to proliferate indefinitely pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="723">
                    <text>Our observations illustrate that human placenta is endowed with biochemical machinery to proliferate indefinitely during pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="724">
                    <text>Our observations illustrate that human placenta is endowed with biochemical machinery to proliferate indefinitely pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="725">
                    <text>Our observations illustrate that human placenta was endowed with biochemical machinery to proliferate during pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="726">
                    <text>Our observations illustrate that human placenta was endowed with biochemical machinery to proliferate indefinitely during pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="727">
                    <text>Our observations illustrate that human placenta was endowed with biochemical machinery to proliferate indefinitely pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="728">
                    <text>Our observations illustrate that human placenta was endowed with biochemical machinery to proliferate pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="729">
                    <text>Our observations illustrate that human placenta will be endowed with biochemical machinery to proliferate indefinitely during pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="730">
                    <text>Our observations illustrate that human placenta will be endowed with biochemical machinery to proliferate indefinitely pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="731">
                    <text>Our observations illustrate that ingenue T cells for adults can be endowed with biochemical machinery to proliferate indefinitely when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="732">
                    <text>Our observations illustrate that ingenue T cells for adults can be endowed with biochemical machinery to proliferate when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="733">
                    <text>Our observations illustrate that ingenue T cells for adults could have been endowed with biochemical machinery to proliferate indefinitely when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="734">
                    <text>Our observations illustrate that ingenue T cells for adults has been endowed with biochemical machinery to proliferate indefinitely when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="735">
                    <text>Our observations illustrate that ingenue T cells for adults is endowed with biochemical machinery to proliferate indefinitely when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="736">
                    <text>Our observations illustrate that ingenue T cells for adults was endowed with biochemical machinery to proliferate indefinitely when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="737">
                    <text>Our observations illustrate that ingenue T cells for adults was endowed with biochemical machinery to proliferate when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="738">
                    <text>Our observations illustrate that ingenue T cells for adults will be endowed with biochemical machinery to proliferate indefinitely when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="739">
                    <text>Our observations illustrate that the human placenta can be endowed with biochemical machinery to proliferate during pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="740">
                    <text>Our observations illustrate that the human placenta can be endowed with biochemical machinery to proliferate indefinitely during pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="741">
                    <text>Our observations illustrate that the human placenta can be endowed with biochemical machinery to proliferate indefinitely through pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="742">
                    <text>Our observations illustrate that the human placenta can be endowed with biochemical machinery to proliferate through pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="743">
                    <text>Our observations illustrate that the human placenta could have been endowed with biochemical machinery to proliferate indefinitely during pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="744">
                    <text>Our observations illustrate that the human placenta could have been endowed with biochemical machinery to proliferate indefinitely through pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="745">
                    <text>Our observations illustrate that the human placenta has been endowed with biochemical machinery to proliferate indefinitely during pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="746">
                    <text>Our observations illustrate that the human placenta has been endowed with biochemical machinery to proliferate indefinitely through pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="747">
                    <text>Our observations illustrate that the human placenta is endowed with biochemical machinery to proliferate indefinitely during pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="748">
                    <text>Our observations illustrate that the human placenta is endowed with biochemical machinery to proliferate indefinitely through pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="749">
                    <text>Our observations illustrate that the human placenta was endowed with biochemical machinery to proliferate during pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="750">
                    <text>Our observations illustrate that the human placenta was endowed with biochemical machinery to proliferate indefinitely during pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="751">
                    <text>Our observations illustrate that the human placenta was endowed with biochemical machinery to proliferate indefinitely through pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="752">
                    <text>Our observations illustrate that the human placenta was endowed with biochemical machinery to proliferate through pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="753">
                    <text>Our observations illustrate that the human placenta will be endowed with biochemical machinery to proliferate indefinitely during pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="754">
                    <text>Our observations illustrate that the human placenta will be endowed with biochemical machinery to proliferate indefinitely through pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="755">
                    <text>T cells adult T cells are able to recover the ability to proliferate when transferred to lymphocytic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="756">
                    <text>T cells human placenta are able to recover the ability to proliferate during pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="757">
                    <text>T cells human placenta are able to recover the ability to proliferate pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="758">
                    <text>T cells ingenue T cells for adults are able to recover the ability to proliferate when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="759">
                    <text>T cells the human placenta are able to recover the ability to proliferate during pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="760">
                    <text>T cells the human placenta are able to recover the ability to proliferate through pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="761">
                    <text>TBI cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="762">
                    <text>TBI cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="763">
                    <text>TBI cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="764">
                    <text>TBI cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="765">
                    <text>TBI cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="766">
                    <text>TBI cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="767">
                    <text>TBI cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="768">
                    <text>TBI cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="769">
                    <text>TBI cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="770">
                    <text>TBI cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="771">
                    <text>The CD4+ HIV T cells capacity that can proliferate in vitro was examined by injection of 3? 106 LVTE cells into the muscle of the calf of 3 immunocompromised mice.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="772">
                    <text>The CD4+ HIV T cells capacity that proliferated in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="773">
                    <text>The CD4+ HIV T cells capacity that will proliferate strongly in vitro has been examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="774">
                    <text>The ability of CD4+ HIV T cells that can proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="775">
                    <text>The ability of CD4+ HIV T cells that can proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="776">
                    <text>The ability of CD4+ HIV T cells that can strongly proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="777">
                    <text>The ability of CD4+ HIV T cells that have proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="778">
                    <text>The ability of CD4+ HIV T cells that have strongly proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="779">
                    <text>The ability of CD4+ HIV T cells that have the ability to proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="780">
                    <text>The ability of CD4+ HIV T cells that is able to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="781">
                    <text>The ability of CD4+ HIV T cells that is capable of proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="782">
                    <text>The ability of CD4+ HIV T cells that is capable of strongly proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="783">
                    <text>The ability of CD4+ HIV T cells that may have proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="784">
                    <text>The ability of CD4+ HIV T cells that may have strongly proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="785">
                    <text>The ability of CD4+ HIV T cells that proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="786">
                    <text>The ability of CD4+ HIV T cells that was observed to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="787">
                    <text>The ability of CD4+ HIV T cells to proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="788">
                    <text>The ability of CD4+ HIV T cells to proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="789">
                    <text>The ability of CD4+ HIV T cells to proliferated in vitro was examined by injection of 3? 106 LVTE into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="790">
                    <text>The adult T cells regained the ability to proliferate the when transferred to lymphocytic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="791">
                    <text>The capacity of CD4+ HIV T cells proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="792">
                    <text>The capacity of CD4+ HIV T cells that may have proliferated strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="793">
                    <text>The human placenta regained the ability to proliferate the during pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="794">
                    <text>The human placenta regained the ability to proliferate the pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="795">
                    <text>The ingenue T cells for adults regained the ability to proliferate the when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="796">
                    <text>The the human placenta regained the ability to proliferate the during pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="797">
                    <text>The the human placenta regained the ability to proliferate the through pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="798">
                    <text>The treatment of CD4+ HIV T cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="799">
                    <text>The treatment of EBD cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="800">
                    <text>The treatment of HD CD4+ T cells specific to HIV in viremics patients of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="801">
                    <text>The treatment of TBI cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="802">
                    <text>The treatment of adult T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="803">
                    <text>The treatment of adult T cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="804">
                    <text>The treatment of adult T cells of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="805">
                    <text>The treatment of adult T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="806">
                    <text>The treatment of adult T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="807">
                    <text>The treatment of androgen cancer cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="808">
                    <text>The treatment of androgens responsive prostate cancer cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="809">
                    <text>The treatment of angiogen prostate cancer cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="810">
                    <text>The treatment of feet cells transplanted intra-splintly of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="811">
                    <text>The treatment of feet cells transplanted intrasplenically of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="812">
                    <text>The treatment of feet cells transplanted intrasplentically of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="813">
                    <text>The treatment of fetal liver cells transplanted intrasplenically of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="814">
                    <text>The treatment of human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate during pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="815">
                    <text>The treatment of human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="816">
                    <text>The treatment of human placenta of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="817">
                    <text>The treatment of human placenta of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate during pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="818">
                    <text>The treatment of human placenta of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="819">
                    <text>The treatment of human placenta of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate during pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="820">
                    <text>The treatment of human placenta of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="821">
                    <text>The treatment of human placenta of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate during pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="822">
                    <text>The treatment of human placenta of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="823">
                    <text>The treatment of ingenue T cells for adults of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="824">
                    <text>The treatment of ingenue T cells for adults of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="825">
                    <text>The treatment of ingenue T cells for adults of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="826">
                    <text>The treatment of ingenue T cells for adults of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="827">
                    <text>The treatment of ingenue T cells for adults of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="828">
                    <text>The treatment of ingenue T cells of adults of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="829">
                    <text>The treatment of intra-splate transplant feet cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="830">
                    <text>The treatment of intra-splenic transplant fetal cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="831">
                    <text>The treatment of intra-splintly transplanted fetal shapes of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="832">
                    <text>The treatment of intrasplens transplanted liver cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="833">
                    <text>The treatment of intrasplensally transplanted fetal cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="834">
                    <text>The treatment of intrasplensally transplanted liver cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="835">
                    <text>The treatment of intrasplintly transplanted fetal cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="836">
                    <text>The treatment of intrasponntically transplanted fetal cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="837">
                    <text>The treatment of intraspontically transplanted fetal cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="838">
                    <text>The treatment of the human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="839">
                    <text>The treatment of the human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="840">
                    <text>The treatment of the human placenta of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="841">
                    <text>The treatment of the human placenta of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="842">
                    <text>The treatment of the human placenta of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="843">
                    <text>The treatment of the human placenta of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="844">
                    <text>The treatment of the human placenta of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="845">
                    <text>The treatment of the human placenta of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="846">
                    <text>The treatment of the human placenta of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="847">
                    <text>The treatment of transplant feet cells intrasplenomegaly of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="848">
                    <text>Treatment of CD4+ HIV T cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="849">
                    <text>Treatment of CD4+ HIV T cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="850">
                    <text>Treatment of CD4+ HIV T cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="851">
                    <text>Treatment of CD4+ HIV T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="852">
                    <text>Treatment of CD4+ HIV T cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="853">
                    <text>Treatment of CD4+ HIV T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="854">
                    <text>Treatment of CD4+ HIV T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="855">
                    <text>Treatment of CD4+ HIV T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="856">
                    <text>Treatment of CD4+ HIV T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="857">
                    <text>Treatment of CD4+ HIV T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="858">
                    <text>Treatment of CD4+ HIV T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="859">
                    <text>Treatment of CD4+ HIV T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="860">
                    <text>Treatment of CD4+ HIV T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="861">
                    <text>Treatment of CD4+ HIV T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="862">
                    <text>Treatment of EBD cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="863">
                    <text>Treatment of EBD cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="864">
                    <text>Treatment of EBD cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="865">
                    <text>Treatment of EBD cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="866">
                    <text>Treatment of EBD cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="867">
                    <text>Treatment of EBD cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="868">
                    <text>Treatment of EBD cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="869">
                    <text>Treatment of EBD cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="870">
                    <text>Treatment of EBD cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="871">
                    <text>Treatment of EBD cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="872">
                    <text>Treatment of EBD cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="873">
                    <text>Treatment of EBD cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="874">
                    <text>Treatment of EBD cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="875">
                    <text>Treatment of EBD cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="876">
                    <text>Treatment of HD CD4+ T cells specific to HIV in viremics patients of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="877">
                    <text>Treatment of HD CD4+ T cells specific to HIV in viremics patients of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="878">
                    <text>Treatment of HD CD4+ T cells specific to HIV in viremics patients of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="879">
                    <text>Treatment of HD CD4+ T cells specific to HIV in viremics patients of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="880">
                    <text>Treatment of HD CD4+ T cells specific to HIV in viremics patients of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="881">
                    <text>Treatment of HD CD4+ T cells specific to HIV in viremics patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="882">
                    <text>Treatment of HD CD4+ T cells specific to HIV in viremics patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="883">
                    <text>Treatment of HD CD4+ T cells specific to HIV in viremics patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="884">
                    <text>Treatment of HD CD4+ T cells specific to HIV in viremics patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="885">
                    <text>Treatment of HD CD4+ T cells specific to HIV in viremics patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="886">
                    <text>Treatment of HD CD4+ T cells specific to HIV in viremics patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="887">
                    <text>Treatment of HD CD4+ T cells specific to HIV in viremics patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="888">
                    <text>Treatment of HD CD4+ T cells specific to HIV in viremics patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="889">
                    <text>Treatment of HD CD4+ T cells specific to HIV in viremics patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="890">
                    <text>Treatment of TBI cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="891">
                    <text>Treatment of TBI cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="892">
                    <text>Treatment of TBI cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="893">
                    <text>Treatment of TBI cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="894">
                    <text>Treatment of TBI cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="895">
                    <text>Treatment of TBI cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="896">
                    <text>Treatment of TBI cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="897">
                    <text>Treatment of TBI cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="898">
                    <text>Treatment of TBI cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="899">
                    <text>Treatment of TBI cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="900">
                    <text>Treatment of TBI cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="901">
                    <text>Treatment of TBI cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="902">
                    <text>Treatment of TBI cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="903">
                    <text>Treatment of TBI cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="904">
                    <text>Treatment of adult T cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="905">
                    <text>Treatment of adult T cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="906">
                    <text>Treatment of adult T cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="907">
                    <text>Treatment of adult T cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="908">
                    <text>Treatment of adult T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="909">
                    <text>Treatment of adult T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="910">
                    <text>Treatment of adult T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="911">
                    <text>Treatment of adult T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="912">
                    <text>Treatment of adult T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="913">
                    <text>Treatment of adult T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="914">
                    <text>Treatment of adult T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="915">
                    <text>Treatment of adult T cells of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="916">
                    <text>Treatment of adult T cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="917">
                    <text>Treatment of adult T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="918">
                    <text>Treatment of adult T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="919">
                    <text>Treatment of adult T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="920">
                    <text>Treatment of adult T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="921">
                    <text>Treatment of adult T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="922">
                    <text>Treatment of adult T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="923">
                    <text>Treatment of adult T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="924">
                    <text>Treatment of adult T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="925">
                    <text>Treatment of adult T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="926">
                    <text>Treatment of androgen cancer cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="927">
                    <text>Treatment of androgen cancer cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="928">
                    <text>Treatment of androgen cancer cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="929">
                    <text>Treatment of androgen cancer cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="930">
                    <text>Treatment of androgen cancer cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="931">
                    <text>Treatment of androgen cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="932">
                    <text>Treatment of androgen cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="933">
                    <text>Treatment of androgen cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="934">
                    <text>Treatment of androgen cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="935">
                    <text>Treatment of androgen cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="936">
                    <text>Treatment of androgen cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="937">
                    <text>Treatment of androgen cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="938">
                    <text>Treatment of androgen cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="939">
                    <text>Treatment of androgen cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="940">
                    <text>Treatment of androgens responsive prostate cancer cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="941">
                    <text>Treatment of androgens responsive prostate cancer cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="942">
                    <text>Treatment of androgens responsive prostate cancer cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="943">
                    <text>Treatment of androgens responsive prostate cancer cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="944">
                    <text>Treatment of androgens responsive prostate cancer cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="945">
                    <text>Treatment of androgens responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="946">
                    <text>Treatment of androgens responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="947">
                    <text>Treatment of androgens responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="948">
                    <text>Treatment of androgens responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="949">
                    <text>Treatment of androgens responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="950">
                    <text>Treatment of androgens responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="951">
                    <text>Treatment of androgens responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="952">
                    <text>Treatment of androgens responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="953">
                    <text>Treatment of androgens responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="954">
                    <text>Treatment of angiogen prostate cancer cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="955">
                    <text>Treatment of angiogen prostate cancer cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="956">
                    <text>Treatment of angiogen prostate cancer cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="957">
                    <text>Treatment of angiogen prostate cancer cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="958">
                    <text>Treatment of angiogen prostate cancer cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="959">
                    <text>Treatment of angiogen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="960">
                    <text>Treatment of angiogen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="961">
                    <text>Treatment of angiogen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="962">
                    <text>Treatment of angiogen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="963">
                    <text>Treatment of angiogen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="964">
                    <text>Treatment of angiogen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="965">
                    <text>Treatment of angiogen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="966">
                    <text>Treatment of angiogen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="967">
                    <text>Treatment of angiogen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="968">
                    <text>Treatment of feet cells transplanted intra-splintly of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="969">
                    <text>Treatment of feet cells transplanted intra-splintly of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="970">
                    <text>Treatment of feet cells transplanted intra-splintly of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="971">
                    <text>Treatment of feet cells transplanted intra-splintly of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="972">
                    <text>Treatment of feet cells transplanted intra-splintly of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="973">
                    <text>Treatment of feet cells transplanted intra-splintly of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="974">
                    <text>Treatment of feet cells transplanted intra-splintly of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="975">
                    <text>Treatment of feet cells transplanted intra-splintly of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="976">
                    <text>Treatment of feet cells transplanted intra-splintly of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="977">
                    <text>Treatment of feet cells transplanted intra-splintly of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="978">
                    <text>Treatment of feet cells transplanted intra-splintly of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="979">
                    <text>Treatment of feet cells transplanted intra-splintly of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="980">
                    <text>Treatment of feet cells transplanted intra-splintly of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="981">
                    <text>Treatment of feet cells transplanted intra-splintly of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="982">
                    <text>Treatment of feet cells transplanted intrasplenically of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="983">
                    <text>Treatment of feet cells transplanted intrasplenically of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="984">
                    <text>Treatment of feet cells transplanted intrasplenically of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="985">
                    <text>Treatment of feet cells transplanted intrasplenically of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="986">
                    <text>Treatment of feet cells transplanted intrasplenically of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="987">
                    <text>Treatment of feet cells transplanted intrasplenically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="988">
                    <text>Treatment of feet cells transplanted intrasplenically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="989">
                    <text>Treatment of feet cells transplanted intrasplenically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="990">
                    <text>Treatment of feet cells transplanted intrasplenically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="991">
                    <text>Treatment of feet cells transplanted intrasplenically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="992">
                    <text>Treatment of feet cells transplanted intrasplenically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="993">
                    <text>Treatment of feet cells transplanted intrasplenically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="994">
                    <text>Treatment of feet cells transplanted intrasplenically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="995">
                    <text>Treatment of feet cells transplanted intrasplenically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="996">
                    <text>Treatment of feet cells transplanted intrasplentically of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="997">
                    <text>Treatment of feet cells transplanted intrasplentically of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="998">
                    <text>Treatment of feet cells transplanted intrasplentically of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="999">
                    <text>Treatment of feet cells transplanted intrasplentically of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="1000">
                    <text>Treatment of feet cells transplanted intrasplentically of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="1001">
                    <text>Treatment of feet cells transplanted intrasplentically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="1002">
                    <text>Treatment of feet cells transplanted intrasplentically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="1003">
                    <text>Treatment of feet cells transplanted intrasplentically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="1004">
                    <text>Treatment of feet cells transplanted intrasplentically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="1005">
                    <text>Treatment of feet cells transplanted intrasplentically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="1006">
                    <text>Treatment of feet cells transplanted intrasplentically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="1007">
                    <text>Treatment of feet cells transplanted intrasplentically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="1008">
                    <text>Treatment of feet cells transplanted intrasplentically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="1009">
                    <text>Treatment of feet cells transplanted intrasplentically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="1010">
                    <text>Treatment of fetal liver cells transplanted intrasplenically of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1011">
                    <text>Treatment of fetal liver cells transplanted intrasplenically of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1012">
                    <text>Treatment of fetal liver cells transplanted intrasplenically of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1013">
                    <text>Treatment of fetal liver cells transplanted intrasplenically of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1014">
                    <text>Treatment of fetal liver cells transplanted intrasplenically of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1015">
                    <text>Treatment of fetal liver cells transplanted intrasplenically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1016">
                    <text>Treatment of fetal liver cells transplanted intrasplenically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1017">
                    <text>Treatment of fetal liver cells transplanted intrasplenically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1018">
                    <text>Treatment of fetal liver cells transplanted intrasplenically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1019">
                    <text>Treatment of fetal liver cells transplanted intrasplenically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1020">
                    <text>Treatment of fetal liver cells transplanted intrasplenically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1021">
                    <text>Treatment of fetal liver cells transplanted intrasplenically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1022">
                    <text>Treatment of fetal liver cells transplanted intrasplenically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1023">
                    <text>Treatment of fetal liver cells transplanted intrasplenically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1024">
                    <text>Treatment of human placenta of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="1025">
                    <text>Treatment of human placenta of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="1026">
                    <text>Treatment of human placenta of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="1027">
                    <text>Treatment of human placenta of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate during pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1028">
                    <text>Treatment of human placenta of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1029">
                    <text>Treatment of human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate during pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1030">
                    <text>Treatment of human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1031">
                    <text>Treatment of human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate during pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1032">
                    <text>Treatment of human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1033">
                    <text>Treatment of human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="1034">
                    <text>Treatment of human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate during pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1035">
                    <text>Treatment of human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1036">
                    <text>Treatment of human placenta of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate during pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1037">
                    <text>Treatment of human placenta of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1038">
                    <text>Treatment of human placenta of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate during pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1039">
                    <text>Treatment of human placenta of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1040">
                    <text>Treatment of human placenta of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate during pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1041">
                    <text>Treatment of human placenta of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1042">
                    <text>Treatment of human placenta of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate during pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1043">
                    <text>Treatment of human placenta of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1044">
                    <text>Treatment of human placenta of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="1045">
                    <text>Treatment of human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="1046">
                    <text>Treatment of human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="1047">
                    <text>Treatment of human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="1048">
                    <text>Treatment of human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="1049">
                    <text>Treatment of human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="1050">
                    <text>Treatment of human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="1051">
                    <text>Treatment of human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="1052">
                    <text>Treatment of human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="1053">
                    <text>Treatment of human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="1054">
                    <text>Treatment of ingenue T cells for adults of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="1055">
                    <text>Treatment of ingenue T cells for adults of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="1056">
                    <text>Treatment of ingenue T cells for adults of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="1057">
                    <text>Treatment of ingenue T cells for adults of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1058">
                    <text>Treatment of ingenue T cells for adults of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1059">
                    <text>Treatment of ingenue T cells for adults of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1060">
                    <text>Treatment of ingenue T cells for adults of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="1061">
                    <text>Treatment of ingenue T cells for adults of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1062">
                    <text>Treatment of ingenue T cells for adults of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1063">
                    <text>Treatment of ingenue T cells for adults of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1064">
                    <text>Treatment of ingenue T cells for adults of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1065">
                    <text>Treatment of ingenue T cells for adults of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1066">
                    <text>Treatment of ingenue T cells for adults of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="1067">
                    <text>Treatment of ingenue T cells for adults of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="1068">
                    <text>Treatment of ingenue T cells for adults of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="1069">
                    <text>Treatment of ingenue T cells for adults of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="1070">
                    <text>Treatment of ingenue T cells for adults of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="1071">
                    <text>Treatment of ingenue T cells for adults of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="1072">
                    <text>Treatment of ingenue T cells for adults of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="1073">
                    <text>Treatment of ingenue T cells for adults of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="1074">
                    <text>Treatment of ingenue T cells for adults of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="1075">
                    <text>Treatment of ingenue T cells for adults of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="1076">
                    <text>Treatment of ingenue T cells of adults of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="1077">
                    <text>Treatment of ingenue T cells of adults of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="1078">
                    <text>Treatment of ingenue T cells of adults of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="1079">
                    <text>Treatment of ingenue T cells of adults of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="1080">
                    <text>Treatment of ingenue T cells of adults of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="1081">
                    <text>Treatment of ingenue T cells of adults of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="1082">
                    <text>Treatment of ingenue T cells of adults of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="1083">
                    <text>Treatment of ingenue T cells of adults of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="1084">
                    <text>Treatment of ingenue T cells of adults of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="1085">
                    <text>Treatment of ingenue T cells of adults of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="1086">
                    <text>Treatment of ingenue T cells of adults of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="1087">
                    <text>Treatment of ingenue T cells of adults of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="1088">
                    <text>Treatment of ingenue T cells of adults of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="1089">
                    <text>Treatment of ingenue T cells of adults of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="1090">
                    <text>Treatment of intra-splate transplant feet cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="1091">
                    <text>Treatment of intra-splate transplant feet cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="1092">
                    <text>Treatment of intra-splate transplant feet cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="1093">
                    <text>Treatment of intra-splate transplant feet cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="1094">
                    <text>Treatment of intra-splate transplant feet cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="1095">
                    <text>Treatment of intra-splate transplant feet cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="1096">
                    <text>Treatment of intra-splate transplant feet cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="1097">
                    <text>Treatment of intra-splate transplant feet cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="1098">
                    <text>Treatment of intra-splate transplant feet cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="1099">
                    <text>Treatment of intra-splate transplant feet cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="1100">
                    <text>Treatment of intra-splate transplant feet cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="1101">
                    <text>Treatment of intra-splate transplant feet cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="1102">
                    <text>Treatment of intra-splate transplant feet cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="1103">
                    <text>Treatment of intra-splate transplant feet cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="1104">
                    <text>Treatment of intra-splenic transplant fetal cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="1105">
                    <text>Treatment of intra-splenic transplant fetal cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="1106">
                    <text>Treatment of intra-splenic transplant fetal cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="1107">
                    <text>Treatment of intra-splenic transplant fetal cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="1108">
                    <text>Treatment of intra-splenic transplant fetal cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="1109">
                    <text>Treatment of intra-splenic transplant fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="1110">
                    <text>Treatment of intra-splenic transplant fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="1111">
                    <text>Treatment of intra-splenic transplant fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="1112">
                    <text>Treatment of intra-splenic transplant fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="1113">
                    <text>Treatment of intra-splenic transplant fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="1114">
                    <text>Treatment of intra-splenic transplant fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="1115">
                    <text>Treatment of intra-splenic transplant fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="1116">
                    <text>Treatment of intra-splenic transplant fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="1117">
                    <text>Treatment of intra-splenic transplant fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="1118">
                    <text>Treatment of intra-splintly transplanted fetal shapes of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="1119">
                    <text>Treatment of intra-splintly transplanted fetal shapes of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="1120">
                    <text>Treatment of intra-splintly transplanted fetal shapes of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="1121">
                    <text>Treatment of intra-splintly transplanted fetal shapes of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="1122">
                    <text>Treatment of intra-splintly transplanted fetal shapes of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="1123">
                    <text>Treatment of intra-splintly transplanted fetal shapes of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="1124">
                    <text>Treatment of intra-splintly transplanted fetal shapes of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="1125">
                    <text>Treatment of intra-splintly transplanted fetal shapes of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="1126">
                    <text>Treatment of intra-splintly transplanted fetal shapes of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="1127">
                    <text>Treatment of intra-splintly transplanted fetal shapes of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="1128">
                    <text>Treatment of intra-splintly transplanted fetal shapes of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="1129">
                    <text>Treatment of intra-splintly transplanted fetal shapes of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="1130">
                    <text>Treatment of intra-splintly transplanted fetal shapes of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="1131">
                    <text>Treatment of intra-splintly transplanted fetal shapes of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="1132">
                    <text>Treatment of intrasplens transplanted liver cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1133">
                    <text>Treatment of intrasplens transplanted liver cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1134">
                    <text>Treatment of intrasplens transplanted liver cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1135">
                    <text>Treatment of intrasplens transplanted liver cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1136">
                    <text>Treatment of intrasplens transplanted liver cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1137">
                    <text>Treatment of intrasplens transplanted liver cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1138">
                    <text>Treatment of intrasplens transplanted liver cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1139">
                    <text>Treatment of intrasplens transplanted liver cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1140">
                    <text>Treatment of intrasplens transplanted liver cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1141">
                    <text>Treatment of intrasplens transplanted liver cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1142">
                    <text>Treatment of intrasplens transplanted liver cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1143">
                    <text>Treatment of intrasplens transplanted liver cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1144">
                    <text>Treatment of intrasplens transplanted liver cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1145">
                    <text>Treatment of intrasplens transplanted liver cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1146">
                    <text>Treatment of intrasplensally transplanted fetal cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1147">
                    <text>Treatment of intrasplensally transplanted fetal cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1148">
                    <text>Treatment of intrasplensally transplanted fetal cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1149">
                    <text>Treatment of intrasplensally transplanted fetal cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1150">
                    <text>Treatment of intrasplensally transplanted fetal cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1151">
                    <text>Treatment of intrasplensally transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1152">
                    <text>Treatment of intrasplensally transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1153">
                    <text>Treatment of intrasplensally transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1154">
                    <text>Treatment of intrasplensally transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1155">
                    <text>Treatment of intrasplensally transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1156">
                    <text>Treatment of intrasplensally transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1157">
                    <text>Treatment of intrasplensally transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1158">
                    <text>Treatment of intrasplensally transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1159">
                    <text>Treatment of intrasplensally transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1160">
                    <text>Treatment of intrasplensally transplanted liver cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1161">
                    <text>Treatment of intrasplensally transplanted liver cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1162">
                    <text>Treatment of intrasplensally transplanted liver cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1163">
                    <text>Treatment of intrasplensally transplanted liver cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1164">
                    <text>Treatment of intrasplensally transplanted liver cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1165">
                    <text>Treatment of intrasplensally transplanted liver cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1166">
                    <text>Treatment of intrasplensally transplanted liver cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1167">
                    <text>Treatment of intrasplensally transplanted liver cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1168">
                    <text>Treatment of intrasplensally transplanted liver cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1169">
                    <text>Treatment of intrasplensally transplanted liver cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1170">
                    <text>Treatment of intrasplensally transplanted liver cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1171">
                    <text>Treatment of intrasplensally transplanted liver cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1172">
                    <text>Treatment of intrasplensally transplanted liver cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1173">
                    <text>Treatment of intrasplensally transplanted liver cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1174">
                    <text>Treatment of intrasplintly transplanted fetal cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1175">
                    <text>Treatment of intrasplintly transplanted fetal cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1176">
                    <text>Treatment of intrasplintly transplanted fetal cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1177">
                    <text>Treatment of intrasplintly transplanted fetal cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1178">
                    <text>Treatment of intrasplintly transplanted fetal cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1179">
                    <text>Treatment of intrasplintly transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1180">
                    <text>Treatment of intrasplintly transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1181">
                    <text>Treatment of intrasplintly transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1182">
                    <text>Treatment of intrasplintly transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1183">
                    <text>Treatment of intrasplintly transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1184">
                    <text>Treatment of intrasplintly transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1185">
                    <text>Treatment of intrasplintly transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1186">
                    <text>Treatment of intrasplintly transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1187">
                    <text>Treatment of intrasplintly transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1188">
                    <text>Treatment of intrasponntically transplanted fetal cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1189">
                    <text>Treatment of intrasponntically transplanted fetal cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1190">
                    <text>Treatment of intrasponntically transplanted fetal cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1191">
                    <text>Treatment of intrasponntically transplanted fetal cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1192">
                    <text>Treatment of intrasponntically transplanted fetal cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1193">
                    <text>Treatment of intrasponntically transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1194">
                    <text>Treatment of intrasponntically transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1195">
                    <text>Treatment of intrasponntically transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1196">
                    <text>Treatment of intrasponntically transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1197">
                    <text>Treatment of intrasponntically transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1198">
                    <text>Treatment of intrasponntically transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1199">
                    <text>Treatment of intrasponntically transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1200">
                    <text>Treatment of intrasponntically transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1201">
                    <text>Treatment of intrasponntically transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1202">
                    <text>Treatment of intraspontically transplanted fetal cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1203">
                    <text>Treatment of intraspontically transplanted fetal cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1204">
                    <text>Treatment of intraspontically transplanted fetal cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1205">
                    <text>Treatment of intraspontically transplanted fetal cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1206">
                    <text>Treatment of intraspontically transplanted fetal cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1207">
                    <text>Treatment of intraspontically transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1208">
                    <text>Treatment of intraspontically transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1209">
                    <text>Treatment of intraspontically transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1210">
                    <text>Treatment of intraspontically transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1211">
                    <text>Treatment of intraspontically transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1212">
                    <text>Treatment of intraspontically transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1213">
                    <text>Treatment of intraspontically transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1214">
                    <text>Treatment of intraspontically transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1215">
                    <text>Treatment of intraspontically transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1216">
                    <text>Treatment of the human placenta of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="1217">
                    <text>Treatment of the human placenta of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="1218">
                    <text>Treatment of the human placenta of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="1219">
                    <text>Treatment of the human placenta of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1220">
                    <text>Treatment of the human placenta of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1221">
                    <text>Treatment of the human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1222">
                    <text>Treatment of the human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1223">
                    <text>Treatment of the human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1224">
                    <text>Treatment of the human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1225">
                    <text>Treatment of the human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="1226">
                    <text>Treatment of the human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1227">
                    <text>Treatment of the human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1228">
                    <text>Treatment of the human placenta of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1229">
                    <text>Treatment of the human placenta of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1230">
                    <text>Treatment of the human placenta of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1231">
                    <text>Treatment of the human placenta of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1232">
                    <text>Treatment of the human placenta of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1233">
                    <text>Treatment of the human placenta of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1234">
                    <text>Treatment of the human placenta of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1235">
                    <text>Treatment of the human placenta of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1236">
                    <text>Treatment of the human placenta of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="1237">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="1238">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="1239">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="1240">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="1241">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="1242">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="1243">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="1244">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="1245">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="1246">
                    <text>Treatment of transplant feet cells intrasplenomegaly of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="1247">
                    <text>Treatment of transplant feet cells intrasplenomegaly of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="1248">
                    <text>Treatment of transplant feet cells intrasplenomegaly of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="1249">
                    <text>Treatment of transplant feet cells intrasplenomegaly of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="1250">
                    <text>Treatment of transplant feet cells intrasplenomegaly of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="1251">
                    <text>Treatment of transplant feet cells intrasplenomegaly of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="1252">
                    <text>Treatment of transplant feet cells intrasplenomegaly of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="1253">
                    <text>Treatment of transplant feet cells intrasplenomegaly of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="1254">
                    <text>Treatment of transplant feet cells intrasplenomegaly of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="1255">
                    <text>Treatment of transplant feet cells intrasplenomegaly of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="1256">
                    <text>Treatment of transplant feet cells intrasplenomegaly of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="1257">
                    <text>Treatment of transplant feet cells intrasplenomegaly of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="1258">
                    <text>Treatment of transplant feet cells intrasplenomegaly of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="1259">
                    <text>Treatment of transplant feet cells intrasplenomegaly of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="1260">
                    <text>adult T cells can regain the ability to proliferate indefinitely when transferred to lymphocytic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="1261">
                    <text>adult T cells can regain the ability to proliferate when transferred to lymphocytic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="1262">
                    <text>adult T cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="1263">
                    <text>adult T cells has regained the ability to proliferate when transferred to lymphocytic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="1264">
                    <text>adult T cells has the probability of recovering the ability to proliferate indefinitely when transferred to lymphocytic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="1265">
                    <text>adult T cells has the probability of recovering the ability to proliferate when transferred to lymphocytic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="1266">
                    <text>adult T cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="1267">
                    <text>adult T cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="1268">
                    <text>adult T cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="1269">
                    <text>adult T cells is likely to proliferate the undefined proliferation capacity when transferred to lymphocytic hosts (picture 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="1270">
                    <text>adult T cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="1271">
                    <text>adult T cells may have regained the ability to proliferate indefinitely when transferred to lymphocytic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="1272">
                    <text>adult T cells may have regained the ability to proliferate when transferred to lymphocytic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="1273">
                    <text>adult T cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="1274">
                    <text>adult T cells may proliferate recovered the undefined proliferation capacity when transferred to lymphocytic hosts (picture 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="1275">
                    <text>adult T cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="1276">
                    <text>adult T cells may proliferate the undefined proliferation capacity when transferred to lymphocytic hosts (picture 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="1277">
                    <text>adult T cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="1278">
                    <text>adult T cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="1279">
                    <text>adult T cells proliferate the undefined proliferation capacity when transferred to lymphocytic hosts (picture 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="1280">
                    <text>adult T cells recovered the ability to proliferate when transferred to lymphocytic hosts (picture 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="1281">
                    <text>adult T cells regained the ability to proliferate indefinitely when transferred to lymphocytic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="1282">
                    <text>adult T cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="1283">
                    <text>adult T cells will proliferate the undefined proliferation capability when transferred to lymphocytic hosts (image 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="1284">
                    <text>adult T cells will regain the ability to proliferate indefinitely when transferred to lymphocytic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="1285">
                    <text>adult T cells will regain the ability to proliferate when transferred to lymphocytic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="1286">
                    <text>adult T cells, which are at rest in normal conditions, are observed to proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="1287">
                    <text>adult T cells, which are at rest in normal conditions, have the ability to proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="1288">
                    <text>adult T cells, which are at rest in normal conditions, will proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="1289">
                    <text>adult T cells, which are at rest under normal conditions, are able to proliferate strongly when transferred to lymphocytic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="1290">
                    <text>adult T cells, which are at rest under normal conditions, are able to proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="1291">
                    <text>adult T cells, which are at rest under normal conditions, are observed to strongly proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="1292">
                    <text>adult T cells, which are at rest under normal conditions, can proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="1293">
                    <text>adult T cells, which are at rest under normal conditions, will proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="1294">
                    <text>androgen cancer cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="1295">
                    <text>androgen cancer cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="1296">
                    <text>androgen cancer cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="1297">
                    <text>androgen cancer cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="1298">
                    <text>androgen cancer cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="1299">
                    <text>androgen cancer cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="1300">
                    <text>androgen cancer cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="1301">
                    <text>androgen cancer cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="1302">
                    <text>androgen cancer cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="1303">
                    <text>androgen cancer cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="1304">
                    <text>androgens responsive prostate cancer cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="1305">
                    <text>androgens responsive prostate cancer cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="1306">
                    <text>androgens responsive prostate cancer cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="1307">
                    <text>androgens responsive prostate cancer cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="1308">
                    <text>androgens responsive prostate cancer cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="1309">
                    <text>androgens responsive prostate cancer cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="1310">
                    <text>androgens responsive prostate cancer cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="1311">
                    <text>androgens responsive prostate cancer cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="1312">
                    <text>androgens responsive prostate cancer cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="1313">
                    <text>androgens responsive prostate cancer cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="1314">
                    <text>angiogen prostate cancer cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="1315">
                    <text>angiogen prostate cancer cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="1316">
                    <text>angiogen prostate cancer cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="1317">
                    <text>angiogen prostate cancer cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="1318">
                    <text>angiogen prostate cancer cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="1319">
                    <text>angiogen prostate cancer cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="1320">
                    <text>angiogen prostate cancer cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="1321">
                    <text>angiogen prostate cancer cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="1322">
                    <text>angiogen prostate cancer cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="1323">
                    <text>angiogen prostate cancer cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="1324">
                    <text>feet cells transplanted intra-splintly has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="1325">
                    <text>feet cells transplanted intra-splintly is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="1326">
                    <text>feet cells transplanted intra-splintly is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="1327">
                    <text>feet cells transplanted intra-splintly is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="1328">
                    <text>feet cells transplanted intra-splintly is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="1329">
                    <text>feet cells transplanted intra-splintly may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="1330">
                    <text>feet cells transplanted intra-splintly may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="1331">
                    <text>feet cells transplanted intra-splintly proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="1332">
                    <text>feet cells transplanted intra-splintly proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="1333">
                    <text>feet cells transplanted intra-splintly will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="1334">
                    <text>feet cells transplanted intrasplenically has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1335">
                    <text>feet cells transplanted intrasplenically is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1336">
                    <text>feet cells transplanted intrasplenically is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1337">
                    <text>feet cells transplanted intrasplenically is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1338">
                    <text>feet cells transplanted intrasplenically is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1339">
                    <text>feet cells transplanted intrasplenically may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1340">
                    <text>feet cells transplanted intrasplenically may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1341">
                    <text>feet cells transplanted intrasplenically proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1342">
                    <text>feet cells transplanted intrasplenically proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1343">
                    <text>feet cells transplanted intrasplenically will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1344">
                    <text>feet cells transplanted intrasplentically has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="1345">
                    <text>feet cells transplanted intrasplentically is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="1346">
                    <text>feet cells transplanted intrasplentically is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="1347">
                    <text>feet cells transplanted intrasplentically is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="1348">
                    <text>feet cells transplanted intrasplentically is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="1349">
                    <text>feet cells transplanted intrasplentically may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="1350">
                    <text>feet cells transplanted intrasplentically may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="1351">
                    <text>feet cells transplanted intrasplentically proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="1352">
                    <text>feet cells transplanted intrasplentically proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="1353">
                    <text>feet cells transplanted intrasplentically will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="1354">
                    <text>fetal liver cells transplanted intrasplenically has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1355">
                    <text>fetal liver cells transplanted intrasplenically is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1356">
                    <text>fetal liver cells transplanted intrasplenically is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1357">
                    <text>fetal liver cells transplanted intrasplenically is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1358">
                    <text>fetal liver cells transplanted intrasplenically is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1359">
                    <text>fetal liver cells transplanted intrasplenically may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1360">
                    <text>fetal liver cells transplanted intrasplenically may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1361">
                    <text>fetal liver cells transplanted intrasplenically proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1362">
                    <text>fetal liver cells transplanted intrasplenically proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1363">
                    <text>fetal liver cells transplanted intrasplenically will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="1364">
                    <text>human placenta can regain the ability to proliferate during pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1365">
                    <text>human placenta can regain the ability to proliferate indefinitely during pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1366">
                    <text>human placenta can regain the ability to proliferate indefinitely pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1367">
                    <text>human placenta can regain the ability to proliferate pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1368">
                    <text>human placenta has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="1369">
                    <text>human placenta has regained the ability to proliferate during pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1370">
                    <text>human placenta has regained the ability to proliferate pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1371">
                    <text>human placenta has the probability of recovering the ability to proliferate during pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1372">
                    <text>human placenta has the probability of recovering the ability to proliferate indefinitely during pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1373">
                    <text>human placenta has the probability of recovering the ability to proliferate indefinitely pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1374">
                    <text>human placenta has the probability of recovering the ability to proliferate pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1375">
                    <text>human placenta is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="1376">
                    <text>human placenta is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="1377">
                    <text>human placenta is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="1378">
                    <text>human placenta is likely to proliferate the undefined proliferation capacity during pregnancy (picture 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1379">
                    <text>human placenta is likely to proliferate the undefined proliferation capacity pregnancy (picture 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1380">
                    <text>human placenta is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="1381">
                    <text>human placenta may have regained the ability to proliferate during pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1382">
                    <text>human placenta may have regained the ability to proliferate indefinitely during pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1383">
                    <text>human placenta may have regained the ability to proliferate indefinitely pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1384">
                    <text>human placenta may have regained the ability to proliferate pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1385">
                    <text>human placenta may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="1386">
                    <text>human placenta may proliferate recovered the undefined proliferation capacity during pregnancy (picture 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1387">
                    <text>human placenta may proliferate recovered the undefined proliferation capacity pregnancy (picture 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1388">
                    <text>human placenta may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="1389">
                    <text>human placenta may proliferate the undefined proliferation capacity during pregnancy (picture 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1390">
                    <text>human placenta may proliferate the undefined proliferation capacity pregnancy (picture 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1391">
                    <text>human placenta proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="1392">
                    <text>human placenta proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="1393">
                    <text>human placenta proliferate the undefined proliferation capacity during pregnancy (picture 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1394">
                    <text>human placenta proliferate the undefined proliferation capacity pregnancy (picture 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1395">
                    <text>human placenta recovered the ability to proliferate during pregnancy (picture 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1396">
                    <text>human placenta recovered the ability to proliferate pregnancy (picture 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1397">
                    <text>human placenta regained the ability to proliferate indefinitely during pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1398">
                    <text>human placenta regained the ability to proliferate indefinitely pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1399">
                    <text>human placenta will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="1400">
                    <text>human placenta will proliferate the undefined proliferation capability during pregnancy (image 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1401">
                    <text>human placenta will proliferate the undefined proliferation capability pregnancy (image 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1402">
                    <text>human placenta will regain the ability to proliferate during pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1403">
                    <text>human placenta will regain the ability to proliferate indefinitely during pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1404">
                    <text>human placenta will regain the ability to proliferate indefinitely pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1405">
                    <text>human placenta will regain the ability to proliferate pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1406">
                    <text>human placenta, which are at rest in normal conditions, are observed to proliferate during pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1407">
                    <text>human placenta, which are at rest in normal conditions, are observed to proliferate pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1408">
                    <text>human placenta, which are at rest in normal conditions, have the ability to proliferate during pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1409">
                    <text>human placenta, which are at rest in normal conditions, have the ability to proliferate pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1410">
                    <text>human placenta, which are at rest in normal conditions, will proliferate during pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1411">
                    <text>human placenta, which are at rest in normal conditions, will proliferate pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1412">
                    <text>human placenta, which are at rest under normal conditions, are able to proliferate during pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1413">
                    <text>human placenta, which are at rest under normal conditions, are able to proliferate pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1414">
                    <text>human placenta, which are at rest under normal conditions, are able to proliferate strongly during pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1415">
                    <text>human placenta, which are at rest under normal conditions, are able to proliferate strongly pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1416">
                    <text>human placenta, which are at rest under normal conditions, are observed to strongly proliferate during pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1417">
                    <text>human placenta, which are at rest under normal conditions, are observed to strongly proliferate pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1418">
                    <text>human placenta, which are at rest under normal conditions, can proliferate during pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1419">
                    <text>human placenta, which are at rest under normal conditions, can proliferate pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1420">
                    <text>human placenta, which are at rest under normal conditions, will proliferate during pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1421">
                    <text>human placenta, which are at rest under normal conditions, will proliferate pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="1422">
                    <text>ingenue T cells for adults can regain the ability to proliferate indefinitely when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1423">
                    <text>ingenue T cells for adults can regain the ability to proliferate when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1424">
                    <text>ingenue T cells for adults has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="1425">
                    <text>ingenue T cells for adults has regained the ability to proliferate when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1426">
                    <text>ingenue T cells for adults has the probability of recovering the ability to proliferate indefinitely when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1427">
                    <text>ingenue T cells for adults has the probability of recovering the ability to proliferate when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1428">
                    <text>ingenue T cells for adults is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="1429">
                    <text>ingenue T cells for adults is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="1430">
                    <text>ingenue T cells for adults is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="1431">
                    <text>ingenue T cells for adults is likely to proliferate the undefined proliferation capacity when transferred to lymphonic hosts (picture 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1432">
                    <text>ingenue T cells for adults is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="1433">
                    <text>ingenue T cells for adults may have regained the ability to proliferate indefinitely when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1434">
                    <text>ingenue T cells for adults may have regained the ability to proliferate when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1435">
                    <text>ingenue T cells for adults may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="1436">
                    <text>ingenue T cells for adults may proliferate recovered the undefined proliferation capacity when transferred to lymphonic hosts (picture 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1437">
                    <text>ingenue T cells for adults may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="1438">
                    <text>ingenue T cells for adults may proliferate the undefined proliferation capacity when transferred to lymphonic hosts (picture 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1439">
                    <text>ingenue T cells for adults proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="1440">
                    <text>ingenue T cells for adults proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="1441">
                    <text>ingenue T cells for adults proliferate the undefined proliferation capacity when transferred to lymphonic hosts (picture 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1442">
                    <text>ingenue T cells for adults recovered the ability to proliferate when transferred to lymphonic hosts (picture 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1443">
                    <text>ingenue T cells for adults regained the ability to proliferate indefinitely when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1444">
                    <text>ingenue T cells for adults will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="1445">
                    <text>ingenue T cells for adults will proliferate the undefined proliferation capability when transferred to lymphonic hosts (image 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1446">
                    <text>ingenue T cells for adults will regain the ability to proliferate indefinitely when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1447">
                    <text>ingenue T cells for adults will regain the ability to proliferate when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1448">
                    <text>ingenue T cells for adults, which are at rest in normal conditions, are observed to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1449">
                    <text>ingenue T cells for adults, which are at rest in normal conditions, have the ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1450">
                    <text>ingenue T cells for adults, which are at rest in normal conditions, will proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1451">
                    <text>ingenue T cells for adults, which are at rest under normal conditions, are able to proliferate strongly when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1452">
                    <text>ingenue T cells for adults, which are at rest under normal conditions, are able to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1453">
                    <text>ingenue T cells for adults, which are at rest under normal conditions, are observed to strongly proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1454">
                    <text>ingenue T cells for adults, which are at rest under normal conditions, can proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1455">
                    <text>ingenue T cells for adults, which are at rest under normal conditions, will proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="1456">
                    <text>ingenue T cells of adults has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="1457">
                    <text>ingenue T cells of adults is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="1458">
                    <text>ingenue T cells of adults is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="1459">
                    <text>ingenue T cells of adults is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="1460">
                    <text>ingenue T cells of adults is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="1461">
                    <text>ingenue T cells of adults may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="1462">
                    <text>ingenue T cells of adults may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="1463">
                    <text>ingenue T cells of adults proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="1464">
                    <text>ingenue T cells of adults proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="1465">
                    <text>ingenue T cells of adults will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="1466">
                    <text>intra-splate transplant feet cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="1467">
                    <text>intra-splate transplant feet cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="1468">
                    <text>intra-splate transplant feet cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="1469">
                    <text>intra-splate transplant feet cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="1470">
                    <text>intra-splate transplant feet cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="1471">
                    <text>intra-splate transplant feet cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="1472">
                    <text>intra-splate transplant feet cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="1473">
                    <text>intra-splate transplant feet cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="1474">
                    <text>intra-splate transplant feet cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="1475">
                    <text>intra-splate transplant feet cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="1476">
                    <text>intra-splenic transplant fetal cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="1477">
                    <text>intra-splenic transplant fetal cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="1478">
                    <text>intra-splenic transplant fetal cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="1479">
                    <text>intra-splenic transplant fetal cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="1480">
                    <text>intra-splenic transplant fetal cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="1481">
                    <text>intra-splenic transplant fetal cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="1482">
                    <text>intra-splenic transplant fetal cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="1483">
                    <text>intra-splenic transplant fetal cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="1484">
                    <text>intra-splenic transplant fetal cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="1485">
                    <text>intra-splenic transplant fetal cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="1486">
                    <text>intra-splintly transplanted fetal shapes has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="1487">
                    <text>intra-splintly transplanted fetal shapes is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="1488">
                    <text>intra-splintly transplanted fetal shapes is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="1489">
                    <text>intra-splintly transplanted fetal shapes is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="1490">
                    <text>intra-splintly transplanted fetal shapes is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="1491">
                    <text>intra-splintly transplanted fetal shapes may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="1492">
                    <text>intra-splintly transplanted fetal shapes may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="1493">
                    <text>intra-splintly transplanted fetal shapes proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="1494">
                    <text>intra-splintly transplanted fetal shapes proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="1495">
                    <text>intra-splintly transplanted fetal shapes will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="1496">
                    <text>intrasplens transplanted liver cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1497">
                    <text>intrasplens transplanted liver cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1498">
                    <text>intrasplens transplanted liver cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1499">
                    <text>intrasplens transplanted liver cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1500">
                    <text>intrasplens transplanted liver cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1501">
                    <text>intrasplens transplanted liver cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1502">
                    <text>intrasplens transplanted liver cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1503">
                    <text>intrasplens transplanted liver cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1504">
                    <text>intrasplens transplanted liver cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1505">
                    <text>intrasplens transplanted liver cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1506">
                    <text>intrasplensally transplanted fetal cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1507">
                    <text>intrasplensally transplanted fetal cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1508">
                    <text>intrasplensally transplanted fetal cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1509">
                    <text>intrasplensally transplanted fetal cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1510">
                    <text>intrasplensally transplanted fetal cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1511">
                    <text>intrasplensally transplanted fetal cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1512">
                    <text>intrasplensally transplanted fetal cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1513">
                    <text>intrasplensally transplanted fetal cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1514">
                    <text>intrasplensally transplanted fetal cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1515">
                    <text>intrasplensally transplanted fetal cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1516">
                    <text>intrasplensally transplanted liver cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1517">
                    <text>intrasplensally transplanted liver cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1518">
                    <text>intrasplensally transplanted liver cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1519">
                    <text>intrasplensally transplanted liver cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1520">
                    <text>intrasplensally transplanted liver cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1521">
                    <text>intrasplensally transplanted liver cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1522">
                    <text>intrasplensally transplanted liver cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1523">
                    <text>intrasplensally transplanted liver cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1524">
                    <text>intrasplensally transplanted liver cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1525">
                    <text>intrasplensally transplanted liver cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="1526">
                    <text>intrasplintly transplanted fetal cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1527">
                    <text>intrasplintly transplanted fetal cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1528">
                    <text>intrasplintly transplanted fetal cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1529">
                    <text>intrasplintly transplanted fetal cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1530">
                    <text>intrasplintly transplanted fetal cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1531">
                    <text>intrasplintly transplanted fetal cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1532">
                    <text>intrasplintly transplanted fetal cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1533">
                    <text>intrasplintly transplanted fetal cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1534">
                    <text>intrasplintly transplanted fetal cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1535">
                    <text>intrasplintly transplanted fetal cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1536">
                    <text>intrasponntically transplanted fetal cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1537">
                    <text>intrasponntically transplanted fetal cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1538">
                    <text>intrasponntically transplanted fetal cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1539">
                    <text>intrasponntically transplanted fetal cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1540">
                    <text>intrasponntically transplanted fetal cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1541">
                    <text>intrasponntically transplanted fetal cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1542">
                    <text>intrasponntically transplanted fetal cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1543">
                    <text>intrasponntically transplanted fetal cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1544">
                    <text>intrasponntically transplanted fetal cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1545">
                    <text>intrasponntically transplanted fetal cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1546">
                    <text>intraspontically transplanted fetal cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1547">
                    <text>intraspontically transplanted fetal cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1548">
                    <text>intraspontically transplanted fetal cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1549">
                    <text>intraspontically transplanted fetal cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1550">
                    <text>intraspontically transplanted fetal cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1551">
                    <text>intraspontically transplanted fetal cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1552">
                    <text>intraspontically transplanted fetal cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1553">
                    <text>intraspontically transplanted fetal cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1554">
                    <text>intraspontically transplanted fetal cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1555">
                    <text>intraspontically transplanted fetal cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="1556">
                    <text>the human placenta can regain the ability to proliferate during pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1557">
                    <text>the human placenta can regain the ability to proliferate indefinitely during pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1558">
                    <text>the human placenta can regain the ability to proliferate indefinitely through pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1559">
                    <text>the human placenta can regain the ability to proliferate through pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1560">
                    <text>the human placenta has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="1561">
                    <text>the human placenta has regained the ability to proliferate during pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1562">
                    <text>the human placenta has regained the ability to proliferate through pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1563">
                    <text>the human placenta has the probability of recovering the ability to proliferate during pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1564">
                    <text>the human placenta has the probability of recovering the ability to proliferate indefinitely during pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1565">
                    <text>the human placenta has the probability of recovering the ability to proliferate indefinitely through pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1566">
                    <text>the human placenta has the probability of recovering the ability to proliferate through pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1567">
                    <text>the human placenta is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="1568">
                    <text>the human placenta is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="1569">
                    <text>the human placenta is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="1570">
                    <text>the human placenta is likely to proliferate the undefined proliferation capacity during pregnancy (picture 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1571">
                    <text>the human placenta is likely to proliferate the undefined proliferation capacity through pregnancy (picture 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1572">
                    <text>the human placenta is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="1573">
                    <text>the human placenta may have regained the ability to proliferate during pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1574">
                    <text>the human placenta may have regained the ability to proliferate indefinitely during pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1575">
                    <text>the human placenta may have regained the ability to proliferate indefinitely through pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1576">
                    <text>the human placenta may have regained the ability to proliferate through pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1577">
                    <text>the human placenta may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="1578">
                    <text>the human placenta may proliferate recovered the undefined proliferation capacity during pregnancy (picture 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1579">
                    <text>the human placenta may proliferate recovered the undefined proliferation capacity through pregnancy (picture 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1580">
                    <text>the human placenta may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="1581">
                    <text>the human placenta may proliferate the undefined proliferation capacity during pregnancy (picture 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1582">
                    <text>the human placenta may proliferate the undefined proliferation capacity through pregnancy (picture 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1583">
                    <text>the human placenta proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="1584">
                    <text>the human placenta proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="1585">
                    <text>the human placenta proliferate the undefined proliferation capacity during pregnancy (picture 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1586">
                    <text>the human placenta proliferate the undefined proliferation capacity through pregnancy (picture 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1587">
                    <text>the human placenta recovered the ability to proliferate during pregnancy (picture 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1588">
                    <text>the human placenta recovered the ability to proliferate through pregnancy (picture 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1589">
                    <text>the human placenta regained the ability to proliferate indefinitely during pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1590">
                    <text>the human placenta regained the ability to proliferate indefinitely through pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1591">
                    <text>the human placenta will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="1592">
                    <text>the human placenta will proliferate the undefined proliferation capability during pregnancy (image 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1593">
                    <text>the human placenta will proliferate the undefined proliferation capability through pregnancy (image 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1594">
                    <text>the human placenta will regain the ability to proliferate during pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1595">
                    <text>the human placenta will regain the ability to proliferate indefinitely during pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1596">
                    <text>the human placenta will regain the ability to proliferate indefinitely through pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1597">
                    <text>the human placenta will regain the ability to proliferate through pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1598">
                    <text>the human placenta, which are at rest in normal conditions, are observed to proliferate during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1599">
                    <text>the human placenta, which are at rest in normal conditions, are observed to proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1600">
                    <text>the human placenta, which are at rest in normal conditions, have the ability to proliferate during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1601">
                    <text>the human placenta, which are at rest in normal conditions, have the ability to proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1602">
                    <text>the human placenta, which are at rest in normal conditions, will proliferate during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1603">
                    <text>the human placenta, which are at rest in normal conditions, will proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1604">
                    <text>the human placenta, which are at rest under normal conditions, are able to proliferate during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1605">
                    <text>the human placenta, which are at rest under normal conditions, are able to proliferate strongly during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1606">
                    <text>the human placenta, which are at rest under normal conditions, are able to proliferate strongly through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1607">
                    <text>the human placenta, which are at rest under normal conditions, are able to proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1608">
                    <text>the human placenta, which are at rest under normal conditions, are observed to strongly proliferate during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1609">
                    <text>the human placenta, which are at rest under normal conditions, are observed to strongly proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1610">
                    <text>the human placenta, which are at rest under normal conditions, can proliferate during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1611">
                    <text>the human placenta, which are at rest under normal conditions, can proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1612">
                    <text>the human placenta, which are at rest under normal conditions, will proliferate during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="1613">
                    <text>the human placenta, which are at rest under normal conditions, will proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="1614">
                    <text>transplant feet cells intrasplenomegaly has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="1615">
                    <text>transplant feet cells intrasplenomegaly is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="1616">
                    <text>transplant feet cells intrasplenomegaly is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="1617">
                    <text>transplant feet cells intrasplenomegaly is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="1618">
                    <text>transplant feet cells intrasplenomegaly is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="1619">
                    <text>transplant feet cells intrasplenomegaly may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="1620">
                    <text>transplant feet cells intrasplenomegaly may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="1621">
                    <text>transplant feet cells intrasplenomegaly proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="1622">
                    <text>transplant feet cells intrasplenomegaly proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="1623">
                    <text>transplant feet cells intrasplenomegaly will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
